{
    "questions": [
        {
            "id": "5a70dfd599e2c3af26000006",
            "body": "What is Dysphoric Milk Ejection Reflex?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20443435",
                "http://www.ncbi.nlm.nih.gov/pubmed/21645333",
                "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                "http://www.ncbi.nlm.nih.gov/pubmed/7250254",
                "http://www.ncbi.nlm.nih.gov/pubmed/488006",
                "http://www.ncbi.nlm.nih.gov/pubmed/7117445",
                "http://www.ncbi.nlm.nih.gov/pubmed/2792248",
                "http://www.ncbi.nlm.nih.gov/pubmed/7358101",
                "http://www.ncbi.nlm.nih.gov/pubmed/780102",
                "http://www.ncbi.nlm.nih.gov/pubmed/19215522"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20443435",
                    "text": "Dysphoric milk ejection reflex (D-MER) results in waves of negative emotions that last from shortly before initial milk ejection until baby starts to feed vigorously Symptoms may decrease by 3 months or they may continue throughout the breastfeeding period.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21645333",
                    "text": "Dysphoric Milk Ejection Reflex (D-MER) is an abrupt emotional \"drop\" that occurs in some women just before milk release and continues for not more than a few minutes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "BACKGROUND Dysphoric milk ejection reflex (D-MER) is characterized by an abrupt dysphoria, or undesirable feeling that occurs with the MER and continues for no more than a few minutes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29115857",
                    "text": "After milk ejection, the dysphoria vanishes.",
                    "offsetInBeginSection": 185,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7250254",
                    "text": "This suggests that, unlike what has been proposed for the rat, sleep is not a necessary component of the milk ejection reflex in the pig.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 596,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7117445",
                    "text": "Our observations suggest that the septum does not represent an essential component of the pathways necessary for the milk ejection reflex induced by suckling, although it could exert an inhibitory action modulating either the intervals between two successive milk ejections, or the amount of oxytocin released.",
                    "offsetInBeginSection": 1214,
                    "offsetInEndSection": 1524,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2792248",
                    "text": "The amount of oxytocin in the perfusates further increased-during facilitation of the milk ejection reflex by intraventricular injections of oxytocin or its analogue, isotocin.",
                    "offsetInBeginSection": 1248,
                    "offsetInEndSection": 1424,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7358101",
                    "text": "From these observations and the knowledge that oxytocin release from the neurohypophysis occurs about 10 s before milk ejection, we conclude that a synchronized EEG pattite for the expression of the milk-ejection reflex in the rat.",
                    "offsetInBeginSection": 1932,
                    "offsetInEndSection": 2163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7358101",
                    "text": "Conversely, milk ejection (n greater than 300) was never observed during long periods of desynchronized, or stage III EEG activity.",
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 890,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19215522",
                    "text": "Thus, the pathways which pass through or originate from the medial septum and which are excitatory for oxytocin release appear not to be involved in the regulation of the milk ejection reflex.",
                    "offsetInBeginSection": 885,
                    "offsetInEndSection": 1077,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76160a83b0d9ea66000020",
            "body": "Which sequence-based algorithm for branch point prediction has been proposed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                "http://www.ncbi.nlm.nih.gov/pubmed/9224618",
                "http://www.ncbi.nlm.nih.gov/pubmed/27293216",
                "http://www.ncbi.nlm.nih.gov/pubmed/26176857",
                "http://www.ncbi.nlm.nih.gov/pubmed/24709818",
                "http://www.ncbi.nlm.nih.gov/pubmed/23566387",
                "http://www.ncbi.nlm.nih.gov/pubmed/27626963",
                "http://www.ncbi.nlm.nih.gov/pubmed/16839417",
                "http://www.ncbi.nlm.nih.gov/pubmed/28222000",
                "http://www.ncbi.nlm.nih.gov/pubmed/29065858"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28633445",
                    "text": "Results We here propose a novel branch point prediction algorithm that utilizes information on the branch point sequence and the polypyrimidine tract.",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 559,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9224618",
                    "text": "A putative branch point consensus sequence for Arabidopsis thaliana resembling the well known metazoan consensus sequence has been proposed, but this is based on search of sequences similar to those in yeast and metazoa.",
                    "offsetInBeginSection": 183,
                    "offsetInEndSection": 403,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27293216",
                    "text": "Based on the proposed HPCS algorithm, we implemented an m(6)A site predictor, called M6A-HPCS, which is freely available at http://csbio.njust.edu.cn/bioinf/M6A-HPCS.",
                    "offsetInBeginSection": 1108,
                    "offsetInEndSection": 1274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176857",
                    "text": "Here we propose a sequence-based hybrid algorithm SNBRFinder (Sequence-based Nucleic acid-Binding Residue Finder) by merging a feature predictor SNBRFinderF and a template predictor SNBRFinderT.",
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176857",
                    "text": "SNBRFinderF was established using the support vector machine whose inputs include sequence profile and other complementary sequence descriptors, while SNBRFinderT was implemented with the sequence alignment algorithm based on profile hidden Markov models to capture the weakly homologous template of query sequence.",
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 862,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24709818",
                    "text": "To map precisely the location of branch points on a genomic scale, we developed LaSSO (Lariat Sequence Site Origin), a data-driven algorithm which utilizes RNA-seq data.",
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 342,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24709818",
                    "text": "LaSSO showed better sensitivity and accuracy than algorithms used for computational branch-point prediction or for empirical branch-point determination.",
                    "offsetInBeginSection": 842,
                    "offsetInEndSection": 994,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24709818",
                    "text": "LaSSO thus provides an effective approach for defining high-resolution maps of branch-site sequences and intronic elements on a genomic scale.",
                    "offsetInBeginSection": 1148,
                    "offsetInEndSection": 1290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27626963",
                    "text": "Based on many known properties of cortical neurons, hierarchical temporal memory (HTM) sequence memory recently has been proposed as a theoretical framework for sequence learning in the cortex.",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 314,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16839417",
                    "text": "RESULTS We proposed a novel clustering-based ensemble algorithm named EMD for de novo motif discovery by combining multiple predictions from multiple runs of one or more base component algorithms.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 687,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9922981d1251d03b000007",
            "body": "How do circRNAs relate to tumorigenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28933584",
                "http://www.ncbi.nlm.nih.gov/pubmed/28991235",
                "http://www.ncbi.nlm.nih.gov/pubmed/29156822",
                "http://www.ncbi.nlm.nih.gov/pubmed/27040497",
                "http://www.ncbi.nlm.nih.gov/pubmed/28928231",
                "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                "http://www.ncbi.nlm.nih.gov/pubmed/29069731",
                "http://www.ncbi.nlm.nih.gov/pubmed/28279183",
                "http://www.ncbi.nlm.nih.gov/pubmed/28737829",
                "http://www.ncbi.nlm.nih.gov/pubmed/28103507"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28933584",
                    "text": "Circular RNAs (circRNAs) are a type of noncoding RNAs generated from back-splicing, which have been verified to mediate multiple tumorigenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928231",
                    "text": "CircRNAs are involved in many regulatory bioprocesses of malignance, including cell cycle, tumorigenesis, invasion, metastasis, apoptosis, vascularization, through adsorbing RNA as a sponge, binding to RNA-binding protein (RBP), modulating transcription, or influencing translation.",
                    "offsetInBeginSection": 523,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928231",
                    "text": "Circular RNAs (circRNAs) are recently regarded as a naturally forming family of widespread and diverse endogenous noncoding RNAs (ncRNAs) that may regulate gene expression in mammals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                    "text": "intronic circRNAs).",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 277,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                    "text": "exonic circRNAs) or introns (i.e.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29034621",
                    "text": "More importantly, several circRNAs play a key role in the occurrence and progression of some tumors, including stomach, liver, colon, breast, cervical, and ovarian cancers.",
                    "offsetInBeginSection": 485,
                    "offsetInEndSection": 657,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731",
                    "text": "Our study for the first time demonstrated that Myc transcription factor regulates the expression of circRNAs, adding a novel component of the Myc tumorigenic program and opening a window to investigate the function of certain circRNAs in tumorigenesis.",
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069731",
                    "text": "Based on miRNA sponge mechanism, we constructed circRNAs/miRNAs network regulated by Myc, suggesting that circRNAs may widely regulate protein expression through miRNA sponge mechanism.",
                    "offsetInBeginSection": 639,
                    "offsetInEndSection": 824,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28737829",
                    "text": "In conclusion, differential expression of circRNAs may be associated with GC tumorigenesis, and circRNA\u20110026 is a promising biomarker for GC diagnosis and targeted therapy.",
                    "offsetInBeginSection": 1457,
                    "offsetInEndSection": 1631,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28103507",
                    "text": "Circular RNAs (circRNAs) are recently identified as widespread and diverse endogenous noncoding RNAs that may harbor vital functions in human and animals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8ee9d1fcd1d6a10c000027",
            "body": "Is there a disease or condition called Exploding Head Syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                "http://www.ncbi.nlm.nih.gov/pubmed/24703829",
                "http://www.ncbi.nlm.nih.gov/pubmed/20726288",
                "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                "http://www.ncbi.nlm.nih.gov/pubmed/11309216",
                "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                "http://www.ncbi.nlm.nih.gov/pubmed/23467433"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2769286",
                    "text": "Fifty patients suffering from the \"exploding head syndrome\" are described.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "text": "Exploding head syndrome episodes were accompanied by clinically significant levels of fear, and a minority (2.80%) experienced it to such a degree that it was associated with clinically significant distress and/or impairment.",
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25773787",
                    "text": "Exploding head syndrome is characterized by the perception of loud noises during sleep-wake or wake-sleep transitions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1896728",
                    "text": "Attention has recently been drawn to a condition termed the exploding head syndrome, which is characterized by unpleasant, even terrifying sensations of flashing lights and/or sounds during reported sleep.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20726288",
                    "text": "Exploding head syndrome is a rare phenomenon but can be a significant disruption to quality of life.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                    "text": "When hypnic headache is recognized, it is eminently treatable, while exploding head syndrome is a benign condition with no reported consequences.",
                    "offsetInBeginSection": 705,
                    "offsetInEndSection": 850,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252589",
                    "text": "The rare headache disorder hypnic headache and the exploding head syndrome are also discussed.",
                    "offsetInBeginSection": 610,
                    "offsetInEndSection": 704,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28622122",
                    "text": "This case report describes the first-ever diagnosis of exploding head syndrome in a patient with longstanding epilepsy and novel nocturnal events.",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 292,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24907167",
                    "text": "BACKGROUND Exploding head syndrome (EHS) is characterized by attacks of a sudden noise or explosive feeling experienced in the head occurring during the transition from wake to sleep or from sleep to wake.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23467433",
                    "text": "INTRODUCTION Exploding head syndrome (EHS) is a rare parasomnia in which affected individuals awaken from sleep with the sensation of a loud bang.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d8a651d1251d03b00001f",
            "body": "What is the BioArchive system?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                "http://www.ncbi.nlm.nih.gov/pubmed/12513800",
                "http://www.ncbi.nlm.nih.gov/pubmed/15812389",
                "http://www.ncbi.nlm.nih.gov/pubmed/18682250",
                "http://www.ncbi.nlm.nih.gov/pubmed/22153685",
                "http://www.ncbi.nlm.nih.gov/pubmed/21199952",
                "http://www.ncbi.nlm.nih.gov/pubmed/18407993",
                "http://www.ncbi.nlm.nih.gov/pubmed/28164570",
                "http://www.ncbi.nlm.nih.gov/pubmed/23090732",
                "http://www.ncbi.nlm.nih.gov/pubmed/18718034"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "Umbilical cord blood (CB) banks usually freeze and store CB for clinical transplantation using conventional controlled-rate freezer or the automated BioArchive system.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "The experiment used 80\u00a0CB units: 40 were conventionally cryopreserved and the remainder were cryopreserved with a BioArchive.",
                    "offsetInBeginSection": 355,
                    "offsetInEndSection": 481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28716596",
                    "text": "CBs cryopreserved with BioArchive showed significantly higher MNC and CD34+ cell viability, and CFU-GM content than those conventionally cryopreserved.",
                    "offsetInBeginSection": 1312,
                    "offsetInEndSection": 1463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12513800",
                    "text": "The aim of this study was to investigate the cryobiological characteristics of placental cord blood (PCB) cryopereserved by using BioArchive auto-preserved liquid nitrogen system (BioArchive system).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15812389",
                    "text": "To validate the use of the sample attached to the UCB unit as a quality-control tool for the final product, UCB units (n = 20) stored in liquid nitrogen with the Bioarchive system were analyzed.",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18682250",
                    "text": "The performance of a small-scale automated cryopreservation and storage system (Mini-BioArchive system) used in the banking of umbilical cord blood (UCB) units was evaluated.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22153685",
                    "text": "In the third period, from January 2009 to June 2010, an automated Sepax-BioArchive procedure was used and the accepted initial TNC count was >10\u00d710(8).",
                    "offsetInBeginSection": 877,
                    "offsetInEndSection": 1029,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18407993",
                    "text": "System 3 evaluated a 2-paddock (A and B) rotational grazing system, and system 4 evaluated a 3-paddock (A, B, and C) rotational grazing system, with paddock C containing orchardgrass (Dactylis glomerata L.) and alfalfa (Medicago sativa L.).",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 1080,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28164570",
                    "text": "A novel automated blood culture system, DL-Bt112TM (DL) was compared with the BACTEC 9050TM (BCT) and BacT/Alert 3DTM (B3D) systems for time-to-detection (TTD) using 10 different clinical bacteria that commonly cause bloodstream infections.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23090732",
                    "text": "Comparisons of the viral loads of the samples from the MagNA Pure 96 system, the Chemagic system, and the QIAamp system with those from the CAP/CTM platform yielded correlation coefficients of 0.977, 0.914, and 0.967, respectively.",
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 1098,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a723a652dc08e987e00000a",
            "body": "Describe mechanism of action of Romosozumab.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27569204",
                "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
                "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                "http://www.ncbi.nlm.nih.gov/pubmed/28428078",
                "http://www.ncbi.nlm.nih.gov/pubmed/27487526",
                "http://www.ncbi.nlm.nih.gov/pubmed/29113523",
                "http://www.ncbi.nlm.nih.gov/pubmed/29113980",
                "http://www.ncbi.nlm.nih.gov/pubmed/24835636",
                "http://www.ncbi.nlm.nih.gov/pubmed/28529724"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569204",
                    "text": "Romosozumab is a humanized immunoglobulin G2 monoclonal antibody that binds and blocks the action of sclerostin, a protein secreted by the osteocyte and an extracellular inhibitor of canonical Wnt signaling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
                    "text": "Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.",
                    "offsetInBeginSection": 1091,
                    "offsetInEndSection": 1263,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28064540",
                    "text": "Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD).",
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 347,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                    "text": "Romosozumab, a humanized monoclonal antibody that binds to sclerostin, prevents sclerostin from exerting this inhibitory effect.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28458516",
                    "text": "Romosozumab holds significant potential, by a novel mechanism of action, to expand our ability to treat osteoporosis.",
                    "offsetInBeginSection": 1325,
                    "offsetInEndSection": 1442,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                    "text": "EXPERT OPINION Blocking sclerostin action with romosozumab is a promising new therapeutic approach to osteoanabolic therapy of osteoporosis; efficacy and safety data on large controlled studies are awaited.",
                    "offsetInBeginSection": 819,
                    "offsetInEndSection": 1025,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24665957",
                    "text": "AREAS COVERED Romosozumab is the first humanized monoclonal sclerostin antibody to be tested in clinical trials.",
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 652,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28428078",
                    "text": "Romosozumab, a humanized monoclonal sclerostin antibody under development for the treatment of osteoporosis, has a unique mechanism of action on bone-increasing bone formation and decreasing bone resorption.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24835636",
                    "text": "Romosozumab is a humanized monoclonal antibody targeting sclerostin.",
                    "offsetInBeginSection": 217,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28529724",
                    "text": "Romosozumab, an anti-sclerostin antibody, inhibits the action of sclerostin, a canonical Wnt signal inhibitor secreted from osteocytes, and enhances canonical Wnt signaling.",
                    "offsetInBeginSection": 1472,
                    "offsetInEndSection": 1645,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76179d83b0d9ea66000021",
            "body": "Which algorithm has been proposed for efficient storage of WGS variant calls?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27085415",
                "http://www.ncbi.nlm.nih.gov/pubmed/28334390",
                "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                "http://www.ncbi.nlm.nih.gov/pubmed/26357316",
                "http://www.ncbi.nlm.nih.gov/pubmed/28334120",
                "http://www.ncbi.nlm.nih.gov/pubmed/26147798",
                "http://www.ncbi.nlm.nih.gov/pubmed/25587064",
                "http://www.ncbi.nlm.nih.gov/pubmed/28786363",
                "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                "http://www.ncbi.nlm.nih.gov/pubmed/28318110"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27085415",
                    "text": "Together, this new selection algorithm and experimental design suggestion significantly reduce the overall cost of variant discovery through WGS experiments, making surveys for causal variants influencing disease and production even more efficient.",
                    "offsetInBeginSection": 1158,
                    "offsetInEndSection": 1406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334390",
                    "text": "Here we introduce a new WGS variant data format implemented in the R/Bioconductor package 'SeqArray' for storing variant calls in an array-oriented manner which provides the same capabilities as VCF, but with multiple high compression options and data access using high-performance parallel computing.",
                    "offsetInBeginSection": 377,
                    "offsetInEndSection": 678,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "In WGS analysis, this results in characteristic and recognizable patterns of variant calls at positions that we term alignable scaffold-discrepant positions (ASDPs).",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "METHODS We developed an algorithm that analyzes the patterns of variant calls in the 178 structurally variable regions of the GRCh38 genome assembly, and infers whether a given sample is most likely to contain sequences from the primary assembly, an alternate locus, or their heterozygous combination at each of these 178 regions.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 673,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27964746",
                    "text": "CONCLUSIONS Our algorithm uses the information contained in the 178 structurally variable regions of the GRCh38 genome assembly to avoid spurious variant calls in cases where samples contain an alternate locus rather than the corresponding segment of the primary assembly.",
                    "offsetInBeginSection": 1589,
                    "offsetInEndSection": 1861,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26357316",
                    "text": "The proposed algorithm has been incorporated into a disease-linked variant prioritization pipeline for WGS (http://gnome.tchlab.org) and its implementation is available at http://ml.ssu.ac.kr/gSearch.",
                    "offsetInBeginSection": 1171,
                    "offsetInEndSection": 1371,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334120",
                    "text": "Results We provide the structural variant prediction viewer, a tool which presents a visual summary of the most relevant features for SV prediction from WGS data.",
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25587064",
                    "text": "BACKGROUND Whole-genome sequencing (WGS) and whole-exome sequencing (WES) technologies are increasingly used to identify disease-contributing mutations in human genomic studies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "MOTIVATION The increasing adoption of clinical whole-genome resequencing (WGS) demands for highly accurate and reproducible variant calling (VC) methods.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28318110",
                    "text": "For the association analysis of whole-genome sequencing (WGS) studies, we propose an efficient and fast spatial-clustering algorithm.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9924ea1d1251d03b000008",
            "body": "What is the association of circular RNA to breast cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27829232",
                "http://www.ncbi.nlm.nih.gov/pubmed/28933584",
                "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                "http://www.ncbi.nlm.nih.gov/pubmed/28739726",
                "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                "http://www.ncbi.nlm.nih.gov/pubmed/29109417",
                "http://www.ncbi.nlm.nih.gov/pubmed/27965971",
                "http://www.ncbi.nlm.nih.gov/pubmed/28349836",
                "http://www.ncbi.nlm.nih.gov/pubmed/28484086",
                "http://www.ncbi.nlm.nih.gov/pubmed/29045858"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                    "text": "Circular RNA (circRNA) is a key regulator in the development and progression of human cancers, however its role in breast cancer tumorigenesis is not well understood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                    "text": "Overall, results identified a new functional circ-ABCB10 in breast cancer tumorigenesis, and reveal the important regulatory role of circ-ABCB10 through sponging miR-1271, providing a novel insight for breast cancer pathogenesis.",
                    "offsetInBeginSection": 975,
                    "offsetInEndSection": 1204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28744405",
                    "text": "Finally, miR-1271 rescued the function of circ-ABCB10 on breast cancer cells, confirming the sponge effect of circ-ABCB10 on miR-1271.",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 974,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                    "text": "Additionally, we discovered a regulatory role of the circ_0006528-miR-7-5p-Raf1 axis in ADM-resistant breast cancer.",
                    "offsetInBeginSection": 825,
                    "offsetInEndSection": 941,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                    "text": "CONCLUSION These results revealed that circRNAs may play a role in breast cancer chemoresistance and that hsa_circ_0006528 might be a promising candidate for further functional analysis.",
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28803498",
                    "text": "AIM We aimed to identify circular RNAs (circRNAs) associated with breast cancer chemoresistance.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29109417",
                    "text": "Overall, our results support the hypothesis of circular RNAs representing a novel factor in the dynamic epigenetic network of gene regulation, which involves the microRNAs, its mRNAs targets, and the circular RNAs-derived genes.",
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29109417",
                    "text": "Previous studies have demonstrated that some circular RNAs act as microRNA sponges, and are associated with cellular proliferation in cancer.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27965971",
                    "text": "Circular RNAs are nontranslated RNAs, typically nonpolyadenylated, with a resistance to exonucleases that gives them the ability to be more stable than the common linear RNA isoforms.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28349836",
                    "text": "Circular RNA, a class of non-coding RNA, is a new group of RNAs and is related to tumorigenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a95765bfcd1d6a10c000028",
            "body": "What part of what body organ controls the circadian clock?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21969583",
                "http://www.ncbi.nlm.nih.gov/pubmed/23704227",
                "http://www.ncbi.nlm.nih.gov/pubmed/28779094",
                "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                "http://www.ncbi.nlm.nih.gov/pubmed/21763748",
                "http://www.ncbi.nlm.nih.gov/pubmed/26144255",
                "http://www.ncbi.nlm.nih.gov/pubmed/16925815",
                "http://www.ncbi.nlm.nih.gov/pubmed/28707700",
                "http://www.ncbi.nlm.nih.gov/pubmed/19849797",
                "http://www.ncbi.nlm.nih.gov/pubmed/27385482"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23704227",
                    "text": "Clock genes control circadian rhythms both centrally, in the suprachiasmatic nucleus of the brain and peripherally, within every organ of the body.",
                    "offsetInBeginSection": 589,
                    "offsetInEndSection": 736,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28779094",
                    "text": "Deficiency of an essential clock gene Bmal1 impairs day-night variations of osmotic pressure gradient in the inner medulla, suggesting that circadian clocks in the medulla part of the kidney may regulate the circadian rhythm of cortico-medullary osmotic pressure gradient, and may contribute physiological day-night rhythm of urination.",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                    "text": "Furthermore, this intestinal clock controls the expression of key cell cycle regulators, such as cdc2, wee1, p21, PCNA and cdk2, but only weakly influences cyclin B1, cyclin B2 and cyclin E1 expression.",
                    "offsetInBeginSection": 620,
                    "offsetInEndSection": 822,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                    "text": "The circadian clock controls cell proliferation in a number of healthy tissues where cell renewal and regeneration are critical for normal physiological function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24013905",
                    "text": "Timed feeding under constant dark conditions is able to drive rhythmic expression not only of circadian clock genes, but also of several cell cycle genes, suggesting that food can entrain the clock, as well as the cell cycle in the intestine.",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1254,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21763748",
                    "text": "humoral factors, activity and body temperature rhythms) or, trough the intrinsic renal circadian clock.",
                    "offsetInBeginSection": 1115,
                    "offsetInEndSection": 1218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26144255",
                    "text": "We conclude that the circadian clock acts to gate auxin signalling during LR development to facilitate organ emergence.",
                    "offsetInBeginSection": 773,
                    "offsetInEndSection": 892,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26144255",
                    "text": "Metabolite and transcript profiling revealed that the circadian clock controls the levels of auxin and auxin-related genes including the auxin response repressor IAA14 and auxin oxidase AtDAO2.",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 687,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28707700",
                    "text": "The suprachiasmatic nucleus houses the central circadian clock and is characterized by the timely regulated expression of clock genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27385482",
                    "text": "Recently, we came to appreciate that the formation and metabolic functions of BAT, a key organ for body temperature maintenance, are under an orchestrated circadian clock regulation.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 511,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa4f47cd6d6b54f7900000a",
            "body": "When is 16S rRNA Gene Sequencing used?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/14535548",
                "http://www.ncbi.nlm.nih.gov/pubmed/27842515",
                "http://www.ncbi.nlm.nih.gov/pubmed/26770469",
                "http://www.ncbi.nlm.nih.gov/pubmed/17037387",
                "http://www.ncbi.nlm.nih.gov/pubmed/26434730",
                "http://www.ncbi.nlm.nih.gov/pubmed/21121044",
                "http://www.ncbi.nlm.nih.gov/pubmed/21240067",
                "http://www.ncbi.nlm.nih.gov/pubmed/14520536",
                "http://www.ncbi.nlm.nih.gov/pubmed/27613736",
                "http://www.ncbi.nlm.nih.gov/pubmed/25226019"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27842515",
                    "text": "A new alternative for full-length bacterial 16S rRNA gene sequencing is offered by PacBio single molecule, real-time (SMRT) technology.",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26770469",
                    "text": "Together, these data present 16S rRNA gene sequencing as a novel VAP diagnosis tool that will further enable pathogen-specific treatment of VAP.",
                    "offsetInBeginSection": 1588,
                    "offsetInEndSection": 1732,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17037387",
                    "text": "To classify mycobacteria not identified by DNA-DNA hybridization (DDH) using sequencing of rpoB and 16S rRNA gene.",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17037387",
                    "text": "Even though sequencing of rpoB and 16S rRNA gene was utilized, it was impossible to classify M. tuberculosis complex, M. avium family, M. marinum and M. ulcerans, and M. fortitum subsp.",
                    "offsetInBeginSection": 842,
                    "offsetInEndSection": 1027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26434730",
                    "text": "BACKGROUND High-throughput bacterial 16S rRNA gene sequencing followed by clustering of short sequences into operational taxonomic units (OTUs) is widely used for microbiome profiling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21121044",
                    "text": "16S rRNA gene sequencing has been widely used for probing the species structure of a variety of environmental bacterial communities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21121044",
                    "text": "Both approaches have their limitations-16S rRNA sequencing may be biased because of unequal amplification of species' 16S rRNA genes, whereas shotgun metagenomic sequencing may not be deep enough to detect the 16S rRNA genes of rare species in a community.",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21240067",
                    "text": "RESULTS Conventional PCR based 16S rRNA gene sequencing and the alignment of the isolate 16S rRNA gene sequence with reference sequences accurately identified 100% of clinical strains of aerobic Actinomycetes.",
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 880,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613736",
                    "text": "For accurate identification at the species level, restriction fragment length polymorphisms (RFLP) in the hsp65 and partial 16S rRNA genes and full gene sequencing of the 16S rRNA gene were used.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 647,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27613736",
                    "text": "Full gene sequencing of the 16S rRNA gene identified Nocardia cyriacigeorgica, N. otitidiscaviarum, Nocardia farcinica, Nocardia transvalensis, and N. nova.",
                    "offsetInBeginSection": 917,
                    "offsetInEndSection": 1073,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a723cd12dc08e987e00000b",
            "body": "Can CD55 deficiency cause thrombosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22696589",
                "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                "http://www.ncbi.nlm.nih.gov/pubmed/23020629",
                "http://www.ncbi.nlm.nih.gov/pubmed/19502272",
                "http://www.ncbi.nlm.nih.gov/pubmed/28516949",
                "http://www.ncbi.nlm.nih.gov/pubmed/11843289",
                "http://www.ncbi.nlm.nih.gov/pubmed/16908271",
                "http://www.ncbi.nlm.nih.gov/pubmed/15004194",
                "http://www.ncbi.nlm.nih.gov/pubmed/26205796",
                "http://www.ncbi.nlm.nih.gov/pubmed/22077430"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657829",
                    "text": "CONCLUSIONS CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (the CHAPLE syndrome) is caused by abnormal complement activation due to biallelic loss-of-function mutations in CD55.",
                    "offsetInBeginSection": 1242,
                    "offsetInEndSection": 1479,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516949",
                    "text": "The gene product of PIGA is required for the biosynthesis of glycosylphosphatidylinositol (GPI) anchors; thus, PIGA mutations lead to a deficiency of GPI-anchored proteins, such as complement decay-accelerating factor (also known as CD55) and CD59 glycoprotein (CD59), which are both complement inhibitors.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 674,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28516949",
                    "text": "Eculizumab, a monoclonal antibody complement inhibitor, is highly effective and the only licensed therapy for PNH.",
                    "offsetInBeginSection": 1340,
                    "offsetInEndSection": 1454,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11843289",
                    "text": "Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder characterized by a decrease or absence of glycosylphosphatidylinositol (GPI)-anchored molecules such as CD55 and CD59 from the surface of affected cells, resulting in intravascular hemolysis, cytopenia, and venous thrombosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16908271",
                    "text": "Paroxysmal nocturnal hemoglobinuria (PNH) results when cells have a somatic defect in the synthesis of GPI anchors and lack CD55 and CD59, as well as CD52.",
                    "offsetInBeginSection": 200,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16908271",
                    "text": "Campath-1H therapy is directed to CD52, a small mw protein that has a glycosylphosphatidylinositol (GPI) anchor, which has a conventional structure similar to other GPI anchors such as CD55 and CD59.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15004194",
                    "text": "Remarkably, although CD59 deficiency alone was inconsequential, CD55/CD59 double deficiency greatly exacerbated IRI.",
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15004194",
                    "text": "Complement depletion in CD55(-/-)CD59(-/-) mice with cobra venom factor prevented these effects.",
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1126,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26205796",
                    "text": "Somatic mutation in the phosphatidylinositol glycan class A (PIG-A), X-linked gene, is responsible for a deficiency in glycosphosphatidylinositol-anchored proteins (GPI-AP).",
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22077430",
                    "text": "Deficiency of the GPI-anchored complement inhibitors CD55 and CD59 on erythrocytes leads to intravascular hemolysis upon complement activation.",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7633a89e632bc066000002",
            "body": "What is the purpose of the Tabix tool?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                "http://www.ncbi.nlm.nih.gov/pubmed/25192739",
                "http://www.ncbi.nlm.nih.gov/pubmed/29087450",
                "http://www.ncbi.nlm.nih.gov/pubmed/25273104",
                "http://www.ncbi.nlm.nih.gov/pubmed/9723930",
                "http://www.ncbi.nlm.nih.gov/pubmed/17911868",
                "http://www.ncbi.nlm.nih.gov/pubmed/23616864",
                "http://www.ncbi.nlm.nih.gov/pubmed/25957240",
                "http://www.ncbi.nlm.nih.gov/pubmed/25125788"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                    "text": "Tabix is implemented as a free command-line tool as well as a library in C, Java, Perl and Python.",
                    "offsetInBeginSection": 335,
                    "offsetInEndSection": 433,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208982",
                    "text": "UNLABELLED Tabix is the first generic tool that indexes position sorted files in TAB-delimited formats such as GFF, BED, PSL, SAM and SQL export, and quickly retrieves features overlapping specified regions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "CONCLUSIONS GFF3sort is a novel tool to sort GFF3 files for tabix indexing.",
                    "offsetInBeginSection": 942,
                    "offsetInEndSection": 1017,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "The latest version of JBrowse supports rendering sorted GFF3 files indexed by tabix, a novel strategy that is more convenient than the original conversion process.",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29137598",
                    "text": "RESULTS We developed GFF3sort, a script to sort GFF3 files for tabix indexing.",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25192739",
                    "text": "SUMMARY We describe mod_bio, a set of modules for the Apache HTTP server that allows the users to access and query fastq, tabix, fasta and bam files through a Web browser.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25273104",
                    "text": "WhopGenome can also read other Tabix-indexed files and create indices to allow fast selective access to FASTA-formatted sequence files.",
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9723930",
                    "text": "The purpose of the present study was to analyze retrieval of instruction of use, mechanical problem solving, and actual tool use in patients with apraxia due to circumscribed lesions of the left hemisphere.",
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 779,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957240",
                    "text": "MATERIAL AND METHODS Three tools (Lyra conical tool \u00d81 mm; GACD SASU, Lyra conical tool \u00d81.05 mm; GACD SASU, and Cerec cylinder pointed tool 12S; Sirona Dental Systems GmbH) and 3 CAD/CAM materials (Lava Ultimate; 3M ESPE, Mark II; VITA Zahnfabrik H. Rauter GmbH, and Enamic; VITA Zahnfabrik H. Rauter GmbH) were tested.",
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 750,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957240",
                    "text": "PURPOSE The purpose of this pilot study was to investigate the influence of the CAD/CAM tool-material couple on tool wear and surface roughness after milling.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 425,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9929ed1d1251d03b000009",
            "body": "What is maternal spindle transfer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                "http://www.ncbi.nlm.nih.gov/pubmed/28429249",
                "http://www.ncbi.nlm.nih.gov/pubmed/28852557",
                "http://www.ncbi.nlm.nih.gov/pubmed/8416845",
                "http://www.ncbi.nlm.nih.gov/pubmed/23949421",
                "http://www.ncbi.nlm.nih.gov/pubmed/28683668",
                "http://www.ncbi.nlm.nih.gov/pubmed/12398808",
                "http://www.ncbi.nlm.nih.gov/pubmed/29121011",
                "http://www.ncbi.nlm.nih.gov/pubmed/28385334",
                "http://www.ncbi.nlm.nih.gov/pubmed/11139230"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973714",
                    "text": "Maternal spindle transfer is, in principle, morally permissible, but only when we have beforehand preselected a sperm and an egg for our reproductive purpose.",
                    "offsetInBeginSection": 992,
                    "offsetInEndSection": 1150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28429249",
                    "text": "This paper examines whether there are moral differences between the mitochondrial replacement techniques that have been recently developed in order to help women afflicted by mitochondrial DNA diseases to have genetically related children\u00a0absent such conditions: maternal spindle transfer (MST) and pronuclear transfer (PNT).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8416845",
                    "text": "To determine when the reproductive capacity of the maternal centrosome is degraded, we transfer meiosis I and meiosis II spindles from just fertilized eggs into other zygotes that are in prophase of first mitosis.",
                    "offsetInBeginSection": 798,
                    "offsetInEndSection": 1011,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8416845",
                    "text": "These observations indicate that the reproductive capacity of maternal centrosomes is degraded during meiosis I, not during oogenesis.",
                    "offsetInBeginSection": 1786,
                    "offsetInEndSection": 1920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8416845",
                    "text": "Meiosis I spindles are stable during first mitosis and are disassembled in first telophase in concert with the host spindle.",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28683668",
                    "text": "In the discussions leading up to the enactment of the UK Human Fertilisation and Embryology (Mitochondrial Donation) Regulations 2015, it was repeatedly emphasised, by many commentators, that maternal spindle transfer (MST) and pronuclear transfer (PNT) did not give rise to children who could be considered as having three or more parents.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12398808",
                    "text": "The meiotic spindle is crucial for normal chromosome alignment and separation of maternal chromosomes during meiosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29121011",
                    "text": "MRT aims to avoid pathogenic mtDNA transmission between generations by maternal spindle transfer, pronuclear transfer or polar body transfer: all involve the transfer of nuclear DNA from an egg or zygote containing defective mitochondria to a corresponding egg or zygote with normal mitochondria.",
                    "offsetInBeginSection": 592,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28385334",
                    "text": "Experimental spindle transfer in metaphase II oocytes, also called mitochondrial replacement therapy, is a novel technology for preventing mtDNA transmission from oocytes to pre-implantation embryos.",
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11139230",
                    "text": "Abnormal oocyte spindle due to the improper function of ooplasm is associated with female infertility of advanced maternal age.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a96c74cfcd1d6a10c000029",
            "body": "What illness is transmitted by the Lone Star Tick, Amblyomma americanum?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                "http://www.ncbi.nlm.nih.gov/pubmed/19054615",
                "http://www.ncbi.nlm.nih.gov/pubmed/19874183",
                "http://www.ncbi.nlm.nih.gov/pubmed/20380308",
                "http://www.ncbi.nlm.nih.gov/pubmed/18452807",
                "http://www.ncbi.nlm.nih.gov/pubmed/20496596",
                "http://www.ncbi.nlm.nih.gov/pubmed/23637969",
                "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                "http://www.ncbi.nlm.nih.gov/pubmed/27729288",
                "http://www.ncbi.nlm.nih.gov/pubmed/19378409"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "In addition to others, species of Rickettsia, Ehrlichia, and Borrelia are all transmitted by the lone star tick.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 372,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19054615",
                    "text": "We reviewed scientific literature pertaining to known and putative disease agents associated with the lone star tick, Amblyomma americanum.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19874183",
                    "text": "Borrelia lonestari, which has been suggested as a possible causative agent of southern tick-associated rash illness, naturally infects white-tailed deer (WTD; Odocoileus virginianus) and is transmitted by the lone star tick (Amblyomma americanum).",
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 345,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20380308",
                    "text": "The lone star tick, Amblyomma americanum (Acari: Ixodidae), is commonly reported from people and animals throughout the eastern U.S. and is associated with transmission of a number of emerging diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18452807",
                    "text": "Lyme-like illness (also known as southern tick-associated rash illness [STARI] or Masters disease) is vectored by the Lone Star tick (Amblyomma americanum).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20496596",
                    "text": "In this study, we evaluated Amblyomma americanum (lone star tick) in Mississippi for the presence of Ehrlichia chaffeensis, causative agent of human monocytic ehrlichiosis; Ehrlichia ewingii, causative agent of human and canine granulocytic ehrlichiosis; Borrelia lonestari, putative agent of southern tick-associated rash illness; Francisella tularensis, the agent of tularemia; and Rickettsia spp., particularly R. amblyommii, a suspected pathogen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23637969",
                    "text": "Here we sought to characterize the growth characteristics and genome of Lone Star virus (LSV), an unclassified bunyavirus originally isolated from the lone star tick Amblyomma americanum.",
                    "offsetInBeginSection": 362,
                    "offsetInEndSection": 549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                    "text": "Amblyomma americanum, the lone star tick, comprised 99.6% of 6,502 specimens collected in suburban landscapes.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27729288",
                    "text": "Monocytic ehrlichiosis in people caused by the intracellular bacterium, Ehrlichia chaffeensis, is an emerging infectious disease transmitted by the lone star tick, Amblyomma americanum.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa50086d6d6b54f7900000c",
            "body": "Which is the function of ubiquilins?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24674348",
                "http://www.ncbi.nlm.nih.gov/pubmed/18307982",
                "http://www.ncbi.nlm.nih.gov/pubmed/22628307",
                "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                "http://www.ncbi.nlm.nih.gov/pubmed/26152284",
                "http://www.ncbi.nlm.nih.gov/pubmed/27345149",
                "http://www.ncbi.nlm.nih.gov/pubmed/17603015",
                "http://www.ncbi.nlm.nih.gov/pubmed/25511991",
                "http://www.ncbi.nlm.nih.gov/pubmed/26225865",
                "http://www.ncbi.nlm.nih.gov/pubmed/18241885"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674348",
                    "text": "BACKGROUND Ubiquilins are proteins that function as ubiquitin receptors in eukaryotes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18307982",
                    "text": "Our data suggest that Herp binding to ubiquilin proteins plays an important role in the ERAD pathway and that ubiquilins are specifically involved in degradation of only a subset of ubiquitinated targets, including Herp-dependent ERAD substrates.",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22628307",
                    "text": "Ubiquilins, a family of ubiquitin-binding proteins, are involved in all protein degradation pathways.",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                    "text": "Ubiquilins (UBQLN), a family of adaptor proteins with partial homology with ubiquitin, are proposed to facilitate proteasomal degradation of ubiquitinated substrates.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398896",
                    "text": "This protective function requires the essential autophagy regulators, Atg5 and Atg7.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26152284",
                    "text": "Ubiquilin-2 inclusions co-localized with ubiquitin, p62/SQSTM, optineurin, and occasionally TDP-43, but were negative for \u03b1-synuclein, neurofilament, tau, and FUS.",
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345149",
                    "text": "Loss of Ubiquilins by genetic ablation or sequestration in polyglutamine aggregates leads to accumulation of non-inserted mitochondrial membrane protein precursors.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 883,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26225865",
                    "text": "Thus, polymorphisms in ubiquilins, which are known to influence susceptibility to neurodegenerative illnesses, might also play a role in host defense against Mtb.",
                    "offsetInBeginSection": 1287,
                    "offsetInEndSection": 1449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26225865",
                    "text": "In autophagy-deficient macrophages, UBQLN1 accumulates around Mtb, consistent with the idea that it marks bacilli that traffic through the autophagy pathway.",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 1010,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18241885",
                    "text": "Ubiquilin/PLIC proteins belong to the family of UBL-UBA proteins implicated in the regulation of the ubiquitin-dependent proteasomal degradation of cellular proteins.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7240aa2dc08e987e00000d",
            "body": "List two human monoclonal antibodies against Clostridium difficile toxins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20089970",
                "http://www.ncbi.nlm.nih.gov/pubmed/23629713",
                "http://www.ncbi.nlm.nih.gov/pubmed/28274145",
                "http://www.ncbi.nlm.nih.gov/pubmed/1900059",
                "http://www.ncbi.nlm.nih.gov/pubmed/16966409",
                "http://www.ncbi.nlm.nih.gov/pubmed/1378062",
                "http://www.ncbi.nlm.nih.gov/pubmed/20150758",
                "http://www.ncbi.nlm.nih.gov/pubmed/25924765",
                "http://www.ncbi.nlm.nih.gov/pubmed/23389929",
                "http://www.ncbi.nlm.nih.gov/pubmed/1500512"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970",
                    "text": "CONCLUSIONS The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection.",
                    "offsetInBeginSection": 1561,
                    "offsetInEndSection": 1723,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20089970",
                    "text": "METHODS We performed a randomized, double-blind, placebo-controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins A (CDA1) and B (CDB1).",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 327,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713",
                    "text": "C. difficile mediates diarrhea and colitis by releasing two toxins, toxin A and toxin B.",
                    "offsetInBeginSection": 123,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23629713",
                    "text": "Recent studies indicated that human monoclonal antibodies (MAbs) against toxins A and B reduce their cytotoxic and secretory activities and prevent CDI in hamsters.",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1900059",
                    "text": "The pathogenicity of Clostridium difficile is due to the production of two toxins (toxins A and B).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1900059",
                    "text": "These data show that passive immunity induced by monoclonal antibodies against toxin A was effective against pseudomembranous cecitis.",
                    "offsetInBeginSection": 826,
                    "offsetInEndSection": 960,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1378062",
                    "text": "Five mouse monoclonal antibodies (MAbs) against Clostridium difficile toxin B have been raised and characterized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150758",
                    "text": "The pathogenicity of Clostridium difficile (C. difficile) is mediated by the release of two toxins, A and B.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25924765",
                    "text": "CDI is mediated by two large exotoxins, toxins A and B.",
                    "offsetInBeginSection": 360,
                    "offsetInEndSection": 415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23389929",
                    "text": "Clostridium difficile produces two major virulence toxins, toxin A (TcdA) and toxin B (TcdB).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76344e9e632bc066000003",
            "body": "Which algorithms are used for compression of SAM files?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29046896",
                "http://www.ncbi.nlm.nih.gov/pubmed/22164252",
                "http://www.ncbi.nlm.nih.gov/pubmed/26026138",
                "http://www.ncbi.nlm.nih.gov/pubmed/23533605",
                "http://www.ncbi.nlm.nih.gov/pubmed/27540265",
                "http://www.ncbi.nlm.nih.gov/pubmed/23148484",
                "http://www.ncbi.nlm.nih.gov/pubmed/23066097",
                "http://www.ncbi.nlm.nih.gov/pubmed/25395305",
                "http://www.ncbi.nlm.nih.gov/pubmed/27663496",
                "http://www.ncbi.nlm.nih.gov/pubmed/24368726"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29046896",
                    "text": "In this work we propose a new reference-based compressor for SAM files, which can accommodate different levels of compression, based on the specific needs of the user.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 515,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22164252",
                    "text": "In this paper, we present SAMZIP, a specialized encoding scheme, for sequence alignment data in SAM (Sequence Alignment/Map) format, which improves the compression ratio of existing compression tools available.",
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533605",
                    "text": "These are compared against existing algorithms for both reference based compression (CRAM, Goby) and non-reference based compression (DSRC, BAM) and other recently published competition entries (Quip, SCALCE).",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 542,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540265",
                    "text": "RESULTS We describe CSAM (Compressed SAM format), a compression approach offering lossless and lossy compression for SAM files.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23066097",
                    "text": "The enormous size of these data motivates the development of data compression algorithms usable for the implementation of the various storage policies that are applied to the produced intermediate and final result files.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27663496",
                    "text": "The algorithm reads the SAM files generated by the alignment algorithms using multiple command option values.",
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 979,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27663496",
                    "text": "Most of the algorithms (Bowtie, Bowtie 2, SHRiMP2, Soap 2, Novoalign) provide similar results with subtle variations.",
                    "offsetInBeginSection": 1384,
                    "offsetInEndSection": 1501,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27663496",
                    "text": "Based on the quality scores of the reads, we propose to calculate a lower bound of the probability of alignment of any fast alignment algorithm that generates SAM files.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 363,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24368726",
                    "text": "METHODS We developed Hierarchical mUlti-reference Genome cOmpression (HUGO), a novel compression algorithm for aligned reads in the sorted Sequence Alignment/Map (SAM) format.",
                    "offsetInBeginSection": 351,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24368726",
                    "text": "CONCLUSIONS The proposed multi-reference-based compression algorithm for aligned reads outperforms existing single-reference based algorithms.",
                    "offsetInBeginSection": 1786,
                    "offsetInEndSection": 1928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a992b371d1251d03b00000a",
            "body": "What does MetaHIT stand for?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                "http://www.ncbi.nlm.nih.gov/pubmed/25291122",
                "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                "http://www.ncbi.nlm.nih.gov/pubmed/28357466",
                "http://www.ncbi.nlm.nih.gov/pubmed/24486053",
                "http://www.ncbi.nlm.nih.gov/pubmed/23431991",
                "http://www.ncbi.nlm.nih.gov/pubmed/23140990",
                "http://www.ncbi.nlm.nih.gov/pubmed/24349412",
                "http://www.ncbi.nlm.nih.gov/pubmed/24997786",
                "http://www.ncbi.nlm.nih.gov/pubmed/23326225"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24949196",
                    "text": "RESULTS IN THIS STUDY WE CONDUCTED A SYSTEMATIC COMPARISON OF THE DNA EXTRACTION METHODS USED BY THE TWO MAJOR COLLABORATIVE EFFORTS: The European MetaHIT and the American Human Microbiome Project (HMP).",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24416266",
                    "text": "In this paper, we use publicly available data from the Human Microbiome Project (HMP) and MetaHIT, both surveys of healthy adults that include obese individuals, plus two smaller studies that specifically examined lean versus obese adults.",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 658,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28357466",
                    "text": "The goals of the Human Microbiome Project and MetaHIT include comparative studies of healthy and diseased individuals.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 583,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24486053",
                    "text": "Comprehensive microbial community surveys such as MetaHit and the Human Microbiome Project have described the composition and molecular functional profile of the healthy (normal) intestinal microbiome.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 331,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23431991",
                    "text": "The importance of microbiome constituency is so relevant that several consortia like the Human Microbiome project (HMP) and Metagenomics of the Human Intestinal Tract (MetaHIT) project are focusing mainly on the human microbiome.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 688,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23140990",
                    "text": "Advances in computing and high-throughput sequencing have enabled population-level surveys such as MetaHIT and the recently released Human Microbiome Project, detailed investigations of the microbiome in human disease, and mechanistic studies employing gnotobiotic model organisms.",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24349412",
                    "text": "The stlA gene is rare when searched against human metagenome datasets such as MetaHit and the Human Microbiome Project and represents a novel and unique salt tolerance determinant which appears to be found exclusively in the human gut environment.",
                    "offsetInBeginSection": 759,
                    "offsetInEndSection": 1006,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24997786",
                    "text": "Here we combined 249 newly sequenced samples of the Metagenomics of the Human Intestinal Tract (MetaHit) project with 1,018 previously sequenced samples to create a cohort from three continents that is at least threefold larger than cohorts used for previous gene catalogs.",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326225",
                    "text": "We tested how the following factors influenced the detection of enterotypes: clustering methodology, distance metrics, OTU-picking approaches, sequencing depth, data type (whole genome shotgun (WGS) vs.16S rRNA gene sequence data), and 16S rRNA region.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 562,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326225",
                    "text": "We included 16S rRNA gene sequences from the Human Microbiome Project (HMP) and from 16 additional studies and WGS sequences from the HMP and MetaHIT.",
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 713,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981dd0fcd1d6a10c00002e",
            "body": "Are sleep apnea and snoring associated with cardiac arrhythmias?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                "http://www.ncbi.nlm.nih.gov/pubmed/1630643",
                "http://www.ncbi.nlm.nih.gov/pubmed/3106890",
                "http://www.ncbi.nlm.nih.gov/pubmed/18024169",
                "http://www.ncbi.nlm.nih.gov/pubmed/207245",
                "http://www.ncbi.nlm.nih.gov/pubmed/15653957",
                "http://www.ncbi.nlm.nih.gov/pubmed/9852540",
                "http://www.ncbi.nlm.nih.gov/pubmed/17511585",
                "http://www.ncbi.nlm.nih.gov/pubmed/3313692"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                    "text": "We conclude that patients with sleep apnea as a group have higher prevalence of cardiac arrhythmias than nonapneic patients and that snoring alone, without concomitant sleep apnea, is not associated with increased frequency of cardiac arrhythmias.",
                    "offsetInBeginSection": 1446,
                    "offsetInEndSection": 1693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7774322",
                    "text": "We investigated the frequency of cardiac arrhythmias in patients suspected of having sleep apnea, and related them to the severity of apnea, snoring, and nocturnal hypoxemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2669355",
                    "text": "Sleep apnea and obstructive snoring are sleep related breathing disorders (SRBD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1630643",
                    "text": "Increasing evidence suggests that snoring and sleep apnea are associated with cerebrovascular diseases.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1630643",
                    "text": "Potential mediators among snoring, obstructive sleep apneas, and stroke include cardiac arrhythmias and other hemodynamic disturbances, increased levels of catecholamines, and disturbances in cerebral blood flow caused by sleep apneas, as well as hypoxemic periods that may potentiate atherosclerosis.",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 999,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3106890",
                    "text": "Severe snoring may be associated with pulmonary and systemic hypertension, secondary polycythemia, and cardiac arrhythmias.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18024169",
                    "text": "BACKGROUND AND PURPOSE Nocturnal cardiac arrhythmias occur in patients with obstructive sleep apnea (OSA), reportedly as a consequence of the autonomic effects of recurrent apnea with subsequent oxygen desaturation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/207245",
                    "text": "Patients with the hypersomnia-sleep apnea syndrome should be provided with a tracheal opening during sleep when severe daytime somnolence, cardiac arrhythmias, and hypertension are present.",
                    "offsetInBeginSection": 735,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15653957",
                    "text": "STUDY OBJECTIVES To compare the frequency of daytime and nocturnal cardiac arrhythmias and ST-segment depression episodes among patients with obstructive sleep apnea-hypopnea syndrome (OSAHS), snoring subjects, and healthy subjects, and to analyze the relationship between the cardiac disturbances, sleep characteristics, and sympathetic tone in patients with OSAHS.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3313692",
                    "text": "Hypersomnia in association with snoring usually signifies obstructive sleep apnea.",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa80873d6d6b54f79000013",
            "body": "List ribosomal biogenesis proteins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28685141",
                "http://www.ncbi.nlm.nih.gov/pubmed/17475909",
                "http://www.ncbi.nlm.nih.gov/pubmed/20188109",
                "http://www.ncbi.nlm.nih.gov/pubmed/25575543",
                "http://www.ncbi.nlm.nih.gov/pubmed/28986221",
                "http://www.ncbi.nlm.nih.gov/pubmed/17804668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19006815",
                "http://www.ncbi.nlm.nih.gov/pubmed/18773413",
                "http://www.ncbi.nlm.nih.gov/pubmed/12957375",
                "http://www.ncbi.nlm.nih.gov/pubmed/19878869"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28685141",
                    "text": "These factors include snoRNPs, nucleases, ATPases, GTPases, RNA helicases, and a vast list of proteins with no predicted enzymatic activity.",
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17475909",
                    "text": "SBDS forms a protein complex with nucleophosmin, a multifunctional protein implicated in ribosome biogenesis and leukemogenesis.",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17475909",
                    "text": "SBDS migrates together with the 60S large ribosomal subunit in sucrose gradients and coprecipitates with 28S ribosomal RNA (rRNA).",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17475909",
                    "text": "Human SBDS is enriched in the nucleolus, the major cellular site of ribosome biogenesis.",
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20188109",
                    "text": "Ribosome biogenesis is facilitated by a growing list of assembly cofactors, including helicases, GTPases, chaperones, and other proteins, but the specific functions of many of these assembly cofactors are still unclear.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25575543",
                    "text": "Ribosomopathies are largely congenital diseases linked to defects in ribosomal proteins or biogenesis factors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28986221",
                    "text": "Unlike most ribosomal proteins, which are incorporated into pre-ribosomal particles during early steps of ribosome biogenesis in the nucleus, P-stalk proteins are attached to the 60S subunit in the cytoplasm.",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 627,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19006815",
                    "text": "The KsgA protein is a universally conserved methyltransferase that dimethylates both A1518 and A1519 of the 16S rRNA of the small ribosomal subunit.",
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18773413",
                    "text": "One newly identified key regulator for ribosomal biogenesis and translation is the oncoprotein c-Myc, whose aberrantly excessive level and activity are highly associated with human cancers, too.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19878869",
                    "text": "The ribosomal protein-MDM2-p53 signaling pathway provides a molecular switch that may constitute a surveillance network monitoring the integrity of ribosomal biogenesis.",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7339372dc08e987e000013",
            "body": "List drugs that are included in the Vosevi polypill.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                "http://www.ncbi.nlm.nih.gov/pubmed/27538505",
                "http://www.ncbi.nlm.nih.gov/pubmed/22570437",
                "http://www.ncbi.nlm.nih.gov/pubmed/26747390",
                "http://www.ncbi.nlm.nih.gov/pubmed/24561141",
                "http://www.ncbi.nlm.nih.gov/pubmed/26652213",
                "http://www.ncbi.nlm.nih.gov/pubmed/29127755",
                "http://www.ncbi.nlm.nih.gov/pubmed/26390808",
                "http://www.ncbi.nlm.nih.gov/pubmed/25944629",
                "http://www.ncbi.nlm.nih.gov/pubmed/26497041"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                    "text": "Polypill is a medication designed for preventing heart attacks through a combination of drugs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                    "text": "This paper investigates a new methodology for the control dosage of a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and simvastatin in a 12.5/2.5/25/40 weight ratio.",
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27818251",
                    "text": "Amlodipine, losartan and simvastatin were released from the polypill-MSN-41 system in a controlled way.",
                    "offsetInBeginSection": 1103,
                    "offsetInEndSection": 1206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22570437",
                    "text": "OBJECTIVE To evaluate the efficacy and safety of the polypill for prevention of cardiovascular disease (CVD) and stroke and to present literature related to the polypill components (statin, aspirin, antihypertensive) for primary prevention of CVD and stroke.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26652213",
                    "text": "The fixed combination of acetylsalicylic acid 100 mg + ramipril 2.5, 5, or 10 mg + either simvastatin 40 mg or atorvastatin 20 mg is the unique cardiovascular polypill that has been registered in 22 countries worldwide.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127755",
                    "text": "Right combination of drugs in the polypill might be a suitable solving of CV disease and diabetes prevention for the patients with metabolic syndrome.Key words: cardiometabolic risk - cardiovascular disease prevention - metabolic syndrome - polypill.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1056,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127755",
                    "text": "Right now polypill (fixed combination of antihypertensives and lipid modifying drugs) are solving in the CV disease prevention.",
                    "offsetInBeginSection": 546,
                    "offsetInEndSection": 673,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26390808",
                    "text": "The polypill here represents a cardiovascular treatment regime with the incorporation of an immediate release compartment with aspirin and hydrochlorothiazide and three sustained release compartments containing pravastatin, atenolol, and ramipril.",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 801,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25944629",
                    "text": "ANZCTRN 12608000583347.",
                    "offsetInBeginSection": 2089,
                    "offsetInEndSection": 2112,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26497041",
                    "text": "Among patients not taking the full complement of recommended CVD preventive therapies, use of a polypill-based strategy (i.e.",
                    "offsetInBeginSection": 467,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7639419e632bc066000005",
            "body": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                "http://www.ncbi.nlm.nih.gov/pubmed/22715364",
                "http://www.ncbi.nlm.nih.gov/pubmed/28961695",
                "http://www.ncbi.nlm.nih.gov/pubmed/19537160",
                "http://www.ncbi.nlm.nih.gov/pubmed/22960368",
                "http://www.ncbi.nlm.nih.gov/pubmed/17428441",
                "http://www.ncbi.nlm.nih.gov/pubmed/15963230",
                "http://www.ncbi.nlm.nih.gov/pubmed/26728066",
                "http://www.ncbi.nlm.nih.gov/pubmed/17274771",
                "http://www.ncbi.nlm.nih.gov/pubmed/28989035"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "Results Here, we present a prediction algorithm using deep neural networks to predict protein subcellular localization relying only on sequence information.",
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 692,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036616",
                    "text": "At its core, the prediction model uses a recurrent neural network that processes the entire protein sequence and an attention mechanism identifying protein regions important for the subcellular localization.",
                    "offsetInBeginSection": 693,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19537160",
                    "text": "Here, we present two machine learning approaches for prediction of the subcellular localization of a protein from the primary sequence information.",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 709,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960368",
                    "text": "This algorithm could significantly improve the prediction accuracy for the subcellular localizations of membrane proteins.",
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 897,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960368",
                    "text": "In this paper, we proposed a novel prediction algorithm, namely Projected Gene Ontology Score, which introduces the Gene Ontology annotation as a descriptor of the protein.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 774,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17428441",
                    "text": "In this report, using a machine learning approach, the Nearest Neighbor Algorithm (NNA), we developed a prediction system for protein SL in which we incorporated a protein functional domain profile.",
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15963230",
                    "text": "RESULTS In this paper, we propose a new algorithm called pSLIP which uses Support Vector Machines (SVMs) in conjunction with multiple physicochemical properties of amino acids to predict protein subcellular localization in eukaryotes across six different locations, namely, chloroplast, cytoplasmic, extracellular, mitochondrial, nuclear and plasma membrane.",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 959,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15963230",
                    "text": "CONCLUSION This study presents a physicochemical property based protein localization prediction algorithm.",
                    "offsetInBeginSection": 1157,
                    "offsetInEndSection": 1263,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17274771",
                    "text": "In silico prediction of protein subcellular localization based on amino acid sequence can reveal valuable information about the protein's innate roles in the cell.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28989035",
                    "text": "In this study, by using the multi-label theory, we developed a new predictor called \"pLoc-mGneg\" for predicting the subcellular localization of Gram-negative bacterial proteins with both single and multiple locations.",
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a99332a1d1251d03b00000e",
            "body": "How is Hsd17b1 associated with endometriosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20586553",
                "http://www.ncbi.nlm.nih.gov/pubmed/28405865",
                "http://www.ncbi.nlm.nih.gov/pubmed/25403437",
                "http://www.ncbi.nlm.nih.gov/pubmed/15640252",
                "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                "http://www.ncbi.nlm.nih.gov/pubmed/26261478",
                "http://www.ncbi.nlm.nih.gov/pubmed/24012197",
                "http://www.ncbi.nlm.nih.gov/pubmed/24411031",
                "http://www.ncbi.nlm.nih.gov/pubmed/22878119",
                "http://www.ncbi.nlm.nih.gov/pubmed/21958689"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20586553",
                    "text": "RESULTS The HSD17B1 A/G SNP A allele increased overall endometriosis risk and the risk of stage I-II disease, while ESR1 longer (TA)(n) repeats only correlated with susceptibility to stage I-II endometriosis.",
                    "offsetInBeginSection": 755,
                    "offsetInEndSection": 963,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20586553",
                    "text": "CONCLUSIONS Genetic variants in ESR1, ESR2, and HSD17B1 genes could modify susceptibility to endometriosis and might influence the fertility status in endometriosis patients.",
                    "offsetInBeginSection": 1294,
                    "offsetInEndSection": 1468,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865",
                    "text": "RESULTS Statistical analysis demonstrated that the HSD17B1 937 A>G SNP is associated with endometriosis in stages I and II.",
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 721,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28405865",
                    "text": "CONCLUSION Our genetic study demonstrated HSD17B1 937 G variant as a risk factor for infertility in women with stage I and II endometriosis in Polish Caucasian patients.",
                    "offsetInBeginSection": 1300,
                    "offsetInEndSection": 1469,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252",
                    "text": "The A-allele of HSD17B1 appears to confer higher risk for endometriosis.",
                    "offsetInBeginSection": 1377,
                    "offsetInEndSection": 1449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15640252",
                    "text": "Here, we evaluated whether the risk and severity of endometriosis are associated with polymorphisms in estradiol-synthesizing enzyme genes: the Ser312Gly polymorphism in 17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) and the Arg264Cys polymorphism in cytochrome P450, subfamily XIX (CYP19).",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 430,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                    "text": "The findings of our study suggest that HSD17B1 and PR polymorphisms are associated with an increased risk of endometriosis.",
                    "offsetInBeginSection": 1079,
                    "offsetInEndSection": 1202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22613790",
                    "text": "Twenty-seven studies on the association of the cytochrome P450 subfamily 17 (CYP17), estrogen receptor gene (ER), progesterone receptor gene (PR), 17-beta-hydroxysteroid dehydrogenase type 1 gene (HSD17B1), and cytochrome P450 subfamily 19 (CYP19) polymorphisms with endometriosis risk were identified.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 520,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24012197",
                    "text": "Ratios between pro- and antiestrogenic enzymes (STS/EST and HSD17B1/HSD17B2) were more in favor of estrogens in ovarian and rectovaginal endometriosis.",
                    "offsetInBeginSection": 1376,
                    "offsetInEndSection": 1527,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22878119",
                    "text": "Our results show that application of medroxyprogestrone acetate, dydrogesterone and dienogest significantly decreases HSD17B1 and CYP19A1 expression and significantly increases HSD17B2 expression.",
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1062,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9eb008d6d6b54f79000001",
            "body": "List the continent of origin for the brown marmorated stinkbug(Halyomorpha halys)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18069789",
                "http://www.ncbi.nlm.nih.gov/pubmed/24586332",
                "http://www.ncbi.nlm.nih.gov/pubmed/28984006",
                "http://www.ncbi.nlm.nih.gov/pubmed/25587021",
                "http://www.ncbi.nlm.nih.gov/pubmed/29069361",
                "http://www.ncbi.nlm.nih.gov/pubmed/28852110",
                "http://www.ncbi.nlm.nih.gov/pubmed/28824355",
                "http://www.ncbi.nlm.nih.gov/pubmed/24787576",
                "http://www.ncbi.nlm.nih.gov/pubmed/28824354",
                "http://www.ncbi.nlm.nih.gov/pubmed/27744285"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18069789",
                    "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l), is a polyphagous pest indigenous to northeastern Asia where it damages various trees, vegetables, and leguminous crops.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24586332",
                    "text": "We examined the salivary gland structure of the brown marmorated stink bug (Pentatomidae: Halyomorpha halys) and developed methods for independent collection of watery saliva and sheath saliva.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28984006",
                    "text": "We describe a unique microsporidian species that infects the green stink bug, Chinavia hilaris; the brown marmorated stink bug, Halyomorpha halys; the brown stink bug, Euschistus servus; and the dusky stink bug, Euschistus tristigmus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25587021",
                    "text": "Phytophagous pentatomid insects can negatively impact agricultural productivity and the brown marmorated stink bug (Halyomorpha halys) is an emerging invasive pest responsible for damage to many fruit crops and ornamental plants in North America.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 246,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29069361",
                    "text": "The invasive brown marmorated stink bug, Halyomorpha halys (St\u00e5l; Hemiptera: Pentatomidae), has recently emerged as a harmful pest of horticultural crops in North America and Europe.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28852110",
                    "text": "The brown marmorated stink bug (BMSB, Halyomorpha halys) is an East Asian species now established across North America and Europe, that in the Eastern United States of America (US) and Italy is causing significant economic losses to agriculture.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 432,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28824355",
                    "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l), is an invasive species native to regions of China, Japan, Korea, and Taiwan.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24787576",
                    "text": "The brown marmorated stink bug, Halyomorpha halys, a native of Asia, has become a serious invasive pest in the USA.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28824354",
                    "text": "The brown marmorated stink bug, Halyomorpha halys (St\u00e5l), native to China, Japan, and Korea, has emerged as a harmful invasive pest of a variety of crops in North America and Europe.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27744285",
                    "text": "Sampling soybean fields for the brown marmorated stink bug, Halyomorpha halys St\u00e5l (Hemiptera: Pentatomidae), can be challenging.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa82180d6d6b54f79000015",
            "body": "Are osteoclasts specialized in bone degradation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19372577",
                "http://www.ncbi.nlm.nih.gov/pubmed/9819571",
                "http://www.ncbi.nlm.nih.gov/pubmed/24992711",
                "http://www.ncbi.nlm.nih.gov/pubmed/8395372",
                "http://www.ncbi.nlm.nih.gov/pubmed/11193210",
                "http://www.ncbi.nlm.nih.gov/pubmed/10968780",
                "http://www.ncbi.nlm.nih.gov/pubmed/22941736",
                "http://www.ncbi.nlm.nih.gov/pubmed/14702187",
                "http://www.ncbi.nlm.nih.gov/pubmed/23966172",
                "http://www.ncbi.nlm.nih.gov/pubmed/3076045"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19372577",
                    "text": "Tumor cells in the bone microenvironment are able to initiate a vicious cycle of bone degradation by mobilizing osteoclasts, multinucleated cells specialized in bone degradation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9819571",
                    "text": "Osteoclasts dissolve bone mineral by massive acid secretion and secrete specialized proteinases that degrade the organic matrix, mainly type I collagen, in this acidic milieu.",
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 867,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9819571",
                    "text": "Osteoclasts are multinucleated monocyte-macrophage derivatives that degrade bone.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711",
                    "text": "These observations reveal that contrarily to bone resorption, the ability of osteoclasts to dissolve minerals is dispensable for the degradation of mineralized hypertrophic cartilage during endochondral bone formation.",
                    "offsetInBeginSection": 1646,
                    "offsetInEndSection": 1864,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24992711",
                    "text": "Osteoclasts are specialized in mineralized tissue degradation, with the combined ability to solubilize hydroxyapatite and to degrade extracellular matrix proteins.",
                    "offsetInBeginSection": 482,
                    "offsetInEndSection": 645,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8395372",
                    "text": "However, specialized differentiation for efficient bone degradation separates the osteoclast from the macrophage.",
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11193210",
                    "text": "Osteoclasts are physiological polykaryons specialized in the resorption of calcified tissue.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22941736",
                    "text": "Osteoclasts are highly specialized cells that resorb bone and contribute to bone remodeling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14702187",
                    "text": "Osteoclasts express specialized proteins including a vacuolar-type H+-ATPase that drives HCl secretion for dissolution of bone mineral.",
                    "offsetInBeginSection": 1219,
                    "offsetInEndSection": 1354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23966172",
                    "text": "Hence, bone resorption by osteoclasts is highly dependent on lysosomes, the organelles specialized in intra- and extracellular material degradation.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a733a672dc08e987e000014",
            "body": "Does temsirolimus improve survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                "http://www.ncbi.nlm.nih.gov/pubmed/24470557",
                "http://www.ncbi.nlm.nih.gov/pubmed/15998902",
                "http://www.ncbi.nlm.nih.gov/pubmed/23564811",
                "http://www.ncbi.nlm.nih.gov/pubmed/23099651",
                "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                "http://www.ncbi.nlm.nih.gov/pubmed/24313573",
                "http://www.ncbi.nlm.nih.gov/pubmed/24692729",
                "http://www.ncbi.nlm.nih.gov/pubmed/21493184"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                    "text": "CONCLUSIONS antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy.",
                    "offsetInBeginSection": 1438,
                    "offsetInEndSection": 1635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15998902",
                    "text": "BACKGROUND Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23564811",
                    "text": "The combination of temsirolimus and antibodies to vascular endothelial factor (VEGF) has not yet been investigated, but with the hypothesis that temsirolimus might provide complimentary therapeutic benefit in combination with bevacizumab, we included patients with progressive GBM after bevacizumab in an open phase II study.",
                    "offsetInBeginSection": 514,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "text": "The addition of temsirolimus to interferon did not improve survival.",
                    "offsetInBeginSection": 1823,
                    "offsetInEndSection": 1891,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "text": "Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease.",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313573",
                    "text": "Temsirolimus, one of the available mTOR inhibitors, has been approved as a single agent in poor-risk mRCC patients based on the pivotal Phase III trial showing a significant superiority in OS versus IFN-\u03b1 or temsirolimus + IFN-\u03b1, which has been verified by a pivotal Phase III trial.",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 847,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313573",
                    "text": "In second-line treatment compared with sorafenib following first-line treatment with sunitinib temsirolimus showed a relative progression-free survival benefit for patients with nonclear cell RCC with temsirolimus.",
                    "offsetInBeginSection": 1009,
                    "offsetInEndSection": 1223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24313573",
                    "text": "In the recent years, various new agents targeting VEGF or VEGF receptor (VEGFR) or the mTOR pathway have been approved for the treatment of mRCC with significant prolongation of progression-free survival and, in part, of overall survival (OS).",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493184",
                    "text": "Novel targeted agents such as bevacizumab, imatinib, erlotinib, temsirolimus, immunotherapy, cilengitide, talampanel, etc.",
                    "offsetInBeginSection": 1244,
                    "offsetInEndSection": 1366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493184",
                    "text": "are helping classical chemotherapeutic agents, like temozolomide, to achieve an increase in overall survival.",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a763b679e632bc066000006",
            "body": "Describe RIblast",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28459942",
                "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/7516089",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800283",
                "http://www.ncbi.nlm.nih.gov/pubmed/25543586",
                "http://www.ncbi.nlm.nih.gov/pubmed/23617612"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe first a field deployable mass spectrometer, based on an ion trap analyzer, and variants of that system.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We describe four sensing and characterization technologies recently developed at Los Alamos National Laboratory; a select set of mass spectral and optical techniques is emphasized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24193825",
                    "text": "We then describe a hand-held, battery-operated optical spectrometer, usable in either absorption, or fluorescence excitation mode.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 621,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18428249",
                    "text": "Several support protocols describe methods for adenovirus growth and purification, biotinylation, inactivation with psoralen, and quantitation of the adenovirus particles.",
                    "offsetInBeginSection": 279,
                    "offsetInEndSection": 450,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8140769",
                    "text": "The authors describe another subtype of antigen HLA-B27, described as HLA-B27P3.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15861591",
                    "text": "Experience of SA-RPE using the simplified technique described by Pogrel et al is describe.",
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                    "text": "We describe a rare, newly described syndrome with features of overgrowth and vascular malformations.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7516089",
                    "text": "We describe here the first case of unilateral, tubal twin pregnancy to be documented by ultrasound, with cardiac activity of two foetuses detected by the endovaginal probe.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 781,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23617612",
                    "text": "PURPOSE To describe a case of unilateral intracranial arachnoid cyst in association with enophthalmos and epiphora on the same side.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23617612",
                    "text": "We also offer hypotheses to describe the paradoxical occurrence of an expanding intracranial mass and inward growth of the orbit and paranasal sinuses.",
                    "offsetInBeginSection": 452,
                    "offsetInEndSection": 603,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a991ee21d1251d03b000005",
            "body": "Are there sex differences in the transcriptome of the mouse hippocampus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                "http://www.ncbi.nlm.nih.gov/pubmed/27053151",
                "http://www.ncbi.nlm.nih.gov/pubmed/17988385",
                "http://www.ncbi.nlm.nih.gov/pubmed/10867819",
                "http://www.ncbi.nlm.nih.gov/pubmed/21542937",
                "http://www.ncbi.nlm.nih.gov/pubmed/28344592",
                "http://www.ncbi.nlm.nih.gov/pubmed/25798087",
                "http://www.ncbi.nlm.nih.gov/pubmed/28685836",
                "http://www.ncbi.nlm.nih.gov/pubmed/26317111",
                "http://www.ncbi.nlm.nih.gov/pubmed/22173874"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28302071",
                    "text": "Additionally, this analysis reveals sex differences in the transcriptome of the developing mouse hippocampus, and further clarifies the need to include both female and male mice in longitudinal studies involving molecular changes in the hippocampus.",
                    "offsetInBeginSection": 1401,
                    "offsetInEndSection": 1650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27053151",
                    "text": "In this study, we compared the changes relative to normal littermates in the proteome and transcriptome of the hippocampus in the C57Bl/6 mouse model of MPS VII, which has well-documented histopathological and neurodegenerative changes.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17988385",
                    "text": "Each CNS region (cerebral cortex, hippocampus, striatum, cerebellum and spinal cord) possessed its own unique transcriptome fingerprint that was independent of age, gender and energy intake.",
                    "offsetInBeginSection": 422,
                    "offsetInEndSection": 612,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344592",
                    "text": "Here we define the transcriptome of developing wild type and dysbindin null Bloc1s8 mouse hippocampus in order to identify mechanisms downstream dysbindin defects.",
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25798087",
                    "text": "By analyzing RNASeq datasets, we demonstrate region specific enrichment of populations of lncRNAs and mRNAs in the mouse hippocampus and pre-frontal cortex (PFC), the two major regions of the brain involved in memory storage and neuropsychiatric disorders.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25798087",
                    "text": "The lncRNAs identified correspond to ~14% of the transcriptome of the hippocampus and PFC and ~70% of the lncRNAs annotated in the mouse genome (NCBIM37) and are localized along the chromosomes as varying numbers of clusters.",
                    "offsetInBeginSection": 607,
                    "offsetInEndSection": 832,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28685836",
                    "text": "We analyzed the transcriptome of the C57BL/6J mouse hypothalamus, hippocampus, neocortex, and cerebellum to determine estrous cycle-specific changes in these four brain regions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26317111",
                    "text": "Thus, we conclude that the postnatal age and sex differences in AR protein expression in combination with the sex differences in circulating T may cause sexual differentiation of the mouse cortex/hippocampus.",
                    "offsetInBeginSection": 1095,
                    "offsetInEndSection": 1303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26317111",
                    "text": "We demonstrated that, as age advanced, AR mRNA levels increased in the cortex/hippocampus of both sexes but showed no sex difference.",
                    "offsetInBeginSection": 661,
                    "offsetInEndSection": 794,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22173874",
                    "text": "The present study examined differences in constitutive gene expression in hippocampus in lines of mice bred for high (HA) and low (LA) swim SIA.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa0495bd6d6b54f79000002",
            "body": "What is the role of the blood-brain barrier?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24501156",
                "http://www.ncbi.nlm.nih.gov/pubmed/16120931",
                "http://www.ncbi.nlm.nih.gov/pubmed/19077110",
                "http://www.ncbi.nlm.nih.gov/pubmed/12742070",
                "http://www.ncbi.nlm.nih.gov/pubmed/21963971",
                "http://www.ncbi.nlm.nih.gov/pubmed/19664711",
                "http://www.ncbi.nlm.nih.gov/pubmed/23508590",
                "http://www.ncbi.nlm.nih.gov/pubmed/28781208",
                "http://www.ncbi.nlm.nih.gov/pubmed/22130026",
                "http://www.ncbi.nlm.nih.gov/pubmed/27655189"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156",
                    "text": "Caveolin-1 is related to the diminished expression of tight junction-associated proteins and metabolic pinocytosis vesicles when the blood-brain barrier is destroyed by outside invaders or malignant stimulus.",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24501156",
                    "text": "It plays an important role in physiological and pathological conditions of the blood-brain barrier and serves as a mediator in drug delivery through the blood-brain barrier.",
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 242,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19077110",
                    "text": "The role of inflammation and the blood-brain barrier will be discussed in cerebral palsy, schizophrenia, Parkinson's disease, Alzheimer's disease and multiple sclerosis, conditions where both inflammation and blood-brain barrier dysfunction occur either during initiation and/or progression of the disease.",
                    "offsetInBeginSection": 554,
                    "offsetInEndSection": 860,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12742070",
                    "text": "In situ brain perfusion in the rat, indicates that blood to brain L-[14C]glutamine transport at the blood-brain barrier is primarily mediated by a pH-dependent, Na(+)-dependent, System N transporter, but that blood to choroid plexus transport is primarily via a pH-independent System N transporter and a Na(+)-independent carrier that is not System L. Transport studies in isolated rat choroid plexuses and primary cultures of choroid plexus epithelial cells indicate that epithelial L-[14C]glutamine transport is polarized (apical uptake>basolateral) and that uptake at the apical membrane is mediated by pH dependent System N transporters (identified as SN1 and SN2 by polymerase chain reaction) and the Na(+)-independent System L. Blood-brain barrier System N transport is markedly effected by cerebral ischemia and may be a good marker of endothelial cell dysfunction.",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 1348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21963971",
                    "text": "Various types of transporters that exhibit substrate specificity are localized on the blood-brain barrier, and play a role in transporting substances from circulating blood and from brain interstitial fluid.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19664711",
                    "text": "The physical barrier between blood and the CNS (the blood-brain barrier, the blood-spinal cord barrier and the blood-CSF barrier) protects the CNS from both toxic and pathogenic agents in the blood.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23508590",
                    "text": "Thus, the transporter protein MRP plays a role in maintaining the blood-brain barrier and modulates the activity of opioids.",
                    "offsetInBeginSection": 1449,
                    "offsetInEndSection": 1573,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23508590",
                    "text": "The ATP-binding cassette (ABC) transporter P-glycoprotein (Pgp) is involved with the barrier, both preventing the influx of agent from the blood into the brain and facilitating the efflux of compounds from the brain into the blood, raising the possibility of a similar role for other transporters.",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28781208",
                    "text": "Blood-brain barrier pathology is recognised as a central factor in the development of many neurological disorders, but much less is known about the role of the blood-brain barrier in psychiatric disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28781208",
                    "text": "We conclude that the complex nature of blood-brain barrier dysfunction in psychosis might be relevant to many aspects of disrupted neuronal and synaptic function, increased permeability to inflammatory molecules, disrupted glutamate homoeostasis, impaired action of antipsychotics, and development of antipsychotic resistance.",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 1055,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa824a8fcf4565872000002",
            "body": "What is the drug Tecfidera used against?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                "http://www.ncbi.nlm.nih.gov/pubmed/27849348",
                "http://www.ncbi.nlm.nih.gov/pubmed/26199353",
                "http://www.ncbi.nlm.nih.gov/pubmed/23946617",
                "http://www.ncbi.nlm.nih.gov/pubmed/25213591",
                "http://www.ncbi.nlm.nih.gov/pubmed/25520780",
                "http://www.ncbi.nlm.nih.gov/pubmed/24259625",
                "http://www.ncbi.nlm.nih.gov/pubmed/28965011",
                "http://www.ncbi.nlm.nih.gov/pubmed/25888198",
                "http://www.ncbi.nlm.nih.gov/pubmed/24494635"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258191",
                    "text": "Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the fumaric acid ester that is Food and Drug Administration approved for treatment of relapsing-remitting multiple sclerosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26199353",
                    "text": "Recently, three progressive multifocal leukoencephalopathy (PML) cases have been reported in multiple sclerosis (MS) patients, two treated with fingolimod (Gilenya, Novartis), the third with dimethyl fumarate (Tecfidera, Biogen).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23946617",
                    "text": "Dimethyl fumarate capsules (Tecfidera) for multiple sclerosis, ado-trastuzumab emtansine injection (Kadcyla) for HER-2-positive breast cancer, and ospemifene tablets (Osphena) for painful intercourse in postmenopausal women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25213591",
                    "text": "We have previously reviewed the use of \u25bcfingolimod for highly active relapsing-remitting MS1 and \u25bcteriflunomide for the management of relapsing-remitting MS in adults.2 Here, we review the evidence for \u25bcdimethyl fumarate (Tecfidera-Biogen Idec Ltd) for the treatment of adults with relapsing-remitting MS.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25520780",
                    "text": "METHODS The Twitter resource\u00a0Topsy was searched for tweets mentioning the following MS treatments: Aubagio, Avonex, Betaferon or Betaseron, Copaxone, Extavia, Gilenya, Lemtrada, Novantrone, Rebif, Tysabri and Tecfidera between 1 Jan 2006 to 31 Jul 2014.",
                    "offsetInBeginSection": 330,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28965011",
                    "text": "Ethyl pyruvate is a redox analogue of dimethyl fumarate (Tecfidera), a drug for multiple sclerosis treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25888198",
                    "text": "After considering the clinical features and measures of drug efficacy in MS clinical trials, we report the phase-III clinical trials results of: (1) 3 oral agents approved within the last 5 years, fingolimod (Gilenya), dimethylfumarate (Tecfidera), and teriflunomide (Aubagio); (2) the oral agent laquinimod; and (3) the monoclonal antibodies daclizumab, ocrelizumab, and alemtuzumab.",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 989,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635",
                    "text": "Recently, 2 new oral DMTs received FDA approval for the treatment of RRMS: teriflunomide (Aubagio) and dimethyl fumarate (Tecfidera).",
                    "offsetInBeginSection": 1094,
                    "offsetInEndSection": 1227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635",
                    "text": "In addition, oral laquinimod, several monoclonal antibodies (eg, alemtuzumab, daclizumab, and ocrelizumab), and other agents have shown preliminary beneficial results in relapsing MS in phase 3 clinical trials.",
                    "offsetInBeginSection": 1228,
                    "offsetInEndSection": 1438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24494635",
                    "text": "These well-known therapies include intramuscular (IM) interferon (IFN) beta-1a (Avonex), subcutaneous (SC) IFN beta-1a (Rebif), SC IFN beta- 1b (Betaseron; Extavia), and SC glatiramer acetate (Copaxone).",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 408,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a733d2a2dc08e987e000015",
            "body": "Is Tocilizumab effective for Giant-Cell Arteritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28745999",
                "http://www.ncbi.nlm.nih.gov/pubmed/27182063",
                "http://www.ncbi.nlm.nih.gov/pubmed/22284606",
                "http://www.ncbi.nlm.nih.gov/pubmed/29146018",
                "http://www.ncbi.nlm.nih.gov/pubmed/28499892",
                "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                "http://www.ncbi.nlm.nih.gov/pubmed/21243547",
                "http://www.ncbi.nlm.nih.gov/pubmed/28116918",
                "http://www.ncbi.nlm.nih.gov/pubmed/22965672",
                "http://www.ncbi.nlm.nih.gov/pubmed/26885650"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745999",
                    "text": "The effect of the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoid tapering was studied in patients with giant-cell arteritis.",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27182063",
                    "text": "CONCLUSION TCZ is effective in GCA.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "Several studies have reported that tocilizumab is effective for aortitis associated with Takayasu's arteritis and giant cell arteritis.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "In conclusion, tocilizumab was effective in treating glucocorticoid- and cyclophosphamide-resistant AAV-associated aortitis.",
                    "offsetInBeginSection": 1053,
                    "offsetInEndSection": 1177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "This is the first report demonstrating the successful treatment of AAV-associated aortitis using tocilizumab.",
                    "offsetInBeginSection": 1178,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24357324",
                    "text": "It indicates that tocilizumab may be therapeutically beneficial for not only aortitis but also AAV itself.",
                    "offsetInBeginSection": 946,
                    "offsetInEndSection": 1052,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21243547",
                    "text": "CONCLUSION Collectively the data suggest that IL-6 blockade using tocilizumab qualifies as a therapeutic option to induce rapid remission in large vessel vasculitides.",
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1283,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28116918",
                    "text": "TNF-\u03b1 blockers are ineffective in giant cell arteritis, while observational evidence and a phase 2 randomized trial support the use of tocilizumab in relapsing giant cell arteritis.",
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22965672",
                    "text": "Herein, we present a case with giant cell arteritis resistant to oral and intravenous steroid, intravenous cyclophosphamide and mycophenolate mofetil, but successfully treated with tocilizumab.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 424,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26885650",
                    "text": "Preliminary clinical trial data suggest that abatacept and tocilizumab reduce the risk of relapse in GCA.",
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 515,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76420c9e632bc066000007",
            "body": "What is MULTOVL?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23071271"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271",
                    "text": "We present the MULTOVL application suite that detects and statistically analyses multiple overlaps of genomic regions in a fast and efficient manner.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271",
                    "text": "The package supports the detection of multiple region intersections, unions and 'solitary' genomic regions.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23071271",
                    "text": "The significance of actually observed overlaps is estimated by comparing them with empirical null distributions generated by random shuffling of the input regions.",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a992d981d1251d03b00000b",
            "body": "Can nanoparticles be used for afterglow imaging?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28657119",
                "http://www.ncbi.nlm.nih.gov/pubmed/29035373",
                "http://www.ncbi.nlm.nih.gov/pubmed/28608898",
                "http://www.ncbi.nlm.nih.gov/pubmed/20798470",
                "http://www.ncbi.nlm.nih.gov/pubmed/27594671",
                "http://www.ncbi.nlm.nih.gov/pubmed/26253653",
                "http://www.ncbi.nlm.nih.gov/pubmed/27345100",
                "http://www.ncbi.nlm.nih.gov/pubmed/21702453",
                "http://www.ncbi.nlm.nih.gov/pubmed/23988232",
                "http://www.ncbi.nlm.nih.gov/pubmed/27419003"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28657119",
                    "text": "This study reports the design principle, synthesis, and proof-of-concept application of organic semiconducting nanoparticles (OSNs) with ultralong phosphorescence for in vivo afterglow imaging.",
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28608898",
                    "text": "Until now, the afterglow emissions of most developed near infrared (NIR)-emitting persistent luminescent nanoparticles (NPLNPs) were located at approximately 700 nm, at the edge of the first tissue transparency window (from 650 to 900 nm), which resulted in relatively low tissue penetration and signal-to-noise ratio (SNR) for in vivo imaging.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 344,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20798470",
                    "text": "The successful observation of the afterglow from water-soluble nanoparticles may open up new applications of afterglow phosphors in biological imaging, detection and treatment.",
                    "offsetInBeginSection": 816,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253653",
                    "text": "Afterglow nanoparticles have been widely investigated as new agents for cancer imaging and as a light source for photodynamic activation for cancer treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26253653",
                    "text": "Here we report the strategies for targeting Sr3MgSi2O8:Eu(2+),Dy(3+) afterglow nanoparticles to tumor cells by conjugating with variety of targeting molecules such as folic acid, RGD peptide, and R-11 peptide.",
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27345100",
                    "text": "Our preliminary study has shown that the ZnS:Ag,Co afterglow nanoparticles can significantly reduce the x-ray dosage used in activation and thus may be a very promising candidate for future x-ray excited photodynamic therapy in deep cancer treatment.",
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21702453",
                    "text": "We finally identify a novel composition (CaMgSi(2)O(6):Eu(2+),Mn(2+),Pr(3+)) for in vivo imaging, displaying a strong near-infrared afterglow centered on 685 nm, and present evidence that intravenous injection of such persistent luminescence nanoparticles in mice allows not only improved but highly sensitive detection through living tissues.",
                    "offsetInBeginSection": 767,
                    "offsetInEndSection": 1110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21702453",
                    "text": "Focusing on the use of nanophosphors for in vivo imaging and diagnosis applications, we used thermally stimulated luminescence (TSL) measurements to study the influence of trivalent lanthanide Ln(3+) (Ln = Dy, Pr, Ce, Nd) electron traps on the optical properties of Mn(2+)-doped diopside-based persistent luminescence nanoparticles.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27419003",
                    "text": "Near-infrared (NIR) persistent phosphor ZnGa2O4:Cr3+ (ZGC) has unique deep-tissue rechargeable afterglow properties.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27419003",
                    "text": "Herein, we report on in vivo rechargeable mesoporous SiO2/ZnGa2O4:Cr3+ (mZGC) afterglow NIR-emitting nanocomposites that are made by a simple, one-step mesoporous template method.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa13fd3d6d6b54f79000003",
            "body": "List 4 drugs used to treat opioid addiction or overdose",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28358791",
                "http://www.ncbi.nlm.nih.gov/pubmed/25583888",
                "http://www.ncbi.nlm.nih.gov/pubmed/20169438",
                "http://www.ncbi.nlm.nih.gov/pubmed/28627395",
                "http://www.ncbi.nlm.nih.gov/pubmed/21668757",
                "http://www.ncbi.nlm.nih.gov/pubmed/23059064",
                "http://www.ncbi.nlm.nih.gov/pubmed/12738346",
                "http://www.ncbi.nlm.nih.gov/pubmed/26495843",
                "http://www.ncbi.nlm.nih.gov/pubmed/22084456",
                "http://www.ncbi.nlm.nih.gov/pubmed/27898133"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28358791",
                    "text": "Methadone is an opioid prescribed for pain management and is also provided through opioid treatment programs to treat opioid use disorders.",
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 342,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169438",
                    "text": "OMT with buprenorphine, buprenorphine-naloxone combination, or other opioid agonists is also discussed.",
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 441,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169438",
                    "text": "Treatments include detoxification using tapered methadone, buprenorphine, adrenergic agonists such as clonidine and lofexidine, and forms of rapid detoxification.",
                    "offsetInBeginSection": 105,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20169438",
                    "text": "The use of the opioid antagonists naloxone (for the treatment of intoxication and overdose) and oral and sustained-release formulations of naltrexone (for relapse prevention) is also considered.",
                    "offsetInBeginSection": 442,
                    "offsetInEndSection": 636,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21668757",
                    "text": "OBJECTIVE To illustrate a system-level, simulation-based approach for evaluating mitigation strategies to address the dramatic rise in abuse, addiction, and overdose deaths associated with the use of pharmaceutical opioid analgesics to treat chronic pain.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843",
                    "text": "10 patients (9/10 with chronic airflow obstruction) undergoing supervised injectable opioid treatment for heroin addiction received their usual prescribed dose of injectable opioid (diamorphine or methadone) (IOT), and their usual prescribed dose of oral opioid (methadone or sustained release oral morphine) after 30 minutes.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 710,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26495843",
                    "text": "We conclude that significant acute respiratory depression is commonly induced by opioid drugs prescribed to treat opioid addiction.",
                    "offsetInBeginSection": 1462,
                    "offsetInEndSection": 1593,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084456",
                    "text": "Suspected opioid addiction is managed with structured opioid therapy, methadone or buprenorphine treatment, or abstinence-based treatment.",
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 1028,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22084456",
                    "text": "Adolescents are at high risk of opioid overdose, misuse, and addiction.",
                    "offsetInBeginSection": 1832,
                    "offsetInEndSection": 1903,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898133",
                    "text": "The United States is amid an epidemic of prescription opioid drug abuse, bringing with it not only high rates of overdose, but growing rates of heroin abuse and addiction.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa825b1fcf4565872000003",
            "body": "Are stress granules membraneous?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/6581717",
                "http://www.ncbi.nlm.nih.gov/pubmed/28305055",
                "http://www.ncbi.nlm.nih.gov/pubmed/3453791",
                "http://www.ncbi.nlm.nih.gov/pubmed/2590850",
                "http://www.ncbi.nlm.nih.gov/pubmed/184753",
                "http://www.ncbi.nlm.nih.gov/pubmed/9973599",
                "http://www.ncbi.nlm.nih.gov/pubmed/7297520",
                "http://www.ncbi.nlm.nih.gov/pubmed/870863",
                "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                "http://www.ncbi.nlm.nih.gov/pubmed/19058516"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6581717",
                    "text": "They consist of azurophilic granules containing membraneous lamellae.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28305055",
                    "text": "Subcortical microfilaments link membraneous organelles to form networks; some are associated with bundles of cortical microfilaments.",
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1124,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28305055",
                    "text": "This is ascribed to the compact rearrangement in the subcortical layer of membraneous organelles such as endoplasmic reticulum and mitochondria.",
                    "offsetInBeginSection": 615,
                    "offsetInEndSection": 759,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/184753",
                    "text": "Endoplasmic reticulum with ribosomes, Golgi apparatus, mitochondria, some filamentous structures and crystalline inclusions (B cell granules) were also effectively disclosed by ion-etching technique.",
                    "offsetInBeginSection": 458,
                    "offsetInEndSection": 657,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9973599",
                    "text": "This 'light' membraneous structure could be the starting point for reassociation of Rab3a with membranes involved in granule formation, or it could be a structure unrelated to granules.",
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 850,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                    "text": "It's proposed that TIA-1 forms prion-like aggregates, and these aggregates are scaffolds for other components of stress granules.",
                    "offsetInBeginSection": 753,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                    "text": "Stress granules are specific RNA-containing structures in the cytoplasm of living cells which arise under stress conditions (e. g. heat shock, UV irradiation, energy depletion and oxidative stress).",
                    "offsetInBeginSection": 70,
                    "offsetInEndSection": 268,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                    "text": "Stress granules are depleted with ternary complex and large ribosomal subunit.",
                    "offsetInBeginSection": 455,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                    "text": "It became evident that stress granules accumulate non-canonical 48S initiation complexes and contain mRNA with associated proteins, small ribosomal subunits and some initiation factors.",
                    "offsetInBeginSection": 269,
                    "offsetInEndSection": 454,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17209421",
                    "text": "Cytoskeletal structures facilitate the accumulation of stress granule components in local cytoplasmic sites.",
                    "offsetInBeginSection": 883,
                    "offsetInEndSection": 991,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a733efc2dc08e987e000016",
            "body": "Describe Achenbach\u2019s syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25709171",
                "http://www.ncbi.nlm.nih.gov/pubmed/2188546",
                "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                "http://www.ncbi.nlm.nih.gov/pubmed/20583180",
                "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                "http://www.ncbi.nlm.nih.gov/pubmed/20446161",
                "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                "http://www.ncbi.nlm.nih.gov/pubmed/12002153",
                "http://www.ncbi.nlm.nih.gov/pubmed/18334805",
                "http://www.ncbi.nlm.nih.gov/pubmed/835533"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "Although there is considerable variability, most individuals with Down syndrome have mental retardation and speech and language deficits, particularly in language production and syntax and poor speech intelligibility.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "Next, we describe language development in Down syndrome, focusing on communication behaviors in the prelinguistic period, then the development of language in children and adolescents, and finally language development in adults and the aging period.",
                    "offsetInBeginSection": 489,
                    "offsetInEndSection": 737,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "We describe language development in individuals with Down syndrome across four domains: phonology, semantics, syntax, and pragmatics.",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 871,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17326116",
                    "text": "This article describes research findings in the language and communication development of individuals with Down syndrome, first briefly describing the physical and cognitive phenotype of Down syndrome, and two communication related domains-hearing and oral motor skills.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 488,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583180",
                    "text": "The purpose of this paper is to describe two new unrelated cases of this unique syndrome that further delineate the phenotype, compare to phenotypically similar syndromes, and postulate that Petty syndrome could represent a new laminopathy.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 1122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20583180",
                    "text": "In addition, evidence suggesting that the Petty syndrome and Fontaine-Farriaux syndromes are variable expressions of the same condition is discussed.",
                    "offsetInBeginSection": 1123,
                    "offsetInEndSection": 1272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18592912",
                    "text": "The Peutz-Jeghers syndrome, the Juvenile plyposys syndrome, the PTEN hamartomatous tumor syndrome, and other less frequent hamartomatous syndroms are described.",
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20446161",
                    "text": "The clinical characteristics of \"paraesthetic-causalgic syndrome\" or \"Madrid syndrome\" as described by Peraita are discussed, and the syndrome is presented in relation to other similar conditions, including Strachan's syndrome and burning feet syndrome.",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 432,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6703533",
                    "text": "Authors describe the phenotype and review the literature on this syndrome.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 233,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18334805",
                    "text": "We describe a neonate with this syndrome having colonic atresia leading to cecal rupture and pneumoperitoneum.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 316,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a774e40faa1ab7d2e000007",
            "body": "Is there a link between nuclear position and DNA repair pathway choice?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                "http://www.ncbi.nlm.nih.gov/pubmed/27266837",
                "http://www.ncbi.nlm.nih.gov/pubmed/25463437",
                "http://www.ncbi.nlm.nih.gov/pubmed/28689661",
                "http://www.ncbi.nlm.nih.gov/pubmed/23811932",
                "http://www.ncbi.nlm.nih.gov/pubmed/19204116",
                "http://www.ncbi.nlm.nih.gov/pubmed/19579069",
                "http://www.ncbi.nlm.nih.gov/pubmed/24320053",
                "http://www.ncbi.nlm.nih.gov/pubmed/26019174",
                "http://www.ncbi.nlm.nih.gov/pubmed/11554304"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25366693",
                    "text": "Our results are consistent with a model in which nuclear position dictates the choice of DNA repair pathway, thus revealing a new level of regulation in DSB repair controlled by spatial organization of DNA within the nucleus.",
                    "offsetInBeginSection": 912,
                    "offsetInEndSection": 1137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27266837",
                    "text": "We aim to highlight the importance of chromatin state along with the nuclear position of the DNA lesions on the choice of DNA repair pathway and maintenance of genome integrity.",
                    "offsetInBeginSection": 544,
                    "offsetInEndSection": 721,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437",
                    "text": "Regulation of DNA repair pathway choice is crucial to avoid genomic instability.",
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 636,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25463437",
                    "text": "In yeast, DSBs are mobile and can scan the entire nucleus to be repaired in specialized DNA repair centers or if they are persistent, in order to associate with the nuclear pores or the nuclear envelope where they can be repaired by specialized repair pathways.",
                    "offsetInBeginSection": 637,
                    "offsetInEndSection": 898,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28689661",
                    "text": "Thus, the spatial and temporal control of acetyl-CoA production by ACLY participates in the mechanism of DNA repair pathway choice.",
                    "offsetInBeginSection": 974,
                    "offsetInEndSection": 1105,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28689661",
                    "text": "ACLY facilitates histone acetylation at double-strand break (DSB) sites, impairing 53BP1 localization and enabling BRCA1 recruitment and DNA repair by homologous recombination.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 785,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23811932",
                    "text": "Our work indicates that cell cycle position has a key role in DNA repair pathway choice and that recruitment of chromatin regulators is tightly coupled to homologous recombination.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 930,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579069",
                    "text": "HnRNP A18, B1, C1/C2 and K interact with important proteins from DNA Damage Response (DDR) pathways, binding DNA-dependent protein kinase (DNA-PK), the Ku antigen (Ku) and tumour suppressor protein 53 (p53) respectively.",
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579069",
                    "text": "Evidence points to a role for hnRNP A1, A18, A2/B1, C1/C2, K and P2 in regulating double-stranded break (DSB) repair pathways by promoting either homologous recombination (HR) or non-homologous end rejoining (NHEJ) repair pathways following IR.",
                    "offsetInBeginSection": 1096,
                    "offsetInEndSection": 1340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24320053",
                    "text": "In this review, we have summarized recent advances in understanding the role of 53BP1 in regulating DNA DSBs repair pathway choice, variable diversity joining [V(D)J] recombination and class-switch recombination (CSR).",
                    "offsetInBeginSection": 670,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a992eac1d1251d03b00000c",
            "body": "Can non ubiquitinated Tomm20 promote mitophagy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27503909",
                "http://www.ncbi.nlm.nih.gov/pubmed/28405902",
                "http://www.ncbi.nlm.nih.gov/pubmed/26071202",
                "http://www.ncbi.nlm.nih.gov/pubmed/26943044",
                "http://www.ncbi.nlm.nih.gov/pubmed/29097221",
                "http://www.ncbi.nlm.nih.gov/pubmed/20890124",
                "http://www.ncbi.nlm.nih.gov/pubmed/20484985",
                "http://www.ncbi.nlm.nih.gov/pubmed/25972374",
                "http://www.ncbi.nlm.nih.gov/pubmed/21705204",
                "http://www.ncbi.nlm.nih.gov/pubmed/25634658"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26071202",
                    "text": "These results suggest that pyruvate is required for CCCP-induced PINK1/PARK2-mediated mitophagy.",
                    "offsetInBeginSection": 1091,
                    "offsetInEndSection": 1187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26071202",
                    "text": "Damaged mitochondria are targeted for degradation by an autophagy pathway known as mitophagy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943044",
                    "text": "Here, we detected mitophagy deficits evidenced by the increased levels of mitophagy markers, including COX IV, TOMM20, and the ratio of mtDNA to genomic DNA indexed as mt-Atp6/Rpl13, in the AD brains and in the human wild type full-length tau (htau) transgenic mice.",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 445,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097221",
                    "text": "Our data showed that resveratrol attenuated A\u03b21-42-induced cell death and significantly enhanced mitophagy including an increase in acidic vesicular organelle number, LC3-II/LC3-I ratio, Parkin and Beclin-1 expression, and LC3 and TOMM20 co-localization in A\u03b21-42-treated PC12 cells.",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 776,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890124",
                    "text": "Similarly, mitochondrial-anchored ubiquitin is sufficient to recruit p62 and promote mitochondrial clustering, but does not promote mitophagy.",
                    "offsetInBeginSection": 1210,
                    "offsetInEndSection": 1352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20890124",
                    "text": "Additionally, we find VDAC1 and VDAC3 are dispensable for the recruitment of p62, mitochondrial clustering and mitophagy.",
                    "offsetInBeginSection": 1637,
                    "offsetInEndSection": 1758,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25972374",
                    "text": "Selective autophagy adaptor proteins, including p62/SQSTM1, play pivotal roles in the targeted degradation of ubiquitinated proteins or organelles through the autophagy-lysosome system.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25972374",
                    "text": "Our results suggest that TBK1-mediated S403 phosphorylation regulates the efficient autophagosomal engulfment of ubiquitinated mitochondria as an immediate response to the mitochondrial depolarization.",
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1231,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21705204",
                    "text": "Proteasomal degradation of the outer mitochondrial membrane (OMM) protein Mcl1 regulates apoptosis whereas Parkin-mediated ubiquitination and degradation of Mitofusins can inhibit mitochondrial fusion and promote mitophagy.",
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 565,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25634658",
                    "text": "Damaged mitochondria can be degraded by a selective type of autophagy, which is termed mitophagy.",
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa304f1d6d6b54f79000004",
            "body": "Is the consumption of chocolate associated with an increase in cardiovascular disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                "http://www.ncbi.nlm.nih.gov/pubmed/26076934",
                "http://www.ncbi.nlm.nih.gov/pubmed/21875885",
                "http://www.ncbi.nlm.nih.gov/pubmed/27493901",
                "http://www.ncbi.nlm.nih.gov/pubmed/15712594",
                "http://www.ncbi.nlm.nih.gov/pubmed/20858571",
                "http://www.ncbi.nlm.nih.gov/pubmed/21666964",
                "http://www.ncbi.nlm.nih.gov/pubmed/26936339",
                "http://www.ncbi.nlm.nih.gov/pubmed/21665390",
                "http://www.ncbi.nlm.nih.gov/pubmed/25646334"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                    "text": "OBJECTIVE To model the long term effectiveness and cost effectiveness of daily dark chocolate consumption in a population with metabolic syndrome at high risk of cardiovascular disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                    "text": "CONCLUSIONS The blood pressure and cholesterol lowering effects of dark chocolate consumption are beneficial in the prevention of cardiovascular events in a population with metabolic syndrome.",
                    "offsetInBeginSection": 1308,
                    "offsetInEndSection": 1500,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653982",
                    "text": "Daily dark chocolate consumption could be an effective cardiovascular preventive strategy in this population.",
                    "offsetInBeginSection": 1501,
                    "offsetInEndSection": 1610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21875885",
                    "text": "The highest levels of chocolate consumption were associated with a 37% reduction in cardiovascular disease (relative risk 0.63 (95% confidence interval 0.44 to 0.90)) and a 29% reduction in stroke compared with the lowest levels.",
                    "offsetInBeginSection": 1581,
                    "offsetInEndSection": 1810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27493901",
                    "text": "BACKGROUND The consumption of chocolate and cocoa has established cardiovascular benefits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15712594",
                    "text": "We evaluated the effects of the regular consumption (14 d) of a flavanol-containing milk chocolate (FCMC) or cocoa butter chocolate (CBC) on variables related to vascular disease risk, oxidative stress and physical activity.",
                    "offsetInBeginSection": 150,
                    "offsetInEndSection": 374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21666964",
                    "text": "Data currently available indicate that daily consumption of cocoa-rich chocolate (rich in polyphenols) may at least partially lower cardiovascular disease risk.",
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936339",
                    "text": "CONCLUSIONS Chocolate consumption is associated with lower risk of MI and ischaemic heart disease.",
                    "offsetInBeginSection": 1586,
                    "offsetInEndSection": 1684,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26936339",
                    "text": "Chocolate consumption was inversely associated with MI risk.",
                    "offsetInBeginSection": 959,
                    "offsetInEndSection": 1019,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25646334",
                    "text": "In secondary analyses, the inverse association of chocolate consumption and risk of DM was slightly stronger in subjects without a history of cardiovascular disease or heart failure (P-trend = 0.023).",
                    "offsetInBeginSection": 1299,
                    "offsetInEndSection": 1499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aacd38efcf4565872000006",
            "body": "Is DNA polymerase \u03b8 involved in DNA repair?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27264557",
                "http://www.ncbi.nlm.nih.gov/pubmed/25775267",
                "http://www.ncbi.nlm.nih.gov/pubmed/28542210",
                "http://www.ncbi.nlm.nih.gov/pubmed/26514729",
                "http://www.ncbi.nlm.nih.gov/pubmed/28695890",
                "http://www.ncbi.nlm.nih.gov/pubmed/26484154",
                "http://www.ncbi.nlm.nih.gov/pubmed/24989122",
                "http://www.ncbi.nlm.nih.gov/pubmed/28668117",
                "http://www.ncbi.nlm.nih.gov/pubmed/21917855",
                "http://www.ncbi.nlm.nih.gov/pubmed/25643323"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27264557",
                    "text": "DNA polymerase theta (pol \u03b8) is encoded in the genomes of many eukaryotes, though not in fungi.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25775267",
                    "text": "DNA polymerase \u03b8 protects against genomic instability via an alternative end-joining repair pathway for DNA double-strand breaks.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28542210",
                    "text": "One of these proteins, DNA Polymerase \u03b8 (Pol \u03b8), coordinates a mutagenic DSB repair pathway named microhomology-mediated end joining (MMEJ) and is also a critical component for bypass or repair of ICLs in several organisms.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26514729",
                    "text": "DNA polymerase theta (Pol \u03b8) is an error-prone A-family polymerase that is highly conserved among multicellular eukaryotes and plays multiple roles in DNA repair and the regulation of genome integrity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890",
                    "text": "Here we show that DNA polymerase \u03b8, despite its minor role in chromosomal DNA repair, substantially contributes to random integration, and that cells lacking both DNA polymerase \u03b8 and DNA ligase IV, which is essential for non-homologous end joining (NHEJ), exhibit 100% efficiency of spontaneous gene targeting by virtue of undetectable levels of random integration.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28695890",
                    "text": "Thus, DNA polymerase \u03b8-mediated end joining is the sole homology-independent repair route in the absence of NHEJ and, intriguingly, their combined absence reveals rare Alu-Alu recombination events utilizing a stretch of homology.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 866,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26484154",
                    "text": "The physiological function of the human DNA polymerase \u03b8 (pol \u03b8) is still unclear despite its in vitro translesion synthesis capacity during DNA damage repair process.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24989122",
                    "text": "Although DNA polymerase \u03b8 (Pol \u03b8) is known to carry out translesion synthesis and has been implicated in DNA repair, its physiological function under normal growth conditions remains unclear.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668117",
                    "text": "DNA polymerase theta (pol \u03b8) is an evolutionarily conserved protein encoded by the POLQ gene in mammalian genomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25643323",
                    "text": "We demonstrate that purified human DNA polymerase \u03b8 (Pol\u03b8) performs MMEJ of DNA containing 3' single-strand DNA overhangs with \u22652 bp of homology, including DNA modeled after telomeres, and show that MMEJ is dependent on Pol\u03b8 in human cells.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 509,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7341fe2dc08e987e000018",
            "body": "What is the link between lithium use during pregnancy and Ebstein anomaly?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18982835",
                "http://www.ncbi.nlm.nih.gov/pubmed/8031346",
                "http://www.ncbi.nlm.nih.gov/pubmed/2743779",
                "http://www.ncbi.nlm.nih.gov/pubmed/6518066",
                "http://www.ncbi.nlm.nih.gov/pubmed/28591541",
                "http://www.ncbi.nlm.nih.gov/pubmed/27572669",
                "http://www.ncbi.nlm.nih.gov/pubmed/1346886",
                "http://www.ncbi.nlm.nih.gov/pubmed/16611133",
                "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
                "http://www.ncbi.nlm.nih.gov/pubmed/24781368"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8031346",
                    "text": "DATA EXTRACTION AND SYNTHESIS In the 1970s a very strong association was suggested between maternal lithium treatment during pregnancy and Ebstein's anomaly of the heart in the offspring.",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 613,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2743779",
                    "text": "Some studies suggest that lithium might be involved as a teratogen increasing the incidence of Ebstein's anomaly in the offspring of female patients with manio-depressive psychosis and lithium-administered during pregnancy.",
                    "offsetInBeginSection": 74,
                    "offsetInEndSection": 297,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28591541",
                    "text": "BACKGROUND There has been concern that exposure to lithium early in pregnancy may be associated with a marked increase in the risk of Ebstein's anomaly (a right ventricular outflow tract obstruction defect) in infants and overall congenital cardiac defects, but data are conflicting and limited.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28591541",
                    "text": "CONCLUSIONS Maternal use of lithium during the first trimester was associated with an increased risk of cardiac malformations, including Ebstein's anomaly; the magnitude of this effect was smaller than had been previously postulated.",
                    "offsetInBeginSection": 1719,
                    "offsetInEndSection": 1952,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27572669",
                    "text": "Our data suggest that Ebstein's anomaly is associated with maternal mental health problems generally rather than lithium or benzodiazepines specifically; therefore, changing or stopping medications may not be preventative.",
                    "offsetInBeginSection": 1780,
                    "offsetInEndSection": 2002,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1346886",
                    "text": "In-utero exposure to lithium during the first trimester of pregnancy might be associated with an increased risk of cardiac malformations, especially the rare Ebstein's anomaly.",
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1346886",
                    "text": "Lithium carbonate is an effective drug for prophylaxis and treatment of major affective disorders.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16611133",
                    "text": "There is a possibility that, in particular, lithium may be associated with the Ebstein anomaly but present evidence cannot definitely affirm or deny this association.",
                    "offsetInBeginSection": 373,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15702702",
                    "text": "A profound ultrasound screening of the organs should be performed in case of lithium exposition, whereas newer studies showed no increase in risk for Ebstein anomaly.",
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1320,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24781368",
                    "text": "CONCLUSIONS Lithium treatment in pregnancy is associated with a higher rate of cardiovascular anomalies.",
                    "offsetInBeginSection": 1708,
                    "offsetInEndSection": 1812,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a774fdcfaa1ab7d2e000008",
            "body": "Which protein is regulated by Tudor interacting repair regulator (TIRR)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                "http://www.ncbi.nlm.nih.gov/pubmed/28213517",
                "http://www.ncbi.nlm.nih.gov/pubmed/14602918",
                "http://www.ncbi.nlm.nih.gov/pubmed/24035451",
                "http://www.ncbi.nlm.nih.gov/pubmed/16415788",
                "http://www.ncbi.nlm.nih.gov/pubmed/20713134",
                "http://www.ncbi.nlm.nih.gov/pubmed/20307547",
                "http://www.ncbi.nlm.nih.gov/pubmed/19234526",
                "http://www.ncbi.nlm.nih.gov/pubmed/19345100",
                "http://www.ncbi.nlm.nih.gov/pubmed/22493508"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "Here we identify an uncharacterized protein, Tudor interacting repair regulator (TIRR), that directly binds the tandem Tudor domain and masks its H4K20me2 binding motif.",
                    "offsetInBeginSection": 424,
                    "offsetInEndSection": 593,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "Upon DNA damage, the protein kinase ataxia-telangiectasia mutated (ATM) phosphorylates 53BP1 and recruits RAP1-interacting factor 1 (RIF1) to dissociate the 53BP1-TIRR complex.",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28241136",
                    "text": "P53-binding protein 1 (53BP1) is a multi-functional double-strand break repair protein that is essential for class switch recombination in B lymphocytes and for sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28213517",
                    "text": "In this study, we identified the Tudor-interacting repair regulator (TIRR) that specifically associates with the ionizing radiation-induced foci formation region of 53BP1.",
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 798,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28213517",
                    "text": "We and others have investigated the downstream effectors of 53BP1, including replication timing regulatory factor 1 (RIF1) and Pax transactivation domain-interacting protein (PTIP), in the past few years to elucidate how loss of the 53BP1-dependent repair pathway results in PARPi resistance in BRCA1 patients.",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 533,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20713134",
                    "text": "In the present study, we identified the molecular interactions between Plasmodium falciparum Tudor-SN and twelve Plasmodium proteins such as Histone h2A, SPT2 (a transcriptional regulator), a Cold-shock DNA binding protein in a bacterial two-hybrid screen.",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20713134",
                    "text": "Tudor Staphylococcal Nuclease (p100 or SND1), a member of the micronuclease family is a multifunctional protein that plays a key role(s) in transcription and splicing processes in many eukaryotic cells.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20713134",
                    "text": "Furthermore, we also identified a molecular interaction between the Tudor domain of PfTudor-SN protein and Plasmodium spliceosomal Sm protein, PfSmD1 advocating the role of PfTudor-SN in the spliceosome assembly.",
                    "offsetInBeginSection": 1314,
                    "offsetInEndSection": 1526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20307547",
                    "text": "The tumor suppressor p53 and the DNA repair factor 53BP1 (p53 binding protein 1) regulate gene transcription and responses to genotoxic stresses.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22493508",
                    "text": "Human Tudor staphylococcal nuclease (Tudor-SN) is composed of four tandem repeats of staphylococcal nuclease (SN)-like domains, followed by a tudor and SN-like domain (TSN) consisting of a central tudor flanked by two partial SN-like sequences.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 244,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9931cd1d1251d03b00000d",
            "body": "Does SARM1 deletion cause neurodegeneration?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28978465",
                "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                "http://www.ncbi.nlm.nih.gov/pubmed/28485482",
                "http://www.ncbi.nlm.nih.gov/pubmed/24993772",
                "http://www.ncbi.nlm.nih.gov/pubmed/26686637",
                "http://www.ncbi.nlm.nih.gov/pubmed/28095293",
                "http://www.ncbi.nlm.nih.gov/pubmed/25009267",
                "http://www.ncbi.nlm.nih.gov/pubmed/25908823",
                "http://www.ncbi.nlm.nih.gov/pubmed/27671644",
                "http://www.ncbi.nlm.nih.gov/pubmed/23885119"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978465",
                    "text": "We therefore propose Sarm1 deletion as a more reliable tool than WldS for investigating Wallerian-like mechanisms in disease models and suggest that SARM1 blockade may have greater therapeutic potential than WLDS-related strategies.",
                    "offsetInBeginSection": 822,
                    "offsetInEndSection": 1054,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27797810",
                    "text": "Hence, genetic deletion of SARM1 blocks the development of vincristine-induced peripheral polyneuropathy in mice.",
                    "offsetInBeginSection": 1936,
                    "offsetInEndSection": 2049,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24993772",
                    "text": "However, recent reports have indicated that neurons express the key players of innate immunity, including Toll-like receptors (TLRs) and their adaptor proteins (Sarm1, Myd88, and Trif), and may produce cytokines in response to pathogen infection.",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 441,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28095293",
                    "text": "Injury-induced (Wallerian) axonal degeneration is regulated via the opposing actions of pro-degenerative factors such as SARM1 and a MAPK signal and pro-survival factors, the most important of which is the NAD+ biosynthetic enzyme NMNAT2 that inhibits activation of the SARM1 pathway.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27671644",
                    "text": "Dimerization of the TIR domain from the Caenorhabditis elegans SARM1 ortholog TIR-1 leads to NAD+ loss and neuronal death, indicating these activities are an evolutionarily conserved feature of SARM1 function.",
                    "offsetInBeginSection": 954,
                    "offsetInEndSection": 1163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27671644",
                    "text": "Sterile alpha and Toll/interleukin receptor (TIR) motif-containing protein 1 (SARM1) is an evolutionarily conserved executioner of this degeneration cascade, also known as Wallerian degeneration; however, the mechanism of SARM1-dependent neuronal destruction is still obscure.",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119",
                    "text": "SARM1, which is known to be an adaptor protein for Toll-like receptor, binds to PINK1 and promotes TRAF6-mediated lysine 63 chain ubiquitination of PINK1 at lysine 433.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 804,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119",
                    "text": "These results indicate that association of PINK1 with SARM1 and TRAF6 is an important step for mitophagy.",
                    "offsetInBeginSection": 1016,
                    "offsetInEndSection": 1121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119",
                    "text": "Mutations in PTEN-induced putative kinase 1 (PINK1) or parkin cause autosomal recessive forms of Parkinson's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23885119",
                    "text": "In this study, we find that PINK1 forms a complex with sterile \u03b1 and TIR motif containing 1 (SARM1) and tumor necrosis factor receptor-associated factor 6 (TRAF6), which is important for import of PINK1 in the outer membrane and stabilization of PINK1 on depolarized mitochondria.",
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa55b65d6d6b54f7900000e",
            "body": "Please list 6 symptoms of Scarlet fever.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1500078",
                "http://www.ncbi.nlm.nih.gov/pubmed/29081840",
                "http://www.ncbi.nlm.nih.gov/pubmed/11086489",
                "http://www.ncbi.nlm.nih.gov/pubmed/28073056",
                "http://www.ncbi.nlm.nih.gov/pubmed/26585817",
                "http://www.ncbi.nlm.nih.gov/pubmed/1919136",
                "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                "http://www.ncbi.nlm.nih.gov/pubmed/20846989",
                "http://www.ncbi.nlm.nih.gov/pubmed/11877116",
                "http://www.ncbi.nlm.nih.gov/pubmed/2772682"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1500078",
                    "text": "Morphologically and culturally the strains isolated from cases of toxic shock-like syndrome cannot be differentiated from isolates of epidemic scarlet fever or sporadic cases.",
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 713,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1500078",
                    "text": "Contrary to toxic scarlet fever the site of primary infection are the lower respiratory tract or soft tissue infections.",
                    "offsetInBeginSection": 234,
                    "offsetInEndSection": 354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11086489",
                    "text": "A further 6 children, outside of this class, had complaints of scarlet fever, impetigo or pharyngitis.",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26585817",
                    "text": "CONCLUSION Scarlet fever pharyngotonsillitis differs from the traditional streptococcal pharyngotonsillitis, and its evaluation using clinical prediction rules such as Centor or McIsaac is questionable.",
                    "offsetInBeginSection": 1354,
                    "offsetInEndSection": 1556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136",
                    "text": "Reinfection or relapse cases of scarlet fever were found in 6.7% (642/9,585).",
                    "offsetInBeginSection": 1542,
                    "offsetInEndSection": 1619,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1919136",
                    "text": "6.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                    "text": "Scarlatinal antistreptococcic serum affords some degree of protection against virulent scarlet fever streptococci but has no protective power against hemolytic streptococci from other diseases.",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19868695",
                    "text": "6.",
                    "offsetInBeginSection": 867,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11877116",
                    "text": "Even though there was some scarlet fever, it was not the first spread of scarlet fever in fact.",
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 874,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2772682",
                    "text": "The severity of symptoms and the demonstration of scarlet fever developing from infection with this organism supports antibiotic treatment of patients with group C streptococcal pharyngitis.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aacd83ffcf4565872000008",
            "body": "What is PARP inhibitor (PARPi) resistance?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23103855",
                "http://www.ncbi.nlm.nih.gov/pubmed/28255272",
                "http://www.ncbi.nlm.nih.gov/pubmed/28973445",
                "http://www.ncbi.nlm.nih.gov/pubmed/28242626",
                "http://www.ncbi.nlm.nih.gov/pubmed/28588062",
                "http://www.ncbi.nlm.nih.gov/pubmed/23450678",
                "http://www.ncbi.nlm.nih.gov/pubmed/23165508",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450426",
                "http://www.ncbi.nlm.nih.gov/pubmed/28510338",
                "http://www.ncbi.nlm.nih.gov/pubmed/26594843"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855",
                    "text": "Importantly, PARPi resistance was minimized by long-term treatment with the novel PARP inhibitor AZD2461, which is a poor P-glycoprotein substrate.",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 842,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23103855",
                    "text": "We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-glycoprotein drug efflux transporter.",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255272",
                    "text": "Therefore, the concept to block PARP enzymes by PARP inhibitor (PARPi) was appreciated in cancer treatment.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 360,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28973445",
                    "text": "ADP-ribosyltransferases promote repair of DNA single strand breaks and disruption of this pathway by Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) is toxic to cells with defects in homologous recombination (HR).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28242626",
                    "text": "ATR inhibitors (ATRis) disrupt BRCA1-independent RAD51 loading to DSBs and stalled forks in PARPi-resistant BRCA1-deficient cells, overcoming both resistance mechanisms.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 938,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28588062",
                    "text": "High-grade epithelial ovarian carcinomas containing mutated BRCA1 or BRCA2 (BRCA1/2) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP inhibitors (PARPi), while restoration of HR function due to secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 323,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23165508",
                    "text": "PARP inhibitors (PARPi) for the treatment of BRCA1 or BRCA2 deficient tumours are currently the focus of seminal clinical trials exploiting the concept of synthetic lethality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28450426",
                    "text": "Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28510338",
                    "text": "Therapeutic inhibition of PARP is therefore perceived as a promising anticancer strategy and a number of PARP inhibitors (PARPi) are currently under development and clinical evaluation.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 495,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26594843",
                    "text": "Conversely, HOXA9 overexpression confers PARPi resistance to AML1-ETO and PML-RAR\u03b1 transformed cells.",
                    "offsetInBeginSection": 999,
                    "offsetInEndSection": 1101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7347a02dc08e987e00001b",
            "body": "Gallbladder carriage is a well recognised means of spread of which bacteria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28018582",
                "http://www.ncbi.nlm.nih.gov/pubmed/24349565",
                "http://www.ncbi.nlm.nih.gov/pubmed/23171127",
                "http://www.ncbi.nlm.nih.gov/pubmed/28096978",
                "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                "http://www.ncbi.nlm.nih.gov/pubmed/27131005",
                "http://www.ncbi.nlm.nih.gov/pubmed/15652608",
                "http://www.ncbi.nlm.nih.gov/pubmed/21086555",
                "http://www.ncbi.nlm.nih.gov/pubmed/25405340",
                "http://www.ncbi.nlm.nih.gov/pubmed/25926879"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28018582",
                    "text": "BACKGROUND Asymptomatic carriage has been recognised as an important risk factor for infection caused by antibiotic resistant bacteria.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23171127",
                    "text": "Because intestinal carriage is a key factor in the epidemiology of ESBL-producing Enterobacteriaceae, the study of the prevalence of these resistant bacteria and risk factors in young children is of particular interest.",
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 647,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23171127",
                    "text": "The fecal flora of children in the community can represent a reservoir for ESBLs genes which are located on highly transmissible plasmids and the spread of these genes among bacterial pathogens is concerning.",
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "DESIGN We screened for the presence of aerobic and anaerobic ESBL-producing bacteria and bla CTX-M in supragingival plaque samples from healthy human adults with culture-verified fecal carriage of CTX-M-producing Escherichia coli.",
                    "offsetInBeginSection": 726,
                    "offsetInEndSection": 956,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "Enterobacteriaceae are commonly found in the gastrointestinal tract and long-term intestinal carriage is considered important for the spread of ESBL and as a source of clinical infections.",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "OBJECTIVE To investigate possible carriage of ESBL-producing bacteria in supragingival plaque of known fecal carriers of these bacteria.",
                    "offsetInBeginSection": 587,
                    "offsetInEndSection": 723,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25206941",
                    "text": "Oral biofilm such as supragingival plaque is known to contain numerous antibiotic resistance determinants and may also represent a poorly investigated site for ESBL carriage and further spread.",
                    "offsetInBeginSection": 391,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15652608",
                    "text": "Strep pneumoniae carriage protected against Staph aureus carriage, and the bacterial interference could be disrupted by vaccinating children with pneumococcal conjugate vaccines that reduced nasopharyngeal carriage of vaccine-type Strep pneumoniae.",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 1101,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25405340",
                    "text": "The rapid resistance spread in Gram-negative bacteria, in particular extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae (ESBL-E), is a global challenge, leading to increased mortality, morbidity and health systems costs worldwide.",
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 464,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25405340",
                    "text": "A high carriage rate of ESBL-E increases the risk of infection with multi-resistant bacteria, and thus the need for usage of last resort antibiotics, such as carbapenems and colistin, in the treatment of common infections.",
                    "offsetInBeginSection": 1533,
                    "offsetInEndSection": 1755,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a775182faa1ab7d2e000009",
            "body": "What is the role of tankyrases in response to Double Strand Breaks (DSBs)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                "http://www.ncbi.nlm.nih.gov/pubmed/25749521",
                "http://www.ncbi.nlm.nih.gov/pubmed/20543558",
                "http://www.ncbi.nlm.nih.gov/pubmed/16479003",
                "http://www.ncbi.nlm.nih.gov/pubmed/11114307",
                "http://www.ncbi.nlm.nih.gov/pubmed/28477128",
                "http://www.ncbi.nlm.nih.gov/pubmed/23209566",
                "http://www.ncbi.nlm.nih.gov/pubmed/20423312",
                "http://www.ncbi.nlm.nih.gov/pubmed/16205111",
                "http://www.ncbi.nlm.nih.gov/pubmed/27375678"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26845027",
                    "text": "The Mediator of DNA damage Checkpoint protein 1 (MDC1) is essential for spreading of the DDR signaling on chromatin surrounding Double Strand Breaks (DSBs) by acting as a scaffold for PI3K kinases and for ubiquitin ligases.",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 402,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20543558",
                    "text": "The protein kinases ATM and DNA-PKcs play critical roles in the cellular response to DNA double strand breaks (DSBs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16479003",
                    "text": "Here we investigate the role of chromatin assembly factor 1 (CAF-1) and its interacting protein, PCNA, in the response of quiescent human cells to DNA double-strand breaks (DSBs).",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16479003",
                    "text": "These results support a novel and essential role for CAF-1 in the response of quiescent human cells to DSBs, possibly by reassembling chromatin following repair of DNA strand breaks.",
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1265,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11114307",
                    "text": "Following challenge with proinflammatory stimuli or generation of DNA double strand breaks (DSBs), transcription factor NF-kappaB translocates from the cytoplasm to the nucleus to activate expression of target genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28477128",
                    "text": "DNA damaging agents such as ionizing irradiation induce lesions in the DNA such as double strand breaks (DSBs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23209566",
                    "text": "Recruitment of 53BP1 to chromatin flanking double strand breaks (DSBs) requires \u03b3H2AX/MDC1/RNF8-dependent ubiquitination of chromatin and interaction of 53BP1 with histone H4 methylated on lysine 20 (H4K20me).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 210,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20423312",
                    "text": "Among several types of DNA lesions, the DNA double strand breaks (DSBs) are one of the most deleterious and harmful.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16205111",
                    "text": "Double strand breaks (DSBs) are arguably the most deleterious DNA lesion that a cell can sustain, and defects in the ability to detect and repair these breaks result in increased genomic instability and have been causatively linked to cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375678",
                    "text": "The cellular response to DNA double strand breaks (DSBs) is a multifaceted signaling program that centers on post-translational modifications including phosphorylation, ubiquitylation and SUMOylation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac4161d1251d03b000010",
            "body": "Does MC1R palmitoylation reduce pigmentation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                "http://www.ncbi.nlm.nih.gov/pubmed/28916587",
                "http://www.ncbi.nlm.nih.gov/pubmed/17616515",
                "http://www.ncbi.nlm.nih.gov/pubmed/17962522",
                "http://www.ncbi.nlm.nih.gov/pubmed/26462499",
                "http://www.ncbi.nlm.nih.gov/pubmed/21898403",
                "http://www.ncbi.nlm.nih.gov/pubmed/26482799",
                "http://www.ncbi.nlm.nih.gov/pubmed/23977400",
                "http://www.ncbi.nlm.nih.gov/pubmed/18282187",
                "http://www.ncbi.nlm.nih.gov/pubmed/24950377"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Here we demonstrate a potential MC1R-targeted intervention strategy in mice to rescue loss-of-function MC1R in MC1R RHC variants for therapeutic benefit by activating MC1R protein palmitoylation.",
                    "offsetInBeginSection": 729,
                    "offsetInEndSection": 924,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Using C57BL/6J-Mc1re/eJ mice, in which endogenous MC1R is prematurely terminated, expressing Mc1r RHC variants, we show that pharmacological activation of palmitoylation rescues the defects of Mc1r RHC variants and prevents melanomagenesis.",
                    "offsetInBeginSection": 1206,
                    "offsetInEndSection": 1446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "The results highlight a central role for MC1R palmitoylation in pigmentation and protection against melanoma.",
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28869973",
                    "text": "Individuals carrying MC1R variants, especially those associated with red hair colour, fair skin and poor tanning ability (denoted as RHC variants), are associated with higher risk of melanoma.",
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 495,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28916587",
                    "text": "Palmitoylation-deficient MC1R variants accelerate BRAFV60E-driven melanomagenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17616515",
                    "text": "Several MC1R variant alleles are associated with red hair, fair skin and increased skin cancer risk.",
                    "offsetInBeginSection": 117,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17962522",
                    "text": "Functional analyses show that this variant reduces MC1R activity to a level that alters hair and/or skin pigmentation in humans.",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 535,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23977400",
                    "text": "Variation in the melanocortin-1 receptor (Mc1r) is associated with pigmentation diversity in wild and domesticated populations of vertebrates, including several species of birds.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282187",
                    "text": "We are designing potent melanocortin analogs that mimic the effects of alpha-MSH as a strategy to prevent skin cancer, particularly in individuals who express MC1R genotypes that reduce but do not abolish MC1R function, or mutations in other melanoma susceptibility genes, such as p16.",
                    "offsetInBeginSection": 1172,
                    "offsetInEndSection": 1457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950377",
                    "text": "The melanocortin 1 receptor (MC1R), which signals through cAMP, is a melanocytic transmembrane receptor involved in pigmentation, adaptive tanning, and melanoma resistance.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a96c886fcd1d6a10c00002a",
            "body": "A bite from the Lone Star Tick Amblyomma americanum, can cause the victim to become allergic to red meat, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                "http://www.ncbi.nlm.nih.gov/pubmed/24690977",
                "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                "http://www.ncbi.nlm.nih.gov/pubmed/25108787",
                "http://www.ncbi.nlm.nih.gov/pubmed/17699076",
                "http://www.ncbi.nlm.nih.gov/pubmed/9722725",
                "http://www.ncbi.nlm.nih.gov/pubmed/4000801",
                "http://www.ncbi.nlm.nih.gov/pubmed/17848069",
                "http://www.ncbi.nlm.nih.gov/pubmed/23540113",
                "http://www.ncbi.nlm.nih.gov/pubmed/29029346"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "Amblyomma americanum, also known as the lone star tick, is found in much of the eastern United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28319627",
                    "text": "In addition to others, species of Rickettsia, Ehrlichia, and Borrelia are all transmitted by the lone star tick.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 372,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24690977",
                    "text": "A link has been discovered between the bite of the Lone Star Tick (Amblyomma americanum) and the development of sensitivity to galactose-\u03b1-1,3-galactose.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 513,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18447622",
                    "text": "Amblyomma americanum, the lone star tick, comprised 99.6% of 6,502 specimens collected in suburban landscapes.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787",
                    "text": "The Lone Star tick, Amblyomma americanum Linnaeus 1758 (Acari; Ixodidae), causes considerable production losses to the southern U.S. cattle industry due to reduced weight, infertility, secondary infections at bite wound sites, damaged hides, and potentially death, as these ticks tend to infest livestock in large numbers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 322,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25108787",
                    "text": "Increased expression of IGHG1, IL6, IL1\u03b1, and IL1RN in bovine tick bite-site biopsies suggests that Th2 differentiation may be important for the local bovine response to A. americanum ticks.",
                    "offsetInBeginSection": 1357,
                    "offsetInEndSection": 1548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9722725",
                    "text": "OBJECTIVE To differentiate cases of physician-diagnosed erythema migrans and erythema migrans-like rashes associated with Lone Star tick (Amblyomma americanum) bites.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17848069",
                    "text": "Two infectious diseases, and one presumably infectious disease, each vectored by or associated with the bite of the lone star tick (Amblyomma americanum), were identified and characterized by clinicians and scientists in the United States during the 1980s and 1990s.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 266,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23540113",
                    "text": "During a recent study on effects of long-term prescribed burning on ticks, differences in species composition were observed with lone star ticks, Amblyomma americanum (L.), preferring unburned habitats and Gulf Coast ticks, Amblyomma maculatum (Koch), preferring burned habitats.",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 406,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29029346",
                    "text": "Amblyomma americanum is the most frequently reported species of tick to bite humans in the southeastern and southcentral United States, and it can transmit diseases that include erhlichiosis, rickettsiosis, tularemia, and protozoan infections.",
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 623,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aad547efcf456587200000b",
            "body": "What is the \"protein inference problem\"?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                "http://www.ncbi.nlm.nih.gov/pubmed/23385215",
                "http://www.ncbi.nlm.nih.gov/pubmed/22954624",
                "http://www.ncbi.nlm.nih.gov/pubmed/17990506",
                "http://www.ncbi.nlm.nih.gov/pubmed/19645593",
                "http://www.ncbi.nlm.nih.gov/pubmed/22626983",
                "http://www.ncbi.nlm.nih.gov/pubmed/22331862",
                "http://www.ncbi.nlm.nih.gov/pubmed/24407311",
                "http://www.ncbi.nlm.nih.gov/pubmed/20562346",
                "http://www.ncbi.nlm.nih.gov/pubmed/15262821"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                    "text": "In fact, the protein inference problem can be regarded as a special protein quantification problem in the sense that truly present proteins are those proteins whose abundance values are not zero.",
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 628,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                    "text": "Thus, we argue that the protein inference problem can be viewed as a special protein quantification problem in which one protein is considered to be present if its abundance is not zero.",
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26935399",
                    "text": "This demonstrates that it is plausible to model the protein inference problem as a special protein quantification task, which opens the door of devising more effective protein inference algorithms from a quantification perspective.",
                    "offsetInBeginSection": 1638,
                    "offsetInEndSection": 1869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23385215",
                    "text": "Based on the concept of peptide detectability, we formulate the protein inference problem as a constrained Lasso regression problem, which can be solved very efficiently through a coordinate descent procedure.",
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22954624",
                    "text": "Based on this simple fact, the protein inference problem is formulated as an optimization problem: minimize the number of proteins with non-zero probabilities under the constraint that the difference between the calculated peptide probability and the peptide probability generated from peptide identification algorithms should be less than some threshold.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 1129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22954624",
                    "text": "Experimental results show that our method is competitive with the state-of-the-art protein inference algorithms.",
                    "offsetInBeginSection": 1402,
                    "offsetInEndSection": 1514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17990506",
                    "text": "A major challenge in shotgun proteomics has been the assignment of identified peptides to the proteins from which they originate, referred to as the protein inference problem.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19645593",
                    "text": "The protein inference problem represents a major challenge in shotgun proteomics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20562346",
                    "text": "Empirical results on two control datasets with synthetic mixtures of proteins and on complex protein samples of Saccharomyces cerevisiae, Drosophila melanogaster, and Arabidopsis thaliana suggest that the results with MIPGEM are competitive with existing tools for protein inference.",
                    "offsetInBeginSection": 791,
                    "offsetInEndSection": 1074,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262821",
                    "text": "Based on a variant of kernel canonical correlation analysis, its originality is in the formalization of the protein network inference problem as a supervised learning problem, and in the integration of heterogeneous genomic data within this framework.",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 813,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a736f0c3b9d13c708000007",
            "body": "What is included in the Mentzer index?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                "http://www.ncbi.nlm.nih.gov/pubmed/19579993",
                "http://www.ncbi.nlm.nih.gov/pubmed/6185967",
                "http://www.ncbi.nlm.nih.gov/pubmed/18192142",
                "http://www.ncbi.nlm.nih.gov/pubmed/25806419",
                "http://www.ncbi.nlm.nih.gov/pubmed/24139948",
                "http://www.ncbi.nlm.nih.gov/pubmed/24388269",
                "http://www.ncbi.nlm.nih.gov/pubmed/28706390",
                "http://www.ncbi.nlm.nih.gov/pubmed/8162086",
                "http://www.ncbi.nlm.nih.gov/pubmed/20628316"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                    "text": "The patient groups were evaluated according to red blood cell (RBC) count; red blood distribution width index; the Mentzer, Shine and Lal, England and Fraser, Srivastava and Bevington, Green and King, Ricerca, Sirdah, and Ehsani indices; mean density of hemoglobin/liter of blood; and mean cell density of hemoglobin.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 953,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                    "text": "The Mentzer index was the most reliable index, as it had the highest sensitivity (98.7%), specificity (82.3%), and Youden's index (81%) for detecting \u03b2 -TT; this was followed by the Ehsani index (94.8%, 73.5%, and 68.3%, resp.)",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818016",
                    "text": "The Mentzer index provided the highest reliabilities for differentiating \u03b2 -TT from IDA.",
                    "offsetInBeginSection": 1245,
                    "offsetInEndSection": 1334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579993",
                    "text": "The best discrimination index according to Youden's criteria was Mentzer (Youden's index = 90.1) followed by the new index (Youden's index = 85.5).",
                    "offsetInBeginSection": 676,
                    "offsetInEndSection": 823,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579993",
                    "text": "Sensitivity, specificity and Youden's index were compared between the proposed index and four other indices, namely England-Fraser, Mentzer, Srivastava and RBC count.",
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 534,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24139948",
                    "text": "METHODS The oral manifestations and mean red blood cell count, corpuscular cell volume, red blood cell distribution width, Mentzer index, and Green and King index as well as blood concentrations of hemoglobin, iron, total iron binding capacity, vitamin B12, folic acid, and homocysteine in 65 TT patients and in 130 age- and sex-matched healthy controls were measured and compared.",
                    "offsetInBeginSection": 214,
                    "offsetInEndSection": 595,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24388269",
                    "text": "METHODS The oral manifestations and mean red blood cell (RBC) count, corpuscular cell volume, RBC distribution width, Mentzer index, and Green and King index as well as blood concentrations of hemoglobin, iron, total iron binding capacity, vitamin B12, folic acid, and homocysteine in 75 IDA patients and in 150 age- and sex-matched healthy controls were measured and compared.",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28706390",
                    "text": "Youden index of the Mentzer index (MI) was the highest (69.0) and S and L, the lowest (13.2) indicating MI to be the most efficient and the S and L, the least in differentiating the two entities.",
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 1063,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8162086",
                    "text": "Mentzer ratio MCV/RBC detected all cases of beta thalassemia but was a poor index for iron deficiency detection.",
                    "offsetInBeginSection": 776,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20628316",
                    "text": "The 12 discrimination indices were red blood cell (RBC) count, RBC distribution width, Mentzer Index, Green and King Index, RBC distribution width Index, England and Fraser Index, Shine and Lal Index, Srivastava Index, Ricerca Index, Ehsani Index, Sirdah Index, and Huber-Herklotz-Index.",
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 611,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a804f71faa1ab7d2e00001d",
            "body": "Which algorithm is used for detection of long repeat expansions?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28887402",
                "http://www.ncbi.nlm.nih.gov/pubmed/9674981",
                "http://www.ncbi.nlm.nih.gov/pubmed/22581592",
                "http://www.ncbi.nlm.nih.gov/pubmed/15096564",
                "http://www.ncbi.nlm.nih.gov/pubmed/24215022",
                "http://www.ncbi.nlm.nih.gov/pubmed/8723679",
                "http://www.ncbi.nlm.nih.gov/pubmed/28451558",
                "http://www.ncbi.nlm.nih.gov/pubmed/26586700",
                "http://www.ncbi.nlm.nih.gov/pubmed/23872203",
                "http://www.ncbi.nlm.nih.gov/pubmed/22536970"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9674981",
                    "text": "Here, the repeat expansion detection (RED) method was used to screen for CAG repeat expansion in 119 French BPAD patients.",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 408,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581592",
                    "text": "To improve and expedite the diagnostic methods for progressive myoclonus epilepsy (EPM1), myotonic dystrophy 2 (DM2) and spinocerebellar ataxia 8 (SCA8) caused by dynamic mutations, we adapted a repeat primed PCR (RP-PCR) assay which was previously developed for testing of other triplet repeat disorders.",
                    "offsetInBeginSection": 278,
                    "offsetInEndSection": 583,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581592",
                    "text": "CONCLUSIONS Here, for the first time, we report detection of large expansions in EPM1 and SCA8 patients.",
                    "offsetInBeginSection": 1446,
                    "offsetInEndSection": 1550,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15096564",
                    "text": "It proved useful for confirming the presence of large expansions in the Friedreich ataxia gene following an ambiguous result of long-range PCR, as well as rapid pre-screening for large repeat expansions associated with Friedreich ataxia and SCA10 and the shorter repeat expansions associated with SCA12.",
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 702,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15096564",
                    "text": "Here we describe a successful application of a fluorescent PCR method for the detection of expanded repeats in FRDA1, SCA10, and SCA12 genes.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 225,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24215022",
                    "text": "MOTIVATION Long expansions of short tandem repeats (STRs), i.e.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24215022",
                    "text": "Our method could also identify common STRs, (AAAG)- and (AAAAG)-repeat expansions, which are remarkably expanded at four positions in an SCA31 sample.",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28451558",
                    "text": "Precise detection of the GAA expansion repeat in frataxin gene has always been a challenge.",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586700",
                    "text": "CONTEXT Myotonic dystrophies (DMs) are a group of autosomal dominant neuromuscular disorders which are caused by large CTG/CCTG-repeat expansions in untranslated regions of DMPK/ZNF9 gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586700",
                    "text": "The \"phenotypic overlap\" in DMs creates complication in distinguishing patients with DM1 from patients with DM2 and underscores the need for these patients to undergo genetic test; therefore, detection and accurate sizing of the CTG/CCTG-repeat expansions are necessary.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac4e81d1251d03b000011",
            "body": "Which brain tumors does neuroligin-3 promote?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25913192",
                "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                "http://www.ncbi.nlm.nih.gov/pubmed/18555979",
                "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                "http://www.ncbi.nlm.nih.gov/pubmed/25957677",
                "http://www.ncbi.nlm.nih.gov/pubmed/24854097",
                "http://www.ncbi.nlm.nih.gov/pubmed/23248271",
                "http://www.ncbi.nlm.nih.gov/pubmed/18974885",
                "http://www.ncbi.nlm.nih.gov/pubmed/23583622"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                    "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 329,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                    "text": "An important mechanism that mediates this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway.",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 848,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18555979",
                    "text": "Recent studies reported that sequence polymorphisms in neuroligin-3 (NLGN3) and neuroligin-4 (NLGN4) genes have been linked to autism spectrum disorders indicating neuroligin genes as candidate targets in brain disorders.",
                    "offsetInBeginSection": 82,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                    "text": "This study indicates that synaptogenetic processes in brain and retina use different molecular machineries, whereby the neuroligins might represent the more distinctly regulated part of the neurexin-neuroligin complexes.",
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1266,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25957677",
                    "text": "demonstrate that this also occurs in the brain, identifying neuronal activity-induced secretion of neuroligin-3 as a novel mechanism promoting glioma proliferation.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24854097",
                    "text": "In this study, we characterized the expression of a gene involved in synaptogenesis and plasticity (neuroligin-3) and one that codes for the rate-limiting enzyme in dopamine biosynthesis (tyrosine hydroxylase; TH1) in the female Xiphophorus nigrensis (northern swordtail) brain as related to mate preference behavior.",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 726,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24854097",
                    "text": "Analysis of TH and neuroligin-3 expression across different brain regions showed that expression patterns varied with the male social environment only for neuroligin-3, where the density of correlated expression between brain regions was positively associated with mate choice contexts that involved a greater number of courting male phenotypes (LS and LL).",
                    "offsetInBeginSection": 1373,
                    "offsetInEndSection": 1730,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23248271",
                    "text": "Likewise, coexpression of both MDGA1 and neuroligin-2 reduced the synaptogenic capacity of neuroligin-2 in an artificial synapse-formation assay by abolishing the ability of neuroligin-2 to form an adhesion complex with neurexins.",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1225,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18974885",
                    "text": "Transcripts of neurexin I and one neuroligin tested were abundant in mushroom bodies, a higher order processing centre in the bee brain.",
                    "offsetInBeginSection": 1331,
                    "offsetInEndSection": 1467,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583622",
                    "text": "Rare mutations in neuroligins and neurexins predispose to autism, including a neuroligin-3 amino acid substitution (R451C) and a neuroligin-3 deletion.",
                    "offsetInBeginSection": 95,
                    "offsetInEndSection": 246,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a96f40cfcd1d6a10c00002b",
            "body": "What is calciphylaxis",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27321367",
                "http://www.ncbi.nlm.nih.gov/pubmed/10764004",
                "http://www.ncbi.nlm.nih.gov/pubmed/20019019",
                "http://www.ncbi.nlm.nih.gov/pubmed/24096524",
                "http://www.ncbi.nlm.nih.gov/pubmed/23663061",
                "http://www.ncbi.nlm.nih.gov/pubmed/28099971",
                "http://www.ncbi.nlm.nih.gov/pubmed/28375870",
                "http://www.ncbi.nlm.nih.gov/pubmed/25960299",
                "http://www.ncbi.nlm.nih.gov/pubmed/11422768",
                "http://www.ncbi.nlm.nih.gov/pubmed/21410615"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367",
                    "text": "WHAT IS NEW AND CONCLUSION Previously only few cases of solely warfarin-induced calciphylaxis have been described.",
                    "offsetInBeginSection": 450,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27321367",
                    "text": "WHAT IS KNOWN AND OBJECTIVE Calciphylaxis is a rare and potentially life-threatening cause of skin necrosis and is poorly recognized by clinicians in non-uraemic patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004",
                    "text": "Key Words: Calciphylaxis, parathyroid hormone, parathyroidectomy, skin necrosis, chronic renal failure.",
                    "offsetInBeginSection": 2001,
                    "offsetInEndSection": 2104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10764004",
                    "text": "OBJECTIVE Calciphylaxis, a rare disorder typically affecting renal failure patients, results in vascular calcification with subsequent skin necrosis, gangrene, and often death from sepsis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20019019",
                    "text": "Although calciphylaxis is most frequently associated with end-stage renal disease (ESRD) and secondary hyperparathyroidism, it has been reported infrequently among patients on warfarin.",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663061",
                    "text": "Calciphylaxis is a metastatic calcification-induced vasculopathy that results in the occlusion of small blood vessels.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663061",
                    "text": "Although calciphylaxis is normally associated with end-stage renal disease, calciphylaxis from non-uremic origin occurs as well.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099971",
                    "text": "Importance Classic calciphylaxis associated with renal failure is a life-threatening disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28099971",
                    "text": "Our review indicates that warfarin-associated calciphylaxis is clinically and pathophysiologically distinct from classic calciphylaxis.",
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 588,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11422768",
                    "text": "Calciphylaxis is associated with a very high mortality.",
                    "offsetInBeginSection": 2100,
                    "offsetInEndSection": 2155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d79ca1d1251d03b00001d",
            "body": "Is the gene CDKN2A nevogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15304099",
                "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                "http://www.ncbi.nlm.nih.gov/pubmed/12406345",
                "http://www.ncbi.nlm.nih.gov/pubmed/15761864",
                "http://www.ncbi.nlm.nih.gov/pubmed/3388933",
                "http://www.ncbi.nlm.nih.gov/pubmed/9537438",
                "http://www.ncbi.nlm.nih.gov/pubmed/9416844",
                "http://www.ncbi.nlm.nih.gov/pubmed/10471040",
                "http://www.ncbi.nlm.nih.gov/pubmed/9839807"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15304099",
                    "text": "Continued accumulation of nevi in mutation carriers supports a nevogenic role for this CDKN2A mutation.",
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10620111",
                    "text": "1), supporting the view that CDKN2A is nevogenic.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 651,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830827",
                    "text": "Our results support the hypothesis that unidentified nevogenic genes are co-inherited with CDKN2A and may influence carcinogenesis.",
                    "offsetInBeginSection": 1187,
                    "offsetInEndSection": 1318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15761864",
                    "text": "Germ-line mutations of the tumor-suppressor gene CDKN2A predispose individuals to melanoma in families worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9537438",
                    "text": "The status and the expression of cyclin-dependent kinase inhibitor A (CDKN2A) family genes, named CDKN2A, CDKN2B, and CDKN2C and of cyclin Ds (D1, D2, and D3) genes were investigated in 14 cases of human hepatoblastomas.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9537438",
                    "text": "These genes were selected because: 1) CDKN2A and CDKN2B are very frequently inactivated in human cancers; 2) cyclin Ds are overexpressed in several tumors and 3) CDKN2A is posttranscriptionally silenced in hepatocellular carcinomas.",
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9416844",
                    "text": "All of these families have now been screened for mutations within CDKN2A and CDK4, as well as for mutations within the CDKN2A homolog and 9p21 neighbor, the CDKN2B gene, and the alternative exon 1 (E1beta) of CDKN2A.",
                    "offsetInBeginSection": 712,
                    "offsetInEndSection": 928,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9416844",
                    "text": "Germline mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identified in a proportion of melanoma kindreds.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10471040",
                    "text": "The tumour suppressor gene CDKN2A, located on chromosome 9p21, encodes the cell cycle regulatory protein p16.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9839807",
                    "text": "The tumor suppressor gene, CDKN2A (p16), encodes a cyclin-dependent kinase inhibitor and functions as a negative regulator in the retinoblastoma pathway that blocks cell cycle progression from the G1 phase.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7373f63b9d13c708000008",
            "body": "Which disease is treated with Fexinidazole?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
                "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
                "http://www.ncbi.nlm.nih.gov/pubmed/22539226",
                "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
                "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
                "http://www.ncbi.nlm.nih.gov/pubmed/21200426",
                "http://www.ncbi.nlm.nih.gov/pubmed/6636983",
                "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
                "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
                "http://www.ncbi.nlm.nih.gov/pubmed/27491458"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
                    "text": "Here, we report that fexinidazole, a drug currently in phase 1 clinical trials for treating African trypanosomiasis, shows promise for treating visceral leishmaniasis.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22301556",
                    "text": "These findings illustrate the potential of fexinidazole as an oral drug therapy for treating visceral leishmaniasis.",
                    "offsetInBeginSection": 1547,
                    "offsetInEndSection": 1663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24841257",
                    "text": "Fexinidazole metabolites were effective in treating T. cruzi in a mouse model of acute infection, with cure rates superior to those achieved with either fexinidazole itself or benznidazole.",
                    "offsetInBeginSection": 1540,
                    "offsetInEndSection": 1729,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
                    "text": "CONCLUSIONS Fexinidazole is an effective oral treatment of acute and chronic experimental CD caused by benznidazole-susceptible, partially resistant, and resistant T. cruzi.",
                    "offsetInBeginSection": 1832,
                    "offsetInEndSection": 2005,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23133682",
                    "text": "Fexinidazole, a 2-subsituted 5-nitroimidazole drug candidate rediscovered following extensive compound mining by the Drugs for Neglected Diseases initiative and currently in Phase I clinical study for the treatment of human African trypanosomiasis, was evaluated in experimental models of acute and chronic CD caused by different strains of Trypanosoma cruzi.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
                    "text": "Therefore, we aimed to assess the safety and efficacy of an oral regimen of fexinidazole (a 2-substituted 5-nitroimidazole with proven trypanocidal activity) versus nifurtimox eflornithine combination therapy in patients with late-stage g-HAT.",
                    "offsetInBeginSection": 451,
                    "offsetInEndSection": 694,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113731",
                    "text": "INTERPRETATION Our findings show that oral fexinidazole is effective and safe for the treatment of T b gambiense infection compared with nifurtimox eflornithine combination therapy in late-stage HAT patients.",
                    "offsetInBeginSection": 3213,
                    "offsetInEndSection": 3421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21200426",
                    "text": "Fexinidazole is the first new clinical drug candidate with the potential for treating advanced-stage sleeping sickness in thirty years.",
                    "offsetInBeginSection": 3566,
                    "offsetInEndSection": 3701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21911566",
                    "text": "Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28552771",
                    "text": "In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.",
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 357,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8056a2faa1ab7d2e00001f",
            "body": "Which web resource for LIR motif-containing proteins in eukaryotes has been developed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                "http://www.ncbi.nlm.nih.gov/pubmed/24589857",
                "http://www.ncbi.nlm.nih.gov/pubmed/23043107",
                "http://www.ncbi.nlm.nih.gov/pubmed/28320742",
                "http://www.ncbi.nlm.nih.gov/pubmed/11522919",
                "http://www.ncbi.nlm.nih.gov/pubmed/23908376",
                "http://www.ncbi.nlm.nih.gov/pubmed/28668392",
                "http://www.ncbi.nlm.nih.gov/pubmed/28253953",
                "http://www.ncbi.nlm.nih.gov/pubmed/22354992"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                    "text": "Here, we have developed the iLIR@viral database ( http://ilir.uk/virus/ ) as a freely accessible web resource listing all the putative canonical LIR motifs identified in viral proteins.",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 929,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28806134",
                    "text": "Additionally, we used a curated text-mining analysis of the literature to identify novel putative LIR motif-containing proteins (LIRCPs) in viruses.",
                    "offsetInBeginSection": 930,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27484196",
                    "text": "Atg8-interacting proteins contain a short linear LC3-interacting region/LC3 recognition sequence/Atg8-interacting motif (LIR/LRS/AIM) motif which is responsible for their interaction with Atg8-family proteins.",
                    "offsetInBeginSection": 901,
                    "offsetInEndSection": 1110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320742",
                    "text": "Among HyD-LIR-GFP sensors harboring LIR motifs of 34 known LC3-binding proteins, HyD-LIR(TP)-GFP using the LIR motif from TP53INP2 allowed detection of all LC3/GABARAPs-positive autophagosomes.",
                    "offsetInBeginSection": 411,
                    "offsetInEndSection": 604,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320742",
                    "text": "Here, we developed new sensors that detect endogenous LC3/GABARAP proteins at the autophagosome using an LC3-interacting region (LIR) and a short hydrophobic domain (HyD).",
                    "offsetInBeginSection": 239,
                    "offsetInEndSection": 410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320742",
                    "text": "In contrast, HyD-LIR(Fy)-GFP using the LIR motif from FYCO1 specifically detected LC3A/B-positive autophagosomes.",
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 840,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28668392",
                    "text": "Although identification of conserved structural features of LIR motifs in complex with LC3-family members has established a canonical LIR motif, atypical conformations of LIR motifs have recently been revealed.",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 563,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253953",
                    "text": "We also describe a biophysical method for studying interactions between Atg8/LC3/GABARAP and LIR-containing proteins and a protocol for preparation and purification of LIR peptides.",
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253953",
                    "text": "Here, we present protocols for the identification of LIR-containing proteins, i.e., by yeast-two-hybrid screening, glutathione S-transferase (GST) pulldown experiments, and peptide arrays.",
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22354992",
                    "text": "Moreover, TBC1D5 could bridge the endosome and autophagosome via its C-terminal LIR motif.",
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac6821d1251d03b000012",
            "body": "How does neuronal activity affect neuroligin-3?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25913192",
                "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                "http://www.ncbi.nlm.nih.gov/pubmed/27725662",
                "http://www.ncbi.nlm.nih.gov/pubmed/15150161",
                "http://www.ncbi.nlm.nih.gov/pubmed/16300891",
                "http://www.ncbi.nlm.nih.gov/pubmed/15152050",
                "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                "http://www.ncbi.nlm.nih.gov/pubmed/19406211",
                "http://www.ncbi.nlm.nih.gov/pubmed/28607166",
                "http://www.ncbi.nlm.nih.gov/pubmed/28067903"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032268",
                    "text": "published in Cell has identified Neuroligin-3 (NLGN3) as a mitogen promoting high-grade glioma growth.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 329,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662",
                    "text": "Strikingly, developmentally early conditional knockout of cerebellin-1 only modestly impaired synaptic transmission, whereas in contrast to the individual single knockouts, developmentally early conditional double knockout of both cerebellin-1 and neuroligin-3 severely decreased synaptic transmission.",
                    "offsetInBeginSection": 1216,
                    "offsetInEndSection": 1518,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725662",
                    "text": "Mutations in neuroligin-3 predispose to autism, but how such mutations affect synaptic function remains incompletely understood.",
                    "offsetInBeginSection": 89,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28959975",
                    "text": "An important mechanism that mediates this neural regulation of brain cancer is activity-dependent cleavage and secretion of the synaptic adhesion molecule neuroligin-3 (NLGN3), which promotes glioma proliferation through the PI3K-mTOR pathway.",
                    "offsetInBeginSection": 605,
                    "offsetInEndSection": 848,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19406211",
                    "text": "The neuroligin (NL) gene family codes for brain specific cell adhesion molecules that play an important role in synaptic connectivity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28607166",
                    "text": "Overexpression of neuroligin-1 in control or neuroligin-deficient neurons increased synaptic transmission and synapse density but not spine numbers, suggesting that these effects reflect a gain-of-function mechanism; whereas overexpression of neuroligin-3, which, like neuroligin-1 is also targeted to excitatory synapses, had no comparable effect.",
                    "offsetInBeginSection": 1417,
                    "offsetInEndSection": 1765,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28607166",
                    "text": "Our data demonstrate that neuroligins are required for the physiological organization of neurotransmitter receptors in postsynaptic specializations and suggest that they do not play a major role in synapse formation.SIGNIFICANCE STATEMENT Human neuroligin genes have been associated with autism, but the cellular functions of different neuroligins and their molecular mechanisms remain incompletely understood.",
                    "offsetInBeginSection": 1766,
                    "offsetInEndSection": 2176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                    "text": "As a result, the neuroligin-3 deletion altered network activity by reducing gamma oscillations and sharp wave ripples, changes associated with a decrease in extinction of contextual fear memories.",
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 865,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                    "text": "Here we show that conditional deletion of the postsynaptic cell adhesion molecule neuroligin-3 in parvalbumin interneurons causes a decrease in NMDA-receptor-mediated postsynaptic currents and an increase in presynaptic glutamate release probability by selectively impairing the inhibition of glutamate release by presynaptic Group III metabotropic glutamate receptors.",
                    "offsetInBeginSection": 299,
                    "offsetInEndSection": 668,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28067903",
                    "text": "These results demonstrate that neuroligin-3 specifies the properties of excitatory synapses on parvalbumin-containing interneurons by a retrograde trans-synaptic mechanism and suggest a molecular pathway whereby neuroligin-3 mutations contribute to neuropsychiatric disorders.",
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9700adfcd1d6a10c00002c",
            "body": "Sclerostin regulates what process?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                "http://www.ncbi.nlm.nih.gov/pubmed/28571484",
                "http://www.ncbi.nlm.nih.gov/pubmed/25030653",
                "http://www.ncbi.nlm.nih.gov/pubmed/28477420",
                "http://www.ncbi.nlm.nih.gov/pubmed/17676017",
                "http://www.ncbi.nlm.nih.gov/pubmed/24152444",
                "http://www.ncbi.nlm.nih.gov/pubmed/21890009",
                "http://www.ncbi.nlm.nih.gov/pubmed/28081119",
                "http://www.ncbi.nlm.nih.gov/pubmed/26826396",
                "http://www.ncbi.nlm.nih.gov/pubmed/22836717"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                    "text": "We found that sclerostin upregulated osteocyte expression of carbonic anhydrase 2 (CA2/Car2), cathepsin K (CTSK/Ctsk), and tartrate-resistant acid phosphatase (ACP5/Acp5).",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 807,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                    "text": "Knockdown in MLO-Y4 cells of each of the putative sclerostin receptors, Lrp4, Lrp5 and Lrp6, using siRNA, inhibited the sclerostin induction of Car2, Catk and Acp5 mRNA, as well as pHo and calcium release.",
                    "offsetInBeginSection": 1496,
                    "offsetInEndSection": 1701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23737439",
                    "text": "The osteocyte product sclerostin is emerging as an important paracrine regulator of bone mass.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28571484",
                    "text": "In humans, the SOST gene encodes sclerostin, an inhibitor of bone growth and remodeling, which also negatively regulates the bone repair process.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25030653",
                    "text": "Therefore, adaptive bone remodeling occurring at a distinct bone compartment is orchestrated by altered sclerostin levels, which regulate the expression of the other osteocyte-specific proteins, such as RANKL, OPG, and proteins encoded by \"mineralization-related genes\" (DMP1, PHEX, and probably FGF23).",
                    "offsetInBeginSection": 1104,
                    "offsetInEndSection": 1407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24152444",
                    "text": "Encoded by the sost gene, sclerostin is expressed in osteocytes and cementocytes of cellular cementum.",
                    "offsetInBeginSection": 426,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21890009",
                    "text": "Sclerostin is a secreted inhibitor of Wnt signaling and plays an essential role in the regulation of bone mass.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28081119",
                    "text": "Sclerostin secreted by osteocytes is mechanosensory and important in bone remodeling.",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26826396",
                    "text": "Sclerostin negatively regulates Wnt signaling pathway and also has an important role in postmenopausal bone loss.",
                    "offsetInBeginSection": 94,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22836717",
                    "text": "Sclerostin regulates bone formation by inhibiting Wnt pathway signaling.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d7caa1d1251d03b00001e",
            "body": "What is Alzheimers disease resilience?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                "http://www.ncbi.nlm.nih.gov/pubmed/27815399",
                "http://www.ncbi.nlm.nih.gov/pubmed/28299413",
                "http://www.ncbi.nlm.nih.gov/pubmed/29124107",
                "http://www.ncbi.nlm.nih.gov/pubmed/18728949",
                "http://www.ncbi.nlm.nih.gov/pubmed/23127468",
                "http://www.ncbi.nlm.nih.gov/pubmed/21069604",
                "http://www.ncbi.nlm.nih.gov/pubmed/27079753",
                "http://www.ncbi.nlm.nih.gov/pubmed/28025282",
                "http://www.ncbi.nlm.nih.gov/pubmed/26984114"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "The following terminology was applied: Alzheimer resilience, brain resilience, metabolic resilience, cardiovascular resilience, mitochondrial resilience and exercise resilience.",
                    "offsetInBeginSection": 1114,
                    "offsetInEndSection": 1291,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "CONCLUSION knowing that disturbances in brain, neuroendocrine, vascular and mitochondria metabolism are important events in neurodegeneration and dementia development, the ability of exercise to trigger adaptive mechanisms might represent an important non-pharmacological strategy to improve resilience to AD.",
                    "offsetInBeginSection": 1609,
                    "offsetInEndSection": 1918,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "Five papers defined Alzheimer's resilience, 15 papers brain resilience, five cardiovascular resilience, one metabolic resilience, 11 mitochondrial resilience, and 7 exercise resilience.",
                    "offsetInBeginSection": 1339,
                    "offsetInEndSection": 1524,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28078981",
                    "text": "BACKGROUND Although Alzheimer's disease (AD) is a neurodegenerative pathology characterized by accumulation of \u03b2-amyloid plaques and neurofibrillary tangles at cerebral level, recent studies highlighted that AD might be the result of many altered physiological processes occurring at whole-organism level.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27815399",
                    "text": "Furthermore, resilience metrics interacted with biomarker status such that biomarker-positive individuals with low resilience showed the greatest risk of subsequent decline.",
                    "offsetInBeginSection": 1265,
                    "offsetInEndSection": 1438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28299413",
                    "text": "However, unlike other conditions (e.g., Alzheimer's disease and coronary artery disease), resilience to trauma is not a disease but an adaptive response to trauma.",
                    "offsetInBeginSection": 1452,
                    "offsetInEndSection": 1615,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18728949",
                    "text": "Social support positively influenced resilience, and caregivers with high family support had the highest probability of elevated resilience.",
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025282",
                    "text": "Objectives Apolipoprotein E (APOE) \u025b4 and Clusterin (CLU) C alleles are risk factors for Alzheimer's disease (AD) and episodic memory (EM) decline.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025282",
                    "text": "Results For both sexes, younger age, higher education, stronger grip, and everyday novel cognitive activity predicted memory resilience.",
                    "offsetInBeginSection": 769,
                    "offsetInEndSection": 905,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26984114",
                    "text": "MBSR training significantly improved the psychological resilience of some of the caregivers.",
                    "offsetInBeginSection": 703,
                    "offsetInEndSection": 795,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7376e33b9d13c708000009",
            "body": "Describe Vanishing lung syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26259424",
                "http://www.ncbi.nlm.nih.gov/pubmed/22564798",
                "http://www.ncbi.nlm.nih.gov/pubmed/25322795",
                "http://www.ncbi.nlm.nih.gov/pubmed/28219569",
                "http://www.ncbi.nlm.nih.gov/pubmed/22937434",
                "http://www.ncbi.nlm.nih.gov/pubmed/28975065",
                "http://www.ncbi.nlm.nih.gov/pubmed/25618882",
                "http://www.ncbi.nlm.nih.gov/pubmed/7272201",
                "http://www.ncbi.nlm.nih.gov/pubmed/24511405",
                "http://www.ncbi.nlm.nih.gov/pubmed/24977015"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424",
                    "text": "Vanishing lung syndrome (VLS) is a rare radiological syndrome in which the lungs appear to be disappearing on X-ray.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26259424",
                    "text": "Eventually, his CT chest revealed the diagnosis of giant bullous disease/vanishing lung syndrome.",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 792,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795",
                    "text": "The present study suggests that vanishing lung syndrome may be associated with autosomal dominant and recessive genetic inheritance.",
                    "offsetInBeginSection": 1316,
                    "offsetInEndSection": 1448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25322795",
                    "text": "Vanishing lung syndrome, also known as idiopathic giant bullous emphysema, is a rare disease characterized by giant emphysematous bullae.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219569",
                    "text": "Vanishing lung syndrome is a clinical presentation of giant bullous emphysema associated with significant morbidity and mortality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28219569",
                    "text": "We present a case of a 50-year-old white woman with vanishing lung syndrome who presented with a spontaneous secondary pneumothorax and an uncontrolled bronchopleural fistula.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22937434",
                    "text": "We describe here a rare case of Idiopathic Bullous Emphysema/Vanishing Lung Syndrome (VLS) in a 33-year-old male patient with a history of marijuana abuse who presents to the hospital with pleuritic chest pain thought to be due to pneumothorax based on the chest radiograph.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28975065",
                    "text": "A small number of case reports have described a pathological entity called vanishing lung syndrome (VLS), which is a rare bullous lung disease usually caused by tobacco smoking.",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24511405",
                    "text": "Vanishing lung syndrome (VLS) is a rare and distinct clinical syndrome that usually affects young men.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24977015",
                    "text": "Giant bullous emphysema (GBE), known as 'vanishing lung syndrome', usually occurs in association with chronic obstructive pulmonary disease (COPD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a80dbaafaa1ab7d2e000026",
            "body": "Are there ways of joint Bayesian inference of risk variants?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                "http://www.ncbi.nlm.nih.gov/pubmed/28334312",
                "http://www.ncbi.nlm.nih.gov/pubmed/28461708",
                "http://www.ncbi.nlm.nih.gov/pubmed/18753153",
                "http://www.ncbi.nlm.nih.gov/pubmed/26450523",
                "http://www.ncbi.nlm.nih.gov/pubmed/16498611",
                "http://www.ncbi.nlm.nih.gov/pubmed/29124304",
                "http://www.ncbi.nlm.nih.gov/pubmed/26599399",
                "http://www.ncbi.nlm.nih.gov/pubmed/24684016",
                "http://www.ncbi.nlm.nih.gov/pubmed/28669401"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "In simulation, RiVIERA promising power in detecting causal variants and causal annotations, the multi-trait joint inference further improved the detection power.",
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 697,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27407109",
                    "text": "Here, we introduce a new Bayesian model RiVIERA (Risk Variant Inference using Epigenomic Reference Annotations) for inference of driver variants from summary statistics across multiple traits using hundreds of epigenomic annotations.",
                    "offsetInBeginSection": 302,
                    "offsetInEndSection": 535,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334312",
                    "text": "Extensive numerical experiments show that our approach outperforms popular variable selection methods and tailored Bayesian procedures, dealing within hours with problems involving hundreds of thousands of genetic variants and tens to hundreds of clinical or molecular outcomes.",
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1353,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28461708",
                    "text": "Using simulation studies and a real data analysis, we demonstrate how posterior inference on the subclonal structure is enhanced with the joint modeling of both structure and sequencing variants on subclonal genomes.",
                    "offsetInBeginSection": 997,
                    "offsetInEndSection": 1213,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18753153",
                    "text": "MOTIVATION Bayesian analysis is one of the most popular methods in phylogenetic inference.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124304",
                    "text": "Transplant matching algorithms and disease association studies involving phasing and imputation of rare variants may benefit from this statistical inference framework.",
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1606,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29124304",
                    "text": "We have applied a Bayesian inference methodology for extending haplotype frequency distributions, using a model where new haplotypes are created by recombination of observed alleles.",
                    "offsetInBeginSection": 999,
                    "offsetInEndSection": 1181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24684016",
                    "text": "We propose a unified Bayesian framework for detecting genetic variants associated with a disease while exploiting image-based features as an intermediate phenotype.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669401",
                    "text": "This procedure can improve inference if only a particular class of variants confers disease risk and can suggest particular disease etiologies related to that class.",
                    "offsetInBeginSection": 935,
                    "offsetInEndSection": 1100,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28669401",
                    "text": "We present a rapid and powerful inference procedure for identifying loci associated with rare hereditary disorders using Bayesian model comparison.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9ac7ba1d1251d03b000013",
            "body": "What does intepirdine target?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                "http://www.ncbi.nlm.nih.gov/pubmed/26562889",
                "http://www.ncbi.nlm.nih.gov/pubmed/23163788",
                "http://www.ncbi.nlm.nih.gov/pubmed/28364242",
                "http://www.ncbi.nlm.nih.gov/pubmed/21569489",
                "http://www.ncbi.nlm.nih.gov/pubmed/26415476",
                "http://www.ncbi.nlm.nih.gov/pubmed/25815448",
                "http://www.ncbi.nlm.nih.gov/pubmed/25707966",
                "http://www.ncbi.nlm.nih.gov/pubmed/20018585"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                    "text": "Studies have shown that the current treatments for AD, cholinesterase inhibitors (ChEI's) and NMDA receptor antagonists, have limited efficacy.",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.",
                    "offsetInBeginSection": 1162,
                    "offsetInEndSection": 1430,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Ongoing Phase III clinical trials via passive immunotherapy against A\u03b2 peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising.",
                    "offsetInBeginSection": 1431,
                    "offsetInEndSection": 1576,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26562889",
                    "text": "Previous research has demonstrated that clutter can hurt search performance and a second target is less likely to be detected in a multiple-target search after a first target has been found, which raises a concern-how does clutter affect multiple-target search performance?",
                    "offsetInBeginSection": 389,
                    "offsetInEndSection": 662,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28364242",
                    "text": "It converts the native target to an artificial target specific for a secondary targeting molecule loaded with the probe or payload (effector).",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28364242",
                    "text": "DNA/cDNA analogs can serve as the recognition pair, i.e., the artificial target and the secondary targeting effector.",
                    "offsetInBeginSection": 507,
                    "offsetInEndSection": 624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28364242",
                    "text": "Differing from the conventional direct-targeting strategy in which a probe or payload is directly loaded onto a targeting molecule that binds to the native target, pretargeting is an improved targeting strategy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21569489",
                    "text": "BACKGROUND Zinc Finger Nucleases (ZFNs) are man-made restriction enzymes useful for manipulating genomes by cleaving target DNA sequences.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21569489",
                    "text": "ZFN off-target sites are outputted with links to genome browsers, facilitating off-target cleavage site screening.",
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 804,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21569489",
                    "text": "RESULTS ZFN-Site is a web interface that searches multiple genomes for ZFN off-target sites.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a981bcffcd1d6a10c00002d",
            "body": "List 3 symptoms of Wernicke encephalopathy.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15141340",
                "http://www.ncbi.nlm.nih.gov/pubmed/24293308",
                "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                "http://www.ncbi.nlm.nih.gov/pubmed/16219837",
                "http://www.ncbi.nlm.nih.gov/pubmed/26653343",
                "http://www.ncbi.nlm.nih.gov/pubmed/27399058",
                "http://www.ncbi.nlm.nih.gov/pubmed/17039990",
                "http://www.ncbi.nlm.nih.gov/pubmed/25856744",
                "http://www.ncbi.nlm.nih.gov/pubmed/23696407",
                "http://www.ncbi.nlm.nih.gov/pubmed/17698536"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340",
                    "text": "Wernicke encephalopathy, a potentially reversible condition, may be unrecognized in terminally ill cancer patients.",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15141340",
                    "text": "Although Wernicke encephalopathy has been reported in the oncological literature, only one terminally ill cancer patient with Wernicke encephalopathy has been reported.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293308",
                    "text": "Wernicke encephalopathy is rare and under-recognized in childhood and may be fatal.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24293308",
                    "text": "Wernicke encephalopathy should be considered in all children with cancer presenting a neurologic deterioration, mainly in brain tumors.",
                    "offsetInBeginSection": 891,
                    "offsetInEndSection": 1026,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                    "text": "The syndrome can develop from unrecognized or undertreated Wernicke encephalopathy.",
                    "offsetInBeginSection": 84,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                    "text": "Self-neglecting alcoholics who are bedridden may have severe illness and probably active Wernicke encephalopathy.",
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1028,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25539041",
                    "text": "The intra-individual course of Wernicke-Korsakoff syndrome has not been studied extensively, nor has the temporal progression of gait disturbances and other symptoms of Wernicke encephalopathy.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 361,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16219837",
                    "text": "Wernicke encephalopathy is a neurologic disorder that results from thiamine deficiency.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25856744",
                    "text": "Wernicke encephalopathy is an acute neuropsychiatric disease with heterogeneous symptoms, including changes in mental status, ataxia and ocular abnormalities; if left untreated, these symptoms can lead to morbidity and even to mortality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17698536",
                    "text": "BACKGROUND AND PURPOSE Wernicke encephalopathy is a severe neurologic disorder that results from a dietary vitamin B1 deficiency.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d8d691d1251d03b000020",
            "body": "What is the association of the protein RAB10 and Alzheimers disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26082458",
                "http://www.ncbi.nlm.nih.gov/pubmed/29127256",
                "http://www.ncbi.nlm.nih.gov/pubmed/27474410",
                "http://www.ncbi.nlm.nih.gov/pubmed/29125462",
                "http://www.ncbi.nlm.nih.gov/pubmed/21454697",
                "http://www.ncbi.nlm.nih.gov/pubmed/28860483",
                "http://www.ncbi.nlm.nih.gov/pubmed/27621483",
                "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                "http://www.ncbi.nlm.nih.gov/pubmed/20643919",
                "http://www.ncbi.nlm.nih.gov/pubmed/26291453"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458",
                    "text": "The target genes SEC22 vesicle trafficking protein homolog B (SEC22B) and SEC63 homolog (SEC63) regulated by miRNA-206, RAB10, member RAS oncogene family (RAB10) regulated by miRNA-655, and fms-related tyrosine kinase 1 (FLT1) regulated by miRNA-30e-3p and miRNA-369-3p were involved in the biological processes of protein transport and regulation of cell motion.",
                    "offsetInBeginSection": 678,
                    "offsetInEndSection": 1041,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26082458",
                    "text": "CONCLUSION The target genes SEC22B, RAB10, and FLT1 may be potential biomarkers of AD.",
                    "offsetInBeginSection": 1044,
                    "offsetInEndSection": 1130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29127256",
                    "text": "In this study, we analyse the selectivity and sensitivity of polyclonal and monoclonal phospho-specific antibodies raised against 9 different LRRK2 phosphorylated Rab proteins (Rab3A/3B/3C/3D, Rab5A/5B/5C, Rab8A/8B, Rab10, Rab12, Rab29[T71], Rab29[S72], Rab35 and Rab43).",
                    "offsetInBeginSection": 334,
                    "offsetInEndSection": 605,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27474410",
                    "text": "Recent work has revealed that LRRK2 directly phosphorylates a conserved threonine/serine residue in the effector-binding switch-II motif of a number of Rab GTPase proteins, including Rab10.",
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125462",
                    "text": "Here, we systematically analyzed the Rab protein family and found 14 of them (Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12, Rab29, Rab35 and Rab43) to be specifically phosphorylated by LRRK2, with evidence for endogenous phosphorylation for ten of them (Rab3A/B/C/D, Rab8A/B, Rab10, Rab12, Rab35 and Rab43).",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 503,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125462",
                    "text": "Affinity enrichment mass spectrometry revealed that the primary ciliogenesis regulator, RILPL1 specifically interacts with the LRRK2-phosphorylated forms of Rab8A and Rab10, whereas RILPL2 binds to phosphorylated Rab8A, Rab10, and Rab12.",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28860483",
                    "text": "The identification of Rab10 phosphorylated at Thr73 as a LRRK2 inhibition marker in human PBMCs strongly support inclusion of assays quantifying Rab10-pThr73 levels in upcoming clinical trials evaluating LRRK2 kinase inhibition as a disease-modifying treatment principle in PD.",
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1416,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                    "text": "We have now determined that a related Rab protein, Rab10, can interact with myosin Va, myosin Vb, and myosin Vc.",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 371,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19008234",
                    "text": "Interaction with Rab10 was dependent on the presence of the alternatively spliced exon D in myosin Va and myosin Vb and the homologous region in myosin Vc.",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 730,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20643919",
                    "text": "Expression of Rab10 is inducible by LPS.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 913,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7379a83b9d13c70800000a",
            "body": "Is Rucaparib effective for ovarian cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29166829",
                "http://www.ncbi.nlm.nih.gov/pubmed/28247266",
                "http://www.ncbi.nlm.nih.gov/pubmed/28790837",
                "http://www.ncbi.nlm.nih.gov/pubmed/23729402",
                "http://www.ncbi.nlm.nih.gov/pubmed/29050241",
                "http://www.ncbi.nlm.nih.gov/pubmed/27002934",
                "http://www.ncbi.nlm.nih.gov/pubmed/28751443",
                "http://www.ncbi.nlm.nih.gov/pubmed/27940438",
                "http://www.ncbi.nlm.nih.gov/pubmed/28057616",
                "http://www.ncbi.nlm.nih.gov/pubmed/27702817"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829",
                    "text": "CONCLUSION Rucaparib appears to be a safe and effective new option in the treatment of relapsed, advanced BRCA1/2 mutant ovarian cancer.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 914,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29166829",
                    "text": "In patients with deleterious BRCA1/2 mutation, an overall response rate of 80% was achieved in the phase II trial Assessment of Rucaparib in Ovarian CancEr Trial 2 (ARIEL2).",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28247266",
                    "text": "Rucaparib is also under phase II or III investigation in ovarian, breast and prostate cancer.",
                    "offsetInBeginSection": 539,
                    "offsetInEndSection": 632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837",
                    "text": "Rucaparib camsylate (CO-338, AG-014699, PF-01367338) is a potent PARP-1, PARP-2, and PARP-3 inhibitor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28790837",
                    "text": "There is evidence to suggest that rucaparib has clinical efficacy against ovarian tumors with high HRD-LOH.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23729402",
                    "text": "These results support further clinical evaluation of rucaparib either as a single agent or as an adjunct to chemotherapy for the treatment of sporadic ovarian cancer.",
                    "offsetInBeginSection": 1607,
                    "offsetInEndSection": 1773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934",
                    "text": "METHODS Phase II, open-label, multicentre trial of rucaparib in proven BRCA-1/2 mutation carriers with advanced breast and or ovarian cancer, WHO PS 0-1 and normal organ function.",
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 592,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27002934",
                    "text": "We investigated the efficacy and safety of single-agent rucaparib in germline (g) BRCA mutation carriers with advanced breast and ovarian cancers.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 410,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940438",
                    "text": "High LOH is associated with response to the PARP inhibitor rucaparib in BRCA wild-type ovarian cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28057616",
                    "text": "The FDA approved the PARP inhibitor rucaparib to treat women with advanced ovarian cancer who have already been treated with at least two chemotherapies and have a BRCA1 or BRCA2 gene mutation identified by an approved companion diagnostic test.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b27e6fcd1d6a10c00001e",
            "body": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                "http://www.ncbi.nlm.nih.gov/pubmed/28449648",
                "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                "http://www.ncbi.nlm.nih.gov/pubmed/27900229",
                "http://www.ncbi.nlm.nih.gov/pubmed/27283893",
                "http://www.ncbi.nlm.nih.gov/pubmed/25027965",
                "http://www.ncbi.nlm.nih.gov/pubmed/24549748",
                "http://www.ncbi.nlm.nih.gov/pubmed/28667567",
                "http://www.ncbi.nlm.nih.gov/pubmed/27917919",
                "http://www.ncbi.nlm.nih.gov/pubmed/28423190"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "text": "RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "text": "UNLABELLED Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                    "text": "OBJECTIVE Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma has been developed for the detection of fetal aneuploidy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27900229",
                    "text": "Introduction\u2003Recent technological advances have yielded a new method of prenatal screening, non-invasive prenatal testing (NIPT), which uses cell-free fetal DNA from the mother's blood to assess for aneuploidy.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 338,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27283893",
                    "text": "Non-invasive prenatal testing (NIPT) based on cell-free DNA in maternal plasma is being expanded to include additional chromosome abnormalities beyond those involving chromosomes 21, 18, 13, X and Y.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25027965",
                    "text": "BACKGROUND Non-invasive prenatal testing (NIPT) for aneuploidies is now available through commercial companies in many countries, including through private practice in the United Kingdom (UK).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24549748",
                    "text": "QUESTIONS UNDER STUDY Prenatal care has been significantly influenced by the introduction of non-invasive prenatal testing (NIPT) for aneuploidies in 2012.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24549748",
                    "text": "They were counselled about the available options for invasive prenatal testing (IPT) and NIPT available at the time of FTS.",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28667567",
                    "text": "Increasingly, high-risk pregnant women opt for non-invasive prenatal testing (NIPT) instead of invasive diagnostic testing.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28423190",
                    "text": "OBJECTIVE In this study, we expanded conventional cell-free fetal DNA (cfDNA)-based non-invasive prenatal testing (NIPT) to cover the entire genome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9acba61d1251d03b000014",
            "body": "Has intepirdine been evaluated in clinical trials? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
                "http://www.ncbi.nlm.nih.gov/pubmed/29131320",
                "http://www.ncbi.nlm.nih.gov/pubmed/29151578",
                "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                "http://www.ncbi.nlm.nih.gov/pubmed/28985716",
                "http://www.ncbi.nlm.nih.gov/pubmed/29155424",
                "http://www.ncbi.nlm.nih.gov/pubmed/28128869",
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                "http://www.ncbi.nlm.nih.gov/pubmed/29047408",
                "http://www.ncbi.nlm.nih.gov/pubmed/29089005"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29131320",
                    "text": "In November 2017, the Council of the European Society of Clinical Investigation (ESCI) evaluated all basic research articles published in the European Journal of Clinical Investigation (EJCI) from November 2016 to October 2017.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "RESULTS This study was started in June 2014 (registration period 2 years, survey period 3 years) and will end in May 2017.",
                    "offsetInBeginSection": 1392,
                    "offsetInEndSection": 1514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "METHODS This prospective survey will involve patients treated with landiolol for the treatment of tachyarrhythmia (AF/AFL) in cardiac dysfunction at Japanese medical facilities from June 2014 to May 2017.",
                    "offsetInBeginSection": 857,
                    "offsetInEndSection": 1061,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25454208",
                    "text": "In November 2013, landiolol hydrochloride (Onoact(\u00ae) 50 for Injection, Ono Pharamaceutical, Osaka, Japan) was approved with the indication for \"tachyarrhythmia (AF/AFL) in patients with cardiac dysfunction.\"",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985716",
                    "text": "Between November 2014 and June 2017, an estimated 110 patients from two sites in Japan were randomized (1:1) to morphine or oxycodone in GG and non-GG groups.",
                    "offsetInBeginSection": 1850,
                    "offsetInEndSection": 2008,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985716",
                    "text": "At the time of manuscript submission (July 2017), Three-quarters of patients have participated.",
                    "offsetInBeginSection": 2548,
                    "offsetInEndSection": 2643,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28128869",
                    "text": "METHODS The Platform for Research Online to investigate Genetics and Cognition in Ageing is a 10-year longitudinal and entirely remote study launched in November 2015.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047408",
                    "text": "From November 2014, a total of 60 patients will be recruited, and recruitment for the study is planned to be complete by October 2017.",
                    "offsetInBeginSection": 1420,
                    "offsetInEndSection": 1554,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29047408",
                    "text": "TRIAL REGISTRATION Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC CTI), trial registration: JAPIC CTI-142747 .",
                    "offsetInBeginSection": 1763,
                    "offsetInEndSection": 1901,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089005",
                    "text": "Implementation recommendations from clinical practice guidelines (CPGs), such as the revised guidelines on knee ligament sprains published in the November 2017 issue of JOSPT, can help to reduce unwarranted variation in clinical physical therapy practice, support evidence-informed practice, and add value at the point of care.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa3fa73d6d6b54f79000008",
            "body": "Is subacute sclerosing panencephalitis caused by the Measles vaccine?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                "http://www.ncbi.nlm.nih.gov/pubmed/2019970",
                "http://www.ncbi.nlm.nih.gov/pubmed/6685828",
                "http://www.ncbi.nlm.nih.gov/pubmed/26587021",
                "http://www.ncbi.nlm.nih.gov/pubmed/894077",
                "http://www.ncbi.nlm.nih.gov/pubmed/850592",
                "http://www.ncbi.nlm.nih.gov/pubmed/3531224",
                "http://www.ncbi.nlm.nih.gov/pubmed/1706253",
                "http://www.ncbi.nlm.nih.gov/pubmed/21311432",
                "http://www.ncbi.nlm.nih.gov/pubmed/2807674"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                    "text": "UNLABELLED Subacute sclerosing panencephalitis (SSPE), in the majority of cases, is caused by the wild measles virus, although there are some reports relating SSPE to vaccination.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15384893",
                    "text": "Subacute sclerosing panencephalitis is a fatal degenerative disease and, although it had largely disappeared because of nearly universal measles vaccination, it still remains a serious infection among children affected by human immunodeficiency virus (HIV).",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 663,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2019970",
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurodegenerative disease caused by the measles (rubeola) virus and is most often seen in children.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6685828",
                    "text": "There was no indication that measles vaccine can induce SSPE.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 888,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26587021",
                    "text": "Subacute Sclerosing Panencephalitis (SSPE), a rare lethal disease of children and young adults due to persistence of measles virus (MeV) in the brain, is caused by wild type (wt) MeV.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/850592",
                    "text": "Because live measles vaccine is highly effective in preventing measles illness and a high proportion of children in the United States have received measles vaccine, these data are consistent with the observed downward trend in SSPE incidence since 1969.",
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3531224",
                    "text": "Finally, persons with subacute sclerosing panencephalitis and atypical measles mounted abnormally high antibody responses to measles virus polypeptides, in particular the P protein.",
                    "offsetInBeginSection": 1005,
                    "offsetInEndSection": 1186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3531224",
                    "text": "The sera were obtained from individuals with a recent or long-past history of natural measles, from persons with a history of immunization with live attenuated measles vaccine, and from patients with multiple sclerosis, subacute sclerosing panencephalitis, or atypical measles.",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 539,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1706253",
                    "text": "Subacute sclerosing panencephalitis (SSPE) has become rare since the widespread use of the measles vaccine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21311432",
                    "text": "Subacute sclerosing panencephalitis (SSPE) is a progressive neurological disorder of childhood and early adolescence caused by persistent defective measles virus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d8ffe1d1251d03b000022",
            "body": "What are pQTLs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27532455",
                "http://www.ncbi.nlm.nih.gov/pubmed/27329291",
                "http://www.ncbi.nlm.nih.gov/pubmed/25087611",
                "http://www.ncbi.nlm.nih.gov/pubmed/23172855",
                "http://www.ncbi.nlm.nih.gov/pubmed/28129359",
                "http://www.ncbi.nlm.nih.gov/pubmed/28031287",
                "http://www.ncbi.nlm.nih.gov/pubmed/25124843",
                "http://www.ncbi.nlm.nih.gov/pubmed/28240269",
                "http://www.ncbi.nlm.nih.gov/pubmed/24823668",
                "http://www.ncbi.nlm.nih.gov/pubmed/21846806"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532455",
                    "text": "Some of these pQTLs [e.g., pQTLs for VDBP, sRAGE (gene = AGER), surfactant protein D (gene = SFTPD), and TNFRSF10C] have been previously associated with COPD phenotypes.",
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1472,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291",
                    "text": "cis-pQTLs for kallikrein and F12 also show trans associations for proteins (uPAR, kininogen) known to be cleaved by kallikrein and with NTproBNP.",
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1313,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27329291",
                    "text": "Here, we identify new common and rare genetic variants associated with cardiovascular-related protein levels (protein quantitative trait loci [pQTLs]).",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611",
                    "text": "Our results suggest that protein-based mechanisms might functionally buffer genetic alterations that influence mRNA expression levels and that pQTLs might contribute phenotypic diversity to a human population independently of influences on mRNA expression.",
                    "offsetInBeginSection": 1296,
                    "offsetInEndSection": 1552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25087611",
                    "text": "We collected more than 250,000 protein level measurements comprising 441 transcription factor and signaling protein isoforms across 68 Yoruba (YRI) HapMap lymphoblastoid cell lines (LCLs) and identified 12 cis and 160 trans protein level QTLs (pQTLs) at a false discovery rate (FDR) of 20%.",
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23172855",
                    "text": "Analyses were confirmed by mechanistic studies and MALDI-TOF/TOF, liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses of the two strongest pQTLs: A pQTL for mass-to-charge ratio (m/z) 3494 (LOD 24.9, D11Mit151) was identified as the N-terminal 35 amino acids of hemoglobin subunit A (Hba) and caused by genetic variation in Hba.",
                    "offsetInBeginSection": 811,
                    "offsetInEndSection": 1154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28129359",
                    "text": "In carrying out a genome wide genotype-protein association study (proteomic Quantitative Trait Loci, pQTL) within the CD patients, we identified 41 distinct proteomic traits influenced by cis pQTLs (underlying SNPs are referred to as pSNPs).",
                    "offsetInBeginSection": 903,
                    "offsetInEndSection": 1144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124843",
                    "text": "The objective of this study is to identify eQTL underlying expression of four gene families encoding isoflavone synthetic enzymes involved in the phenylpropanoid pathway, which are phenylalanine ammonia-lyase (PAL; EC 4.3.1.5), chalcone synthase (CHS; EC 2.3.1.74), 2-hydroxyisoflavanone synthase (IFS; EC1.14.13.136) and flavanone 3-hydroxylase (F3H; EC 1.14.11.9).",
                    "offsetInBeginSection": 285,
                    "offsetInEndSection": 651,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25124843",
                    "text": "Overlapped loci of eQTLs and phenotypic QTLs (pQTLs) were analyzed to identify the potential candidate genes underlying the accumulation of isoflavone in soybean seed.",
                    "offsetInBeginSection": 900,
                    "offsetInEndSection": 1067,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21846806",
                    "text": "These colocalizing correlated cis-eQTLs (c3-eQTLs) are highly attractive as primary susceptibility loci for the colocalizing pQTLs.",
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1095,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7428090384be9551000001",
            "body": "What can be predicted with the Wells criteria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12908858",
                "http://www.ncbi.nlm.nih.gov/pubmed/9447391",
                "http://www.ncbi.nlm.nih.gov/pubmed/23293869",
                "http://www.ncbi.nlm.nih.gov/pubmed/8065869",
                "http://www.ncbi.nlm.nih.gov/pubmed/22653873",
                "http://www.ncbi.nlm.nih.gov/pubmed/28260193",
                "http://www.ncbi.nlm.nih.gov/pubmed/1474394",
                "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                "http://www.ncbi.nlm.nih.gov/pubmed/19421941",
                "http://www.ncbi.nlm.nih.gov/pubmed/28119448"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9447391",
                    "text": "Specific research questions include: to what extent can consensus be achieved on definitions and accompanying rules of inference for criteria, the relationship of meta-analysis to the criterion of consistency, and the interrelationships of criteria such as consistency, strength of association, and biological plausibility.",
                    "offsetInBeginSection": 985,
                    "offsetInEndSection": 1308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9447391",
                    "text": "In theory, causal criteria can be used to either refute or predict causal effects.",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 777,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22653873",
                    "text": "Cyanide can be toxic to aquatic organisms, and the U.S. Environmental Protection Agency has developed ambient water-quality criteria to protect aquatic life.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28260193",
                    "text": "CONCLUSIONS Wienecke criteria can be an appropriate points-scoring system to predict prognosis for adrenocortical tumors in children.",
                    "offsetInBeginSection": 1284,
                    "offsetInEndSection": 1417,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1474394",
                    "text": "We also determined that these simple geometric criteria can be used to predict the degree of coupling between NADH consumption and product formation for a given substrate, which was in good agreement with the experimental values.",
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "METHODS We assessed the sensitivity, specificity, and positive and negative predictive values of the clinical criteria of the Consortium on dementia with Lewy Bodies (CDLB) in 18 patients with autopsy-proven DLB and in 76 patients with dementia not associated with Lewy bodies, using postmortem diagnosis as a gold standard.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 437,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "OBJECTIVE To assess the clinical validity of clinical diagnostic criteria for dementia with Lewy bodies (DLB).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "Clinical criteria had higher predictive validity in patients with pure DLB than in patients with DLB and AD.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 710,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "CDLB criteria for probable DLB (two or more major criteria) distinguished DLB from AD with a sensitivity of 78% and a specificity of 64%.",
                    "offsetInBeginSection": 1000,
                    "offsetInEndSection": 1137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10599768",
                    "text": "Positive predictive value of 75% can be achieved by a combination of any three major or minor criteria, providing the analysis is confined to patients with mild to moderate dementia.",
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8b292afcd1d6a10c00001f",
            "body": "Is there any role of interleukin-11 in cardiovascular fibrosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20100971",
                "http://www.ncbi.nlm.nih.gov/pubmed/29160304",
                "http://www.ncbi.nlm.nih.gov/pubmed/23229370",
                "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                "http://www.ncbi.nlm.nih.gov/pubmed/9369414",
                "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                "http://www.ncbi.nlm.nih.gov/pubmed/9416001",
                "http://www.ncbi.nlm.nih.gov/pubmed/8244270",
                "http://www.ncbi.nlm.nih.gov/pubmed/10612573",
                "http://www.ncbi.nlm.nih.gov/pubmed/26199463"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                    "text": "These results indicate that NF-\u03baB has an essential role in mediating the cardiovascular inflammatory response to angiotensin II and suggest that targeting the balance of I\u03baB\u03b1 and I\u03baB\u03b2 expression might be a novel therapeutic modality in preventing fibrosis in hypertensive cardiovascular disease.",
                    "offsetInBeginSection": 1620,
                    "offsetInEndSection": 1920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                    "text": "The development of cardiovascular fibrosis is associated with chronic inflammation, where activation of nuclear factor \u03baB (NF-\u03baB) signaling may play a critical role.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21646597",
                    "text": "Replacement of I\u03baB\u03b1 with I\u03baB\u03b2 significantly attenuated angiotensin II infusion-induced expression of interleukin 1\u03b2, interleukin 6, monocyte chemotactic protein 1, collagen I and III, fibronectin, and tissue inhibitor of metalloproteinase 1 in the hearts.",
                    "offsetInBeginSection": 1027,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                    "text": "Here, we tested the hypothesis that deletion of interleukin-6 protects against the development of hypertension, cardiac inflammation, fibrosis, remodeling and dysfunction induced by high salt diet and angiotensin II (Ang II).",
                    "offsetInBeginSection": 291,
                    "offsetInEndSection": 516,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25304471",
                    "text": "CONCLUSION In conclusion, absence of interleukin -6 did not alter the development of Ang II-high salt-induced hypertension and cardiac hypertrophy, but it prevented the development of cardiac dysfunction, myocardial inflammation, and fibrosis.",
                    "offsetInBeginSection": 1345,
                    "offsetInEndSection": 1588,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8244270",
                    "text": "The inflammatory cytokines interleukin-1 beta, interleukin-6, interleukin-11, leukemia inhibitory factor and ciliary neurotrophic factor were also capable of stimulating expression of mRNA of tissue inhibitors of metalloproteinases-1.",
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 961,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8244270",
                    "text": "The combination of interleukin-1 beta, interleukin-6 and interleukin-11 synergistically up-regulated mRNA of tissue inhibitors of metalloproteinases-1.",
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10612573",
                    "text": "CONCLUSIONS Our results suggest that interleukin-4 may be involved in progression of interstitial fibrosis in idiopathic pulmonary fibrosis, in which we confirmed a significant contribution of eosinophils and mast cells to interleukin-4 production.",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10612573",
                    "text": "METHODOLOGY We compared interleukin-4 expressing cells in tissues from 11 patients with pathologically confirmed idiopathic pulmonary fibrosis with early stage inflammatory lesions versus advanced lesions.",
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26199463",
                    "text": "Importance of chronic fibroproliferative diseases (FDs) including pulmonary fibrosis, chronic kidney diseases, inflammatory bowel disease, and cardiovascular or liver fibrosis is rapidly increasing and they have become a major public health problem.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9acc7b1d1251d03b000015",
            "body": "What is crenezumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28924036",
                "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                "http://www.ncbi.nlm.nih.gov/pubmed/27996029",
                "http://www.ncbi.nlm.nih.gov/pubmed/24803227",
                "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                "http://www.ncbi.nlm.nih.gov/pubmed/25483498",
                "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                "http://www.ncbi.nlm.nih.gov/pubmed/26721364",
                "http://www.ncbi.nlm.nih.gov/pubmed/27025652"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                    "text": "In conclusion, the biosimilar antibodies Solanezumab, Crenezumab and Bapineuzumab strongly react with amyloid plaques, which are in contrast to the NT4X antibody that hardly recognizes plaques in human tissue.",
                    "offsetInBeginSection": 1742,
                    "offsetInEndSection": 1951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                    "text": "In contrast to the biosimilar antibodies of Solanezumab, Crenezumab and Bapineuzumab, the murine NT4X antibody shows a unique target engagement.",
                    "offsetInBeginSection": 1350,
                    "offsetInEndSection": 1494,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                    "text": "Solanezumab and Crenezumab are two humanized antibodies targeting Amyloid-\u03b2 (A\u03b2) which are currently tested in multiple clinical trials for the prevention of Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27996029",
                    "text": "Crenezumab is a humanized anti-A\u03b2 monoclonal IgG4 that binds multiple forms of A\u03b2, with higher affinity for aggregated forms, and that blocks A\u03b2 aggregation, and promotes disaggregation.",
                    "offsetInBeginSection": 284,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24803227",
                    "text": "The most developed method for targeting A\u03b2 is the use of monoclonal antibodies including bapineuzumab, solanezumab and crenezumab.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 302,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                    "text": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-\u03b2 (A\u03b2) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                    "text": "Two other monoclonal antibodies, gantenerumab, which preferentially binds to fibrillar A\u03b2, and crenezumab, which preferentially binds to soluble, oligomeric and fibrillar A\u03b2 deposits, are being tested in secondary prevention trials in presymptomatic subjects with autosomal dominant AD mutations.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 1076,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                    "text": "Second-generation active A\u03b2 vaccines (CAD106, ACC-001, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) have been developed and are under clinical testing.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26721364",
                    "text": "Ongoing clinical trials with A\u03b2 antibodies (solanezumab, gantenerumab, crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1 and ACI-35) are now in early-stage trials.",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1017,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025652",
                    "text": "Confirmation that presenilin is the catalytic site of \u03b3-secretase has provided a linchpin: all dominant mutations causing early-onset AD occur either in the substrate (amyloid precursor protein, APP) or the protease (presenilin) of the reaction that generates A\u03b2.",
                    "offsetInBeginSection": 312,
                    "offsetInEndSection": 577,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa3fb7ad6d6b54f79000009",
            "body": "What drug cures hepatitis C?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27790121",
                "http://www.ncbi.nlm.nih.gov/pubmed/26043288",
                "http://www.ncbi.nlm.nih.gov/pubmed/22504355",
                "http://www.ncbi.nlm.nih.gov/pubmed/26209383",
                "http://www.ncbi.nlm.nih.gov/pubmed/28644739",
                "http://www.ncbi.nlm.nih.gov/pubmed/21652618",
                "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                "http://www.ncbi.nlm.nih.gov/pubmed/28035197",
                "http://www.ncbi.nlm.nih.gov/pubmed/26035170",
                "http://www.ncbi.nlm.nih.gov/pubmed/20227031"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26043288",
                    "text": "Peginterferon combined with ribavirin and even the first-wave protease inhibitors telaprevir and boceprevir now belong to the milestones that had an important, although historical, role in the final conquest of hepatitis C.",
                    "offsetInBeginSection": 1364,
                    "offsetInEndSection": 1587,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26209383",
                    "text": "We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy.",
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 602,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644739",
                    "text": "The advent of oral direct-acting antivirals (DAA) has revolutionized the hepatitis C virus (HCV) therapeutic landscape providing cure rates over 90%.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21652618",
                    "text": "To maximize treatment success and reduce the likelihood of drug resistance selection, a proper individualization of hepatitis C therapy will be required, choosing the most convenient drugs and strategies according to distinct viral and host profiles.",
                    "offsetInBeginSection": 1256,
                    "offsetInEndSection": 1506,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21652618",
                    "text": "The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "INTRODUCTION The combination of pegylated interferon-\u03b1 plus ribavirin (pegIFN\u03b1-RBV) has been the only therapeutic option for patients with chronic hepatitis C virus (HCV) infection during the last decade.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "The addition of any of the two recently approved HCV protease inhibitors, boceprevir or telaprevir, to pegIFN\u03b1-RBV results in the cure for two-thirds of HCV genotype 1, interferon-naive patients.",
                    "offsetInBeginSection": 454,
                    "offsetInEndSection": 650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "AREAS COVERED This paper reviews new antivirals for hepatitis C and HCV treatment failures, along with HCV drug resistance and rescue therapies.",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 797,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242928",
                    "text": "The recent introduction of new direct-acting antivirals (DAA) has revolutionized the hepatitis C field.",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26035170",
                    "text": "Given that chronic hepatitis C affects globally around 20% of HIV persons, major attention has been focused on the HIV/HCV-coinfected population.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d96564e03427e73000001",
            "body": "List major risk factors for Alzheimer's disease. ",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21655757",
                "http://www.ncbi.nlm.nih.gov/pubmed/11884656",
                "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                "http://www.ncbi.nlm.nih.gov/pubmed/10396132",
                "http://www.ncbi.nlm.nih.gov/pubmed/16478285",
                "http://www.ncbi.nlm.nih.gov/pubmed/9240002",
                "http://www.ncbi.nlm.nih.gov/pubmed/16945215",
                "http://www.ncbi.nlm.nih.gov/pubmed/22169231",
                "http://www.ncbi.nlm.nih.gov/pubmed/20182020",
                "http://www.ncbi.nlm.nih.gov/pubmed/10822478"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11884656",
                    "text": "The apolipoprotein E E4 allele and a positive family history (FH) are both genetic risk factors for AD.",
                    "offsetInBeginSection": 102,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                    "text": "Three other important modifiable risk factors should also be added to this list: midlife hypercholesterolemia, late life atrial fibrillation, and chronic kidney disease.",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1034,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                    "text": "Among the 93 identified risk factors, seven major modifiable ones should be considered: low education, sedentary lifestyle, midlife obesity, midlife smoking, hypertension, diabetes, and midlife depression.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 864,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16478285",
                    "text": "Several epidemiological studies have indicated that the long-term use of NSAIDs, most of which are cyclo-oxygenase (COX) inhibitors, may reduce the risk of Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215",
                    "text": "Apolipoprotein E is the major risk factor for Alzheimer's disease.",
                    "offsetInBeginSection": 581,
                    "offsetInEndSection": 647,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215",
                    "text": "RESULTS Alzheimer's disease and vascular dementia both share significant risk attributable to cardiovascular risk factors.",
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 271,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16945215",
                    "text": "Diabetes and obesity are also risk factors for dementia.",
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22169231",
                    "text": "In addition to Apoliprotein E (APOE) \u03b54, the major genetic risk factor, recent genome-wide association studies (GWAS) have identified a growing list of sequence variations associated with the disease.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 293,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20182020",
                    "text": "The major vascular risk factors such as diabetes and impaired glycemic control, hypertension, obesity, and hyper- or dyslipidemia have been associated both with Alzheimer's disease and vascular dementia.",
                    "offsetInBeginSection": 223,
                    "offsetInEndSection": 426,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20182020",
                    "text": "Midlife diabetes mellitus, hypertension, and obesity are established risk factors for clinically defined Alzheimer's disease as well as vascular dementia.",
                    "offsetInBeginSection": 838,
                    "offsetInEndSection": 992,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7486a90384be9551000003",
            "body": "Which molecules are inhibited by anticancer drug Dovitinib?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                "http://www.ncbi.nlm.nih.gov/pubmed/25521244",
                "http://www.ncbi.nlm.nih.gov/pubmed/22674553",
                "http://www.ncbi.nlm.nih.gov/pubmed/27025387",
                "http://www.ncbi.nlm.nih.gov/pubmed/26149476",
                "http://www.ncbi.nlm.nih.gov/pubmed/23908597",
                "http://www.ncbi.nlm.nih.gov/pubmed/22027573",
                "http://www.ncbi.nlm.nih.gov/pubmed/22180308",
                "http://www.ncbi.nlm.nih.gov/pubmed/23443805",
                "http://www.ncbi.nlm.nih.gov/pubmed/29101463"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib inhibited the catalytic decatenation activity of topoisomerase II\u03b1.",
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 893,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib (TKI258/CHIR258) is a multi-kinase inhibitor in phase III development for the treatment of several cancers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Finally, dovitinib inhibited the topoisomerase I-catalyzed relaxation of plasmid DNA and acted as a cellular topoisomerase I poison.",
                    "offsetInBeginSection": 1365,
                    "offsetInEndSection": 1497,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231",
                    "text": "Dovitinib is a benzimidazole-quinolinone compound that structurally resembles the bisbenzimidazole minor groove binding dye Hoechst 33258.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25521244",
                    "text": "Dovitinib weakly inhibited CYP2C19, CYP3A4, P-gp and OATPs.",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1022,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22674553",
                    "text": "Dovitinib, a drug in clinical development, showed greater activity than sunitinib and sirolimus.",
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1382,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26149476",
                    "text": "INTRODUCTION Erlotinib is a FDA approved small molecule inhibitor of epidermal growth factor receptor and dovitinib is a novel small molecule inhibitor of fibroblast growth factor and vascular endothelial growth factor receptor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23443805",
                    "text": "Here, we explore the therapeutic potential of 2 FGFR inhibitors, the multikinase inhibitor dovitinib (TKI258) and the more selective FGFR inhibitor NVP-BGJ398 for the treatment of endometrial cancer.",
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23443805",
                    "text": "Dovitinib and NVP-BGJ398 warrant further clinical evaluation in patients with FGFR2-mutated endometrial cancer.",
                    "offsetInBeginSection": 1565,
                    "offsetInEndSection": 1676,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29101463",
                    "text": "PURPOSE Dovitinib is an orally available multi tyrosine kinase inhibitor which inhibits VEGFR 1-3, FGFR 1-3, and PDGFR.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67c497b750ff4455000012",
            "body": "Which method is available for whole genome identification of pathogenic regulatory variants in mendelian disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                "http://www.ncbi.nlm.nih.gov/pubmed/27354691",
                "http://www.ncbi.nlm.nih.gov/pubmed/22258526",
                "http://www.ncbi.nlm.nih.gov/pubmed/20577567",
                "http://www.ncbi.nlm.nih.gov/pubmed/26448358",
                "http://www.ncbi.nlm.nih.gov/pubmed/25024279",
                "http://www.ncbi.nlm.nih.gov/pubmed/28844620",
                "http://www.ncbi.nlm.nih.gov/pubmed/26405949",
                "http://www.ncbi.nlm.nih.gov/pubmed/28518168",
                "http://www.ncbi.nlm.nih.gov/pubmed/26110593"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "Overall, Genomiser is able to identify causal regulatory variants as the\u00a0top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian disease.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 929,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance to\u00a0discover variants associated to specific Mendelian disorders.",
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 718,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569544",
                    "text": "The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mendelian disease, especially for single-nucleotide and other small non-coding variants.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27354691",
                    "text": "The results suggest that Mendelian disease genes with autosomal dominant (AD) inheritance mode are more haploinsufficiency and de novo mutation sensitive, whereas those autosomal recessive (AR) genes have significantly more non-synonymous variants and regulatory transcript isoforms.",
                    "offsetInBeginSection": 620,
                    "offsetInEndSection": 903,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258526",
                    "text": "Next generation sequencing can be used to search for Mendelian disease genes in an unbiased manner by sequencing the entire protein-coding sequence, known as the exome, or even the entire human genome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20577567",
                    "text": "Here we sequenced the whole genome of a single patient with the dominant Mendelian disease, metachondromatosis (OMIM 156250), and used partial linkage data from her small family to focus our search for the responsible variant.",
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 590,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25024279",
                    "text": "Whole exome and whole genome sequencing are now routinely used in the study of inherited disease, and some of their major successes have been the identification of genes involved in disease predisposition in pedigrees where disease seems to follow Mendelian inheritance patterns.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28844620",
                    "text": "Among several variations of NGS, whole exome sequencing (WES) has emerged as a smart strategy that enables identification of disease causing variants present within the coding region of the human genome.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 725,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26405949",
                    "text": "Therefore, an automatic and efficient pipeline for finding disease variants in Mendelian disorders is designed by exploiting a combination of variants filtering steps to analyze the family-based exome sequencing approach.",
                    "offsetInBeginSection": 429,
                    "offsetInEndSection": 650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28518168",
                    "text": "PurposeWhole-exome and whole-genome sequencing have transformed the discovery of genetic variants that cause human Mendelian disease, but discriminating pathogenic from benign variants remains a daunting challenge.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9acd921d1251d03b000016",
            "body": "In what phase of clinical trials is crenezumab? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                "http://www.ncbi.nlm.nih.gov/pubmed/24803227",
                "http://www.ncbi.nlm.nih.gov/pubmed/26721364",
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                "http://www.ncbi.nlm.nih.gov/pubmed/26467270",
                "http://www.ncbi.nlm.nih.gov/pubmed/25483498",
                "http://www.ncbi.nlm.nih.gov/pubmed/28066098"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25880481",
                    "text": "Solanezumab (Eli Lilly) and crenezumab (Genentech) are the leading clinical antibodies targeting Amyloid-\u03b2 (A\u03b2) to be tested in multiple Phase III clinical trials for the prevention of Alzheimer's disease in at-risk individuals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                    "text": "Second-generation active A\u03b2 vaccines (ACC-001, CAD106, and Affitope AD02) and new passive anti-A\u03b2 immunotherapies (gantenerumab and crenezumab) are being tested in prodromal Alzheimer's disease patients, in presymptomatic individuals with Alzheimer's disease-related mutations, or in asymptomatic individuals at risk of developing Alzheimer's disease to definitely test the A\u03b2 cascade hypothesis of Alzheimer's disease.",
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                    "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.",
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 826,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24445401",
                    "text": "Another antibody, solanezumab, directed at the mid-region of A\u03b2, failed in two Phase III clinical trials in mild-to-moderate Alzheimer's disease patients.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 982,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26721364",
                    "text": "Ongoing clinical trials with A\u03b2 antibodies (solanezumab, gantenerumab, crenezumab) seem to be promising, while vaccines against the tau protein (AADvac1 and ACI-35) are now in early-stage trials.",
                    "offsetInBeginSection": 821,
                    "offsetInEndSection": 1017,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Ongoing Phase III clinical trials via passive immunotherapy against A\u03b2 peptides (crenezumab, gantenerumab, and aducanumab) seem to be promising.",
                    "offsetInBeginSection": 1431,
                    "offsetInEndSection": 1576,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.",
                    "offsetInBeginSection": 1577,
                    "offsetInEndSection": 1795,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                    "text": "INTRODUCTION Two humanized monoclonal antibodies, bapineuzumab and solanezumab, directed against the N terminus and mid-region of \u03b2-amyloid (A\u03b2), respectively, were recently tested in large, long-term Phase III trials in patients with mild-to-moderate Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24981190",
                    "text": "Two other monoclonal antibodies, gantenerumab, which preferentially binds to fibrillar A\u03b2, and crenezumab, which preferentially binds to soluble, oligomeric and fibrillar A\u03b2 deposits, are being tested in secondary prevention trials in presymptomatic subjects with autosomal dominant AD mutations.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 1076,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24490853",
                    "text": "Among passive immunotherapeutics, two Phase III clinical trials in mild-to-moderate AD patients with bapineuzumab, a humanized monoclonal antibody directed at the N-terminal sequence of A\u03b2, were disappointing.",
                    "offsetInBeginSection": 159,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa55b45d6d6b54f7900000d",
            "body": "What organism causes scarlet fever also known as scarletina?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
                "http://www.ncbi.nlm.nih.gov/pubmed/19868926",
                "http://www.ncbi.nlm.nih.gov/pubmed/19869458",
                "http://www.ncbi.nlm.nih.gov/pubmed/26819960",
                "http://www.ncbi.nlm.nih.gov/pubmed/7405299",
                "http://www.ncbi.nlm.nih.gov/pubmed/8219499",
                "http://www.ncbi.nlm.nih.gov/pubmed/10405382",
                "http://www.ncbi.nlm.nih.gov/pubmed/1485296",
                "http://www.ncbi.nlm.nih.gov/pubmed/125514",
                "http://www.ncbi.nlm.nih.gov/pubmed/23305889"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
                    "text": "Additionally, S. pyogenes induces toxin-mediated syndromes, i. e. scarlet fever, streptococcal toxic shock syndrome (STSS) and necrotizing fasciitis (NF).",
                    "offsetInBeginSection": 594,
                    "offsetInEndSection": 748,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19947304",
                    "text": "Most scientists recommend penicillins (benzylpenicillin, phenoxymethylpenicllin) as drugs of first choice for treatment of Streptococcus tonsillopharyngitis and scarlet fever.",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819960",
                    "text": "Far East scarlet-like fever is caused by Yersinia pseudotubuclosis infection, an organism that typically causes self-limiting gastroenteritis in Europe.",
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26819960",
                    "text": "Far East scarlet-like fever (FESLF) is a severe inflammatory disease that occurs sporadically and in outbreaks in Russia and Japan.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7405299",
                    "text": "More discussed are the infectious hospitalism, the salmonellial enteritis, the yersinioses, typhoid fever, paratyphoid fever, bacterial dysentery, scarlet fever, diphtheria, meningitis, brucelloses, leptospiroses, listerioses, pneumonias, bronchitis, obstructive diseases of the respiratory tract as well as pyelonephritis and bacterial carditis.",
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 945,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8219499",
                    "text": "Erythrogenic toxin type A (ETA) is assumed to play a causative role in both scarlet fever and the streptococcal toxic shock-like syndrome (TSLS).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8219499",
                    "text": "Increased occurrence of the speA gene among scarlet fever and TSLS-associated strains does not seem to be sufficient to support the hypothesis that ETA may have a causative role in both diseases since a considerable number of strains in these groups did not possess the speA gene.",
                    "offsetInBeginSection": 1055,
                    "offsetInEndSection": 1335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10405382",
                    "text": "We suggest that staphylococcal enterotoxins G and I may be capable of causing human staphylococcal toxic shock syndrome and staphylococcal scarlet fever.",
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1068,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/125514",
                    "text": "Consequently, a higher immunological reactivity of the organism in children in Ashkhabad (promoting rapid formation of both the antitoxic and the antimicrobial immunity and limiting of the spread of marked scarlet fever affections) underlied the differences in the level of scarlet fever morbidity in different climatic zones.",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23305889",
                    "text": "Group A Streptococcus (GAS) is the only pathogen known to cause scarlet fever.",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9da8df4e03427e73000006",
            "body": "What is emicizumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
                "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
                "http://www.ncbi.nlm.nih.gov/pubmed/28451690",
                "http://www.ncbi.nlm.nih.gov/pubmed/27223146",
                "http://www.ncbi.nlm.nih.gov/pubmed/27384849",
                "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
                "http://www.ncbi.nlm.nih.gov/pubmed/27885373",
                "http://www.ncbi.nlm.nih.gov/pubmed/27405674",
                "http://www.ncbi.nlm.nih.gov/pubmed/27960628"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
                    "text": "This phase 3, multicenter trial assessed once-weekly subcutaneous emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691557",
                    "text": "BACKGROUND Emicizumab (ACE910) bridges activated factor IX and factor X to restore the function of activated factor VIII, which is deficient in persons with hemophilia A.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
                    "text": "FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, si-RNA to reduce antithrombin expression and the bispecific antibody ACE910/Emicizumab.",
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042366",
                    "text": "Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa (FIXa) and the substrate factor X (FX).",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28451690",
                    "text": "Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a manner similar to FVIIIa.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27795538",
                    "text": "ACE910 (emicizumab) is a humanized bispecific antibody recognizing factor IXa and X mimicking factor VIII function.",
                    "offsetInBeginSection": 350,
                    "offsetInEndSection": 465,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27885373",
                    "text": "A promising approach in 2016 is the development of emicizumab (ACE910), a bi-specific IgG antibody to factor IXa and factor X, that mimics the cofactor function of factor VIII.",
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27405674",
                    "text": "Recently, recombinant porcine FVIII (rpFVIII, Obixur, OBI-1, BAX801) has been developed for the haemostatic treatment of both congenital haemophilia with inhibitor (CHAWI) and acquired haemophilia A (AHA).",
                    "offsetInBeginSection": 547,
                    "offsetInEndSection": 752,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27405674",
                    "text": "These are humanized asymmetric antibody mimicking FVIIIa function by maintaining a suitable interaction between FIXa and FX (Emicizumab, ACE910), and small interfering RNAs (siRNA, ALN-AT3) suppress liver production of AT through post-transcriptional gene silencing and a humanized anti-TFPI monoclonal antibody (Concizumab).",
                    "offsetInBeginSection": 1082,
                    "offsetInEndSection": 1407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27960628",
                    "text": "Of these, 5 mAbs are for cancer (durvalumab, JNJ-56022473, ublituximab, anetumab ravtansine, glembatumumab vedotin) and 15 mAbs are for non-cancer indications (caplacizumab, lanadelumab, roledumab, tralokinumab, risankizumab, SA237, emapalumab, suptavumab, erenumab, eptinezumab, fremanezumab, fasinumab, tanezumab, lampalizumab, brolucizumab).",
                    "offsetInBeginSection": 1609,
                    "offsetInEndSection": 1953,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75df9883b0d9ea66000002",
            "body": "Which cancers compose Carney's triad?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19561114",
                "http://www.ncbi.nlm.nih.gov/pubmed/3827356",
                "http://www.ncbi.nlm.nih.gov/pubmed/9591034",
                "http://www.ncbi.nlm.nih.gov/pubmed/11878780",
                "http://www.ncbi.nlm.nih.gov/pubmed/12893072",
                "http://www.ncbi.nlm.nih.gov/pubmed/8091266",
                "http://www.ncbi.nlm.nih.gov/pubmed/3361958",
                "http://www.ncbi.nlm.nih.gov/pubmed/22664948",
                "http://www.ncbi.nlm.nih.gov/pubmed/12149713",
                "http://www.ncbi.nlm.nih.gov/pubmed/1620943"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356",
                    "text": "Carney's Triad comprises a triad of neoplasms: gastric stromal tumor, extra-adrenal paraganglioma (usually functional), and pulmonary chondroma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3827356",
                    "text": "Thus, the Triad may be a disorder of the autonomic nervous system rather than a multiple endocrine neoplasia syndrome or multiple hamartoma syndrome.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 787,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11878780",
                    "text": "This report encourages clinicians to consider a diagnosis of Carney's triad in patients with multifocal gastric stromal sarcoma, extraadrenal paraganglioma (predominantly mediastinal), or pulmonary chondroma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893072",
                    "text": "Carney's triad is a syndrome of unknown etiology, representing a combination of gastrointestinal stromal tumors, bronchial chondromas and vagal, adrenal or paraadrenal paragangliomas.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12893072",
                    "text": "Two of the Carney's triad components-the paragangliomas and the gastrointestinal stromal tumors-are potentially lethal.",
                    "offsetInBeginSection": 184,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8091266",
                    "text": "Carney's triad, a rare disorder affecting young females, is characterized by the presence of at least two of the three following neoplasms: gastric epithelioid leiomyosarcoma, extra-adrenal paraganglioma, and pulmonary chondroma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8091266",
                    "text": "MRI is as effective as MIBG scintigraphy in detecting functioning paragangliomas.",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3361958",
                    "text": "Carney's triad--gastric leiomyosarcoma, pulmonary chondroma, and extra-adrenal paraganglioma--is a syndrome that occurs primarily in young women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12149713",
                    "text": "Carney's triad represents the association of gastric gastrointestinal stromal tumor, pulmonary chondroma, and extraadrenal paraganglioma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1620943",
                    "text": "We communicate a case with the Carney triad (gastric leiomyosarcoma, pulmonary chondromatosis and extra-adrenal paraganglioma).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d28981d1251d03b000017",
            "body": "Does verubecestat activate BACE?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
                "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
                "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                "http://www.ncbi.nlm.nih.gov/pubmed/28749667",
                "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
                "http://www.ncbi.nlm.nih.gov/pubmed/28800329",
                "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
                "http://www.ncbi.nlm.nih.gov/pubmed/17429617",
                "http://www.ncbi.nlm.nih.gov/pubmed/22152059",
                "http://www.ncbi.nlm.nih.gov/pubmed/27934506"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27807285",
                    "text": "We show that verubecestat (MK-8931) is a potent, selective, structurally unique BACE1 inhibitor that reduced plasma, cerebrospinal fluid (CSF), and brain concentrations of A\u03b240, A\u03b242, and sAPP\u03b2 (a direct product of BACE1 enzymatic activity) after acute and chronic administration to rats and monkeys.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27023706",
                    "text": "The most progressed mechanism-based therapies to date consist of immunological interventions to clear A\u03b2 oligomers, and pharmacological drugs to inhibit the secretase enzymes that produce A\u03b2, namely \u03b2-site amyloid precursor-cleaving enzyme (BACE) and \u03b3-secretase.",
                    "offsetInBeginSection": 948,
                    "offsetInEndSection": 1215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "These investigations include acetylcholinesterase inhibitors, agonists and antagonists of neurotransmitter receptors, \u03b2-secretase (BACE) or \u03b3-secretase inhibitors, vaccines or antibodies targeting A\u03b2 clearance or tau protein, as well as anti-inflammation compounds.",
                    "offsetInBeginSection": 1162,
                    "offsetInEndSection": 1430,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Using small molecules blocking 5-HT6 serotonin receptor (intepirdine), inhibiting BACE activity (E2609, AZD3293, and verubecestat), or reducing tau aggregation (TRx0237) are also currently in Phase III clinical trials.",
                    "offsetInBeginSection": 1577,
                    "offsetInEndSection": 1795,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28720101",
                    "text": "Recent therapeutic approaches have been strongly influenced by five neuropathological hallmarks of AD: acetylcholine deficiency, glutamate excitotoxicity, extracellular deposition of amyloid-\u03b2 (A\u03b2 plague), formation of intraneuronal neurofibrillary tangles (NTFs), and neuroinflammation.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
                    "text": "Expert opinion: Drugs in Phase III clinical development for AD include one inhibitor of the \u03b2-secretase cleaving enzyme (BACE) (verubecestat), three anti-A\u03b2 monoclonal antibodies (solanezumab, gantenerumab, and aducanumab), an inhibitor of receptor for advanced glycation end products (RAGE) (azeliragon) and the combination of cromolyn sodium and ibuprofen (ALZT-OP1).",
                    "offsetInBeginSection": 520,
                    "offsetInEndSection": 891,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27933948",
                    "text": "Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 315,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17429617",
                    "text": "Beta-secretase (BACE, i.e., BACE1), a prerequisite for Abeta genesis, is elevated in sporadic AD.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 242,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17429617",
                    "text": "All agents caused elevations of BACE proteins and beta-site amyloid precursor protein (APP) cleavage product, beta-CTF, in retinal lysates in a dose-dependant manner.",
                    "offsetInBeginSection": 847,
                    "offsetInEndSection": 1013,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22152059",
                    "text": "RESULTS Here, we report that BER could not only significantly decrease the production of beta-amyloid40/42 and the expression of beta-secretase (BACE), but was also able to activate the extracellular signal-regulated kinase1/2 (ERK1/2) pathway in a dose- and time-dependent manner in HEK293 cells stably transfected with APP695 containing the Swedish mutation.",
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 872,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9dad764e03427e73000007",
            "body": "What is the preDIVA clinical trial?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                "http://www.ncbi.nlm.nih.gov/pubmed/20306005",
                "http://www.ncbi.nlm.nih.gov/pubmed/28263374",
                "http://www.ncbi.nlm.nih.gov/pubmed/22818266",
                "http://www.ncbi.nlm.nih.gov/pubmed/19812459",
                "http://www.ncbi.nlm.nih.gov/pubmed/24418410",
                "http://www.ncbi.nlm.nih.gov/pubmed/28488553",
                "http://www.ncbi.nlm.nih.gov/pubmed/25548315",
                "http://www.ncbi.nlm.nih.gov/pubmed/21930719",
                "http://www.ncbi.nlm.nih.gov/pubmed/27688858"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28596452",
                    "text": "METHODS The preDIVA trial (Prevention of Dementia by Intensive Vascular Care) was an open-label, cluster-randomized controlled trial in community-dwelling individuals aged 70 to 78 years.",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 435,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20306005",
                    "text": "DESIGN, SETTING AND PARTICIPANTS Multi-center, open, cluster-randomized controlled clinical trial (preDIVA) including 3535 non-demented subjects aged 70-78, executed in primary practice and coordinated from one academic hospital.",
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263374",
                    "text": "OBJECTIVES To explore and compare sociodemographic, clinical, and neuropsychiatric determinants of dropout and nonadherence in older people participating in an open-label cluster-randomized controlled trial-the Prevention of Dementia by Intensive Vascular care (preDIVA) trial-over 6 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28263374",
                    "text": "INTERVENTION Nurse-led multidomain intervention targeting cardiovascular risk factors to prevent dementia.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 569,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22818266",
                    "text": "Three large RCTs on multi-component interventions to prevent dementia (preDIVA, FINGER, MAPT) have been initiated in Europe to address these issues.",
                    "offsetInBeginSection": 329,
                    "offsetInEndSection": 477,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19812459",
                    "text": "Intensive vascular care comprises treatment of hypertension, hypercholesterolemia, diabetes and reducing overweight, smoking cessation, and stimulating physical exercise.",
                    "offsetInBeginSection": 840,
                    "offsetInEndSection": 1010,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24418410",
                    "text": "At the moment, it includes three large ongoing European trials: Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER), Prevention of Dementia by Intensive Vascular Care (preDIVA), and Multidomain Alzheimer Prevention study (MAPT).",
                    "offsetInBeginSection": 922,
                    "offsetInEndSection": 1191,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25548315",
                    "text": "DESIGN AND SETTING Qualitative study of current and former participants of the ongoing \u22656 year PreDIVA (prevention of dementia by intensive vascular care) trial in primary care practices in suburban areas in the Netherlands.",
                    "offsetInBeginSection": 428,
                    "offsetInEndSection": 654,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21930719",
                    "text": "DESIGN Cross-sectional analysis of Dutch community-dwelling subjects aged 70-78 years without dementia who were included in the cluster randomized preDIVA trial (Prevention of Dementia by Intensive Vascular care).",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27688858",
                    "text": "The first results of RCTs of multimodal interventions (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, Multidomain Alzheimer Prevention Study, and Prediva) brought more optimism.",
                    "offsetInBeginSection": 1552,
                    "offsetInEndSection": 1767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76072283b0d9ea66000013",
            "body": "Does armodafinil improve fatigue of glioma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                "http://www.ncbi.nlm.nih.gov/pubmed/26542272",
                "http://www.ncbi.nlm.nih.gov/pubmed/25370889",
                "http://www.ncbi.nlm.nih.gov/pubmed/25972454",
                "http://www.ncbi.nlm.nih.gov/pubmed/21777715",
                "http://www.ncbi.nlm.nih.gov/pubmed/16908126",
                "http://www.ncbi.nlm.nih.gov/pubmed/17874255",
                "http://www.ncbi.nlm.nih.gov/pubmed/16684437",
                "http://www.ncbi.nlm.nih.gov/pubmed/22960434",
                "http://www.ncbi.nlm.nih.gov/pubmed/23983964"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "CONCLUSIONS While treatment was well-tolerated, an 8-week course of armodafinil did not improve fatigue or QOL in glioma patients undergoing RT in this pilot study.",
                    "offsetInBeginSection": 1326,
                    "offsetInEndSection": 1490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902850",
                    "text": "We evaluated whether armodafinil, a wakefulness-promoting medication, improves fatigue in glioma patients undergoing RT.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26542272",
                    "text": "Armodafinil did not improve cancer-related fatigue (CRF) and did not change the efficacy of CBT-I.",
                    "offsetInBeginSection": 1847,
                    "offsetInEndSection": 1945,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26542272",
                    "text": "Armodafinil alone did not show a statistically significant effect on fatigue levels (all Ps\u2009>\u20090.40) nor did the drug influence the efficacy of CBT-I.",
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1520,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25370889",
                    "text": "Armodafinil is a drug known to promote wakefulness, which is related to modafinil, a compound that improves fatigue in some cancer patients treated with chemotherapeutic agents.",
                    "offsetInBeginSection": 74,
                    "offsetInEndSection": 251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25972454",
                    "text": "We hypothesized that armodafinil (a wakefulness-promoting drug known to reduce fatigue and increase cognitive function in breast cancer patients receiving chemotherapy) would result in reduced fatigue and sleepiness for patients receiving brain RT.",
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22960434",
                    "text": "CONCLUSIONS Results provide preliminary evidence that armodafinil may improve delayed verbal recall in patients with MS. A larger trial showing enhanced memory among patients taking long-term armodafinil could serve as a foundation for its possible clinical use as a memory enhancer in patients with MS.",
                    "offsetInBeginSection": 1279,
                    "offsetInEndSection": 1582,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "text": "It has been suggested that modafinil and its isomer armodafinil as an add-on strategy to antipsychotic treatment in patients with schizophrenia may improve cognitive functioning, attenuate fatigue, inactiveness and other negative functions as well as weight gain.",
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 487,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "text": "The addition of modafinil or armodafinil to an antipsychotic regime, despite theoretical and preclinical considerations, has not been proved to enhance cognitive function, attenuate fatigue, enhance activity, improve negative symptoms and reduce weight in patients with schizophrenia.",
                    "offsetInBeginSection": 1855,
                    "offsetInEndSection": 2139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "text": "Evidence for the use of modafinil or armodafinil as add-on therapy to antipsychotic drugs to alleviate fatigue, sleepiness and inactivity is inconclusive.",
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 948,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d29571d1251d03b000018",
            "body": "What effect does azeliragon have on RAGE?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                "http://www.ncbi.nlm.nih.gov/pubmed/27678025",
                "http://www.ncbi.nlm.nih.gov/pubmed/25523934",
                "http://www.ncbi.nlm.nih.gov/pubmed/28722189",
                "http://www.ncbi.nlm.nih.gov/pubmed/16133426",
                "http://www.ncbi.nlm.nih.gov/pubmed/25559468",
                "http://www.ncbi.nlm.nih.gov/pubmed/21072897",
                "http://www.ncbi.nlm.nih.gov/pubmed/19591173",
                "http://www.ncbi.nlm.nih.gov/pubmed/27720951",
                "http://www.ncbi.nlm.nih.gov/pubmed/19815443"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27612394",
                    "text": "Blockade of RAGE by antibodies anti-RAGE, TTP488 (azeliragon), or rRAGE prevents or limits the deleterious effect of AGEs.",
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 738,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28722189",
                    "text": "The results suggest that calcitriol has therapeutic potential in treating RAGE-mediated cardiovascular complications.",
                    "offsetInBeginSection": 1617,
                    "offsetInEndSection": 1734,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16133426",
                    "text": "Despite the lack of effect seen in adaptive immunity by the deletion of RAGE, administration of the receptor decoy, sRAGE, still afforded a protective effect in RAGE-/- mice.",
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1509,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16133426",
                    "text": "The involvement of RAGE in pathophysiologic processes has been demonstrated in murine models of chronic disease using either a receptor decoy such as soluble RAGE (sRAGE), RAGE neutralizing antibodies, or a dominant-negative form of the receptor.",
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 881,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25559468",
                    "text": "Herein, we strengthened the cardioprotective effect with combinatorial treatment of soluble RAGE (sRAGE) and RAGE siRNA (siRAGE) causing more effective suppression of RAGE-mediated signaling transduction.",
                    "offsetInBeginSection": 307,
                    "offsetInEndSection": 511,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25559468",
                    "text": "For pharmacological blockade of RAGE, sRAGE, the extracellular ligand binding domain of RAGE, acts as a pharmacological ligand decoy and inhibits the interaction between RAGE and its ligands.",
                    "offsetInBeginSection": 512,
                    "offsetInEndSection": 703,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19591173",
                    "text": "Cells were stimulated with agonist S100A4, fusion protein of RAGE encompassing the extracellular domain of RAGE (ex-RAGE), ex-RAGE followed by S100A4, or S100A4 followed by ex-RAGE.",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 588,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19591173",
                    "text": "In conclusion, ex-RAGE down-regulates RAGE expression and inhibits p65 and p52 activation in HSG, providing evidence that ex-RAGE functions as a \"decoy\" to RAGE-ligand interaction and thus potentially dampening inflammatory conditions.",
                    "offsetInBeginSection": 1041,
                    "offsetInEndSection": 1276,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27720951",
                    "text": "Single particle tracking experiments that use quantum dots specifically bound to hemagglutinin (HA)-tagged RAGE (HA-RAGE) are reported to elucidate the effect of ligand binding on HA-RAGE diffusion in GM07373 cell membranes.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 399,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19815443",
                    "text": "Anti-RAGE antibody inhibited the effect of glycated proteins.",
                    "offsetInBeginSection": 1293,
                    "offsetInEndSection": 1354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9e2386de7cb99d40000004",
            "body": "What is the drug forxiga used for?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                "http://www.ncbi.nlm.nih.gov/pubmed/24030968",
                "http://www.ncbi.nlm.nih.gov/pubmed/25418019",
                "http://www.ncbi.nlm.nih.gov/pubmed/26410245",
                "http://www.ncbi.nlm.nih.gov/pubmed/28282104",
                "http://www.ncbi.nlm.nih.gov/pubmed/18808211",
                "http://www.ncbi.nlm.nih.gov/pubmed/15630785",
                "http://www.ncbi.nlm.nih.gov/pubmed/20014050",
                "http://www.ncbi.nlm.nih.gov/pubmed/11069442",
                "http://www.ncbi.nlm.nih.gov/pubmed/20803315"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "This study explores the molecular interactions between AChE and SGLT2 with a new US Food and Drug Administration approved antidiabetic drug Forxiga (dapagliflozin) to explore a possible link between the treatments of AD and diabetes.",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 693,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "Hence, dapagliflozin might act as a potent dual inhibitor of SGLT2 and AChE.",
                    "offsetInBeginSection": 1088,
                    "offsetInEndSection": 1164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402624",
                    "text": "Sodium glucose co-transporter 2 (SGLT2) is one of the best targets in the treatment of diabetes, whereas acetylcholinesterase (AChE) has long been regarded as a therapeutic target for AD.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 459,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24030968",
                    "text": "Dapagliflozin (Forxiga) belongs to a new class of oral glucose-lowering drugs that inhibit renal glucose reabsorption and promote glycosuria.",
                    "offsetInBeginSection": 601,
                    "offsetInEndSection": 742,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25418019",
                    "text": "INTRODUCTION Dapagliflozin (DAPA) (Farxiga or Forxiga) is a sodium glucose cotransporter 2 (SGLT2) inhibitor approved for type 2 diabetes mellitus(T2DM) treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18808211",
                    "text": "CONCLUSION Anticholinergic drug use is more common among cholinesterase inhibitor users than non-users, even though anticholinergic drugs may antagonize the effect of cholinesterase inhibitors.",
                    "offsetInBeginSection": 2199,
                    "offsetInEndSection": 2392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18808211",
                    "text": "OBJECTIVE To investigate (i) whether anticholinergic drug use is more common among users than non-users of cholinesterase inhibitors, and (ii) which factors are associated with use of anticholinergic drugs among users of cholinesterase inhibitors.",
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18808211",
                    "text": "The prevalence of use of anticholinergic drugs in users of cholinesterase inhibitors was compared with that in non-users of cholinesterase inhibitors and logistic regression was used to study the association between use of cholinesterase inhibitors and anticholinergic drugs.",
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20014050",
                    "text": "AIM The aim of the present study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) concomitantly or concurrently used psychotropic drugs and analgesics and the association between this drug use and the patients' gender and age.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20803315",
                    "text": "AIM The purpose of this study was to investigate to what extent patients using prescription antiobesity drugs (orlistat, sibutramine and rimonabant) used cardiovascular and antidiabetic drugs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 192,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a761ac3aacfb9cd4c000002",
            "body": "What is the most common feature of the Doege\u2013Potter syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23806618",
                "http://www.ncbi.nlm.nih.gov/pubmed/24745007",
                "http://www.ncbi.nlm.nih.gov/pubmed/9407565",
                "http://www.ncbi.nlm.nih.gov/pubmed/20585360",
                "http://www.ncbi.nlm.nih.gov/pubmed/3293678",
                "http://www.ncbi.nlm.nih.gov/pubmed/23918762",
                "http://www.ncbi.nlm.nih.gov/pubmed/18391497",
                "http://www.ncbi.nlm.nih.gov/pubmed/9451408",
                "http://www.ncbi.nlm.nih.gov/pubmed/22459315",
                "http://www.ncbi.nlm.nih.gov/pubmed/7485233"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23806618",
                    "text": "Similar phenotypes result from mutation of oral-facial-digital syndrome 1 (Ofd1), suggesting that aberrant transcription of Fgf8 is a common feature of ciliopathies.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 774,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23806618",
                    "text": "High arched palate is also a prevalent feature of fibroblast growth factor (FGF) hyperactivation syndromes.",
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9407565",
                    "text": "Pulmonary disease is a common presenting feature and complication of T-cell immunodeficiency.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20585360",
                    "text": "Since growth retardation is not a common feature of Crouzon syndrome, we reviewed the literature for the incidence of hydrocephalus in Crouzon syndrome and the association with growth hormone deficiency.",
                    "offsetInBeginSection": 824,
                    "offsetInEndSection": 1027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918762",
                    "text": "The present findings indicate that infantile hepatopathy is a cardinal feature of MEGDEL syndrome.",
                    "offsetInBeginSection": 965,
                    "offsetInEndSection": 1063,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918762",
                    "text": "3-Methylglutaconic aciduria (3-MGCA) type IV is defined as a heterogeneous group of inborn errors featuring in common 3-MGCA and associated with primary mitochondrial dysfunction leading to a spectrum of multisystem conditions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18391497",
                    "text": "More than 100 syndromes in which craniosynostosis is a feature have been documented and here the most common conditions including Apert and Crouzon syndromes are described as well as other conditions with a particularly interesting molecular etiology, such as Saethre- Chotzen and craniofrontonasal syndrome.",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 478,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459315",
                    "text": "RESULTS Syndromic mitochondrial disorders obligatory associated with epilepsy include Alpers-Huttenlocher-syndrome (AHS), ataxia neuropathy spectrum (ANS), Leigh-syndrome, MELAS-syndrome, myoclonic epilepsy, myopathy, and sensory ataxia (MEMSA) syndrome, and MERRF-syndrome, Occasionally, epilepsy is a phenotypic feature in IOSCA, KSS, LHON, LBSL, or NARP, All types of seizures occur but most frequently generalized tonic-clonic seizures, partial seizures, myoclonic jerks, or West-syndrome was reported.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 1033,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22459315",
                    "text": "CONCLUSIONS Epilepsy is a common phenotypic feature of syndromic as well as non-syndromic mitochondrial disorders.",
                    "offsetInBeginSection": 1344,
                    "offsetInEndSection": 1458,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7485233",
                    "text": "We suggest, therefore, that word-finding difficulties and verbal dyspraxia can be a common feature within the spectrum of this syndrome.",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 764,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d2a8f1d1251d03b000019",
            "body": "What is INCB3619?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                "http://www.ncbi.nlm.nih.gov/pubmed/17363546",
                "http://www.ncbi.nlm.nih.gov/pubmed/27489286",
                "http://www.ncbi.nlm.nih.gov/pubmed/18757423"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                    "text": "A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin.",
                    "offsetInBeginSection": 409,
                    "offsetInEndSection": 532,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                    "text": "In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC.",
                    "offsetInBeginSection": 533,
                    "offsetInEndSection": 660,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16843264",
                    "text": "We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17363546",
                    "text": "RESULTS INCB3619 was identified as a representative selective, potent, orally bioavailable small-molecule inhibitor of a subset of ADAM proteases that block shedding of ErbB ligands.",
                    "offsetInBeginSection": 956,
                    "offsetInEndSection": 1138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17363546",
                    "text": "Further, INCB3619 synergized with clinically relevant cancer therapeutics and showed no overt or compounding toxicities, including fibroplasia, the dose-limiting toxicity associated with broad-spectrum matrix metalloprotease inhibitors.",
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1570,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "Combining INCB3619 with a lapatinib-like dual inhibitor of EGFR and HER-2/neu kinases resulted in synergistic growth inhibition in MCF-7 and HER-2/neu-transfected MCF-7 human breast cancer cells.",
                    "offsetInBeginSection": 1288,
                    "offsetInEndSection": 1483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "Use of ErbB-specific antibodies to the receptors (Herceptin or Erbitux) or ErbB-specific small-molecule inhibitors of the receptor tyrosine kinase activity (Iressa or Tarceva) has shown clinical efficacy in several solid tumors.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "This study has shown that addition of INCB3619, a potent inhibitor of ADAM10 and ADAM17, reduces in vitro HER-2/neu and amphiregulin shedding, confirming that it interferes with both HER-2/neu and EGFR ligand cleavage.",
                    "offsetInBeginSection": 1069,
                    "offsetInEndSection": 1287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "ADAM 10 is the main sheddase of epidermal growth factor (EGF) and HER-2/neu cleavage, whereas ADAM17 is required for cleavage of additional EGF receptor (EGFR) ligands (transforming growth factor-alpha, amphiregulin, heregulin, heparin binding EGF-like ligand).",
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 1068,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18757423",
                    "text": "This sheddase activity is attributed to the ADAM (a disintegrin and metalloprotease) family of proteins.",
                    "offsetInBeginSection": 702,
                    "offsetInEndSection": 806,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa4faaed6d6b54f7900000b",
            "body": "Is Citrobacter rodentium pathogenic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19897651",
                "http://www.ncbi.nlm.nih.gov/pubmed/17557113",
                "http://www.ncbi.nlm.nih.gov/pubmed/16309456",
                "http://www.ncbi.nlm.nih.gov/pubmed/25624355",
                "http://www.ncbi.nlm.nih.gov/pubmed/11381624",
                "http://www.ncbi.nlm.nih.gov/pubmed/25088150",
                "http://www.ncbi.nlm.nih.gov/pubmed/22144475",
                "http://www.ncbi.nlm.nih.gov/pubmed/24831469",
                "http://www.ncbi.nlm.nih.gov/pubmed/11101562",
                "http://www.ncbi.nlm.nih.gov/pubmed/24358033"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651",
                    "text": "Citrobacter rodentium (formally Citrobacter freundii biotype 4280) is a highly infectious pathogen that causes colitis and transmissible colonic hyperplasia in mice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19897651",
                    "text": "In common with enteropathogenic and enterohemorrhagic Escherichia coli (EPEC and EHEC, respectively), C. rodentium exploits a type III secretion system (T3SS) to induce attaching and effacing (A/E) lesions that are essential for virulence.",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17557113",
                    "text": "The bacterial mouse pathogen Citrobacter rodentium causes attaching and effacing (AE) lesions in the same manner as pathogenic Escherichia coli, and is an important model for this mode of pathogenesis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 201,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16309456",
                    "text": "This classical genome organization is well illustrated by a group of extracellular enteric pathogens, which includes enteropathogenic Escherichia coli (EPEC), enterohaemorrhagic E. coli (EHEC) and Citrobacter rodentium, all of which use attaching and effacing (A/E) lesion formation as a major mechanism of tissue targeting and infection.",
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 758,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25624355",
                    "text": "A well-studied example is the RegA regulon of the enteric pathogen Citrobacter rodentium.",
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11381624",
                    "text": "Murine pathogenic Escherichia coli O115a,c:K(B) (MPEC) is the causative agent of mouse megaenteron, the pathology of which resembles that of transmissible murine colonic hyperplasia caused by Citrobacter rodentium.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25088150",
                    "text": "Citrobacter rodentium is a mucosal pathogen of mice that shares several pathogenic mechanisms with enteropathogenic Escherichia coli (EPEC) and enterohaemorrhagic E. coli (EHEC), which are two clinically important human gastrointestinal pathogens.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22144475",
                    "text": "The attaching and effacing mouse pathogen Citrobacter rodentium associates intimately with the intestinal epithelium, and infections result in acute colitis.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 325,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24831469",
                    "text": "Citrobacter rodentium infection is a murine model of pathogenic Escherichia coli infection that allows investigation of the cellular and molecular mechanisms involved in host-protective immunity and bacterial-induced intestinal inflammation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 241,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24358033",
                    "text": "Citrobacter rodentium (C. rodentium) is a member of the family of enteropathogens that provide an excellent in vivo model to investigate the host-pathogen interactions in real-time.",
                    "offsetInBeginSection": 212,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a679e8cb750ff4455000006",
            "body": "Milwaukee protocol was tested for treatment of which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21208030",
                "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                "http://www.ncbi.nlm.nih.gov/pubmed/26639059",
                "http://www.ncbi.nlm.nih.gov/pubmed/25956434",
                "http://www.ncbi.nlm.nih.gov/pubmed/11890620",
                "http://www.ncbi.nlm.nih.gov/pubmed/18305449",
                "http://www.ncbi.nlm.nih.gov/pubmed/23369672",
                "http://www.ncbi.nlm.nih.gov/pubmed/19545499",
                "http://www.ncbi.nlm.nih.gov/pubmed/27730539",
                "http://www.ncbi.nlm.nih.gov/pubmed/21865193"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21208030",
                    "text": "Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                    "text": "RESULTS Milwaukee brace 23-hours wearing protocol was most effective for the treatment of adolescent idiopathic scoliosis.",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                    "text": "CONCLUSION With part-time wearing protocol, the Milwaukee brace can survive today as a treatment option for idiopathic scoliosis with thoracic curve or double curve.",
                    "offsetInBeginSection": 808,
                    "offsetInEndSection": 973,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18465396",
                    "text": "Our Milwaukee brace part-time wearing treatment was effective, and by its use combined with physical therapy, better results than the natural history were obtained.",
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059",
                    "text": "Therapies suggested in the Milwaukee protocol include therapeutic coma, ketamine infusion, amantadine, and the screening/prophylaxis/management of cerebral vasospasm.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 550,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059",
                    "text": "The recommendations made by the Milwaukee protocol warrant serious reconsideration before any future use of this failed protocol.",
                    "offsetInBeginSection": 724,
                    "offsetInEndSection": 853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26639059",
                    "text": "The Milwaukee protocol has been attributed to survival in rabies encephalitis despite a lack of scientific evidence supporting its therapeutic measures.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25956434",
                    "text": "We report a case of a patient with paralytic rabies who survived after being treated with what is now known as Milwaukee protocol.",
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18305449",
                    "text": "This report summarizes the clinical course of disease in that patient, who was treated using the Milwaukee Protocol, an experimental treatment protocol similar to one used for the rabies survivor described in 2005.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 403,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19545499",
                    "text": "The Milwaukee protocol involves induction of therapeutic coma; however, there is no clear rationale for a neuroprotective role of this therapy, many reports exist of its failures, and its use should be abandoned.",
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 826,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d2dd21d1251d03b00001a",
            "body": "What do the trispecific HIV antibodies target?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                "http://www.ncbi.nlm.nih.gov/pubmed/27725635",
                "http://www.ncbi.nlm.nih.gov/pubmed/28981915",
                "http://www.ncbi.nlm.nih.gov/pubmed/10331185",
                "http://www.ncbi.nlm.nih.gov/pubmed/29097089",
                "http://www.ncbi.nlm.nih.gov/pubmed/22936109",
                "http://www.ncbi.nlm.nih.gov/pubmed/1655465",
                "http://www.ncbi.nlm.nih.gov/pubmed/28184223",
                "http://www.ncbi.nlm.nih.gov/pubmed/19169956"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28931639",
                    "text": "We engineered trispecific antibodies (Abs) that allow a single molecule to interact with three independent HIV-1 envelope determinants: the CD4 binding site, the membrane-proximal external region (MPER), and the V1V2 glycan site.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 404,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176328",
                    "text": "To test whether simultaneous targeting of EphA2, EphA4, and EphB4 would be an effective approach to cancer therapy, we generated a recombinant trispecific antibody using the variable domain genes of anti-EphA2, anti-EphA4, and anti-EphB4 monoclonal antibodies.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725635",
                    "text": "Recent innovations in antibody engineering have resulted in novel immunotherapeutics such as bispecific dual-affinity re-targeting (DART) molecules and other bi- and trispecific antibody designs that can recognize HIV-1 Env and recruit cytotoxic effector cells to kill CD4+ T cells latently infected with HIV-1.",
                    "offsetInBeginSection": 609,
                    "offsetInEndSection": 920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27725635",
                    "text": "Upon reactivation of proviral gene expression, HIV-1 envelope (HIV-1 Env) glycoproteins are expressed on the cell surface, transforming latently infected cells into targets for HIV-1 Env-specific monoclonal antibodies (mAbs), which can engage immune effector cells to kill productively infected CD4+ T cells and thus limit the spread of progeny virus.",
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981915",
                    "text": "Here, a novel CD16A (Fc\u03b3RIIIa)-directed trispecific, tetravalent antibody format, termed aTriFlex, is described, that is capable of redirecting NK cell cytotoxicity to two surface-expressed antigens.",
                    "offsetInBeginSection": 786,
                    "offsetInEndSection": 986,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10331185",
                    "text": "A trispecific F(ab')3 antibody conjugate (TAC) with specificities for the Fc gamma receptor I (Fc gamma RI/CD64), the epidermal growth factor receptor (EGFR) and the HER2/neu antigen has been developed to redirect effector cell-mediated cytotoxicity against cancer cells expressing both or either of the tumor-associated antigens.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 330,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10331185",
                    "text": "In step one, a bispecific antibody was prepared by linking the Fab' fragments of mAb m22 (a murine IgG1 specific for Fc gamma RI) and mAb H425 (a humanized IgG1 antibody recognizing EGFR).",
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 631,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097089",
                    "text": "Anti-HIV passive immunization with human neutralizing monoclonal antibodies (nmAbs) has made exciting gains: (i) identification of the HIV envelope V2 apex as a new in vivo protective epitope, (ii) a novel clade C SHIV for challenge studies, and (iii) a highly protective, trispecific nmAb.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 290,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1655465",
                    "text": "Previously we proposed a concept for tumor immunotherapy in which two different bispecific antibody conjugates, an anti-target x anti-CD3 and an anti-target x anti-CD28 conjugate, induce the activation of resting human T cells upon binding to the respective tumor target cells.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 277,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28184223",
                    "text": "Impressively, antibody fragments such as bispecific T-cell engager, bispecific killer cell engager, trispecific killer cell engager, tandem diabody, and dual-affinity-retargeting are showing exciting results in terms of recruiting and activating self-immune effector cells to target and lyse tumor cells.",
                    "offsetInBeginSection": 617,
                    "offsetInEndSection": 921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa6c800d6d6b54f79000012",
            "body": "What is liquid liquid phase transition?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16095377",
                "http://www.ncbi.nlm.nih.gov/pubmed/28641428",
                "http://www.ncbi.nlm.nih.gov/pubmed/16942294",
                "http://www.ncbi.nlm.nih.gov/pubmed/20805512",
                "http://www.ncbi.nlm.nih.gov/pubmed/22069236",
                "http://www.ncbi.nlm.nih.gov/pubmed/17155045",
                "http://www.ncbi.nlm.nih.gov/pubmed/26165855",
                "http://www.ncbi.nlm.nih.gov/pubmed/11102052",
                "http://www.ncbi.nlm.nih.gov/pubmed/25349962",
                "http://www.ncbi.nlm.nih.gov/pubmed/19566187"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16095377",
                    "text": "A possible order parameter and the universality class of liquid-liquid phase transitions in one-component fluids are discussed.",
                    "offsetInBeginSection": 1014,
                    "offsetInEndSection": 1141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16942294",
                    "text": "As an example the glacial phase formation and the first-order liquid-liquid phase transition in triphenyl phosphate are considered and discussed.",
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1034,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16942294",
                    "text": "These boundaries separate different phase states-amorphous solid, heterophase liquid, and fluid phases.",
                    "offsetInBeginSection": 404,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805512",
                    "text": "Proving the existence of the liquid-liquid phase transition in silicon, the hypothesized liquid-liquid scenario for water is strongly supported.",
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1662,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20805512",
                    "text": "As the relevant phases are easily distinguishable in their electronic structure, we track how silicon melts into the low-density-liquid phase while a second phase transition into the high-density-liquid phase only occurs after the latent heat for the first-order phase transition has been transferred to the atomic structure.",
                    "offsetInBeginSection": 1192,
                    "offsetInEndSection": 1517,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069236",
                    "text": "The temperature of the solid-to-liquid-crystalline phase transition seems mostly unaffected by the confinement, whereas the temperature of the liquid-crystalline-to-liquid phase transition is depressed for smaller pore sizes.",
                    "offsetInBeginSection": 353,
                    "offsetInEndSection": 578,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22069236",
                    "text": "The contact layer exhibits a phase transition at a temperature 30 K lower than the solid-to-liquid-crystalline phase transition observed for the neat ILC.",
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 802,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26165855",
                    "text": "Liquid-liquid transition, a phase transition of one liquid phase to another with the same composition, provides a key opportunity for investigating the relationship between liquid structures and dynamics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11102052",
                    "text": "Our model suggests a new possibility that (i) even an ordinary molecular liquid can have a hidden liquid-liquid phase transition and (ii) it may be the origin of a second amorphous phase (e.g., \"glacial phase\") and critical-like, large-scale fluctuations (\"Fischer clusters\") observed in supercooled molecular liquids.",
                    "offsetInBeginSection": 626,
                    "offsetInEndSection": 944,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19566187",
                    "text": "Therefore, the inference that liquid-liquid phase transition in supercooled liquid Si is a fragile-to-strong transition is unjustifiable.",
                    "offsetInBeginSection": 599,
                    "offsetInEndSection": 736,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ec6899e2c3af2600000c",
            "body": "Is pregabalin effective for sciatica?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23845078",
                "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                "http://www.ncbi.nlm.nih.gov/pubmed/15067505",
                "http://www.ncbi.nlm.nih.gov/pubmed/26818733",
                "http://www.ncbi.nlm.nih.gov/pubmed/26633090",
                "http://www.ncbi.nlm.nih.gov/pubmed/22685578",
                "http://www.ncbi.nlm.nih.gov/pubmed/23157108",
                "http://www.ncbi.nlm.nih.gov/pubmed/25682273",
                "http://www.ncbi.nlm.nih.gov/pubmed/19921480",
                "http://www.ncbi.nlm.nih.gov/pubmed/19092248"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23845078",
                    "text": "The impact of this research may allow the future development of a cost-effective conservative treatment strategy for patients with sciatica.",
                    "offsetInBeginSection": 2042,
                    "offsetInEndSection": 2182,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                    "text": "Pregabalin is effective in the treatment of some types of neuropathic pain.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28328324",
                    "text": "CONCLUSIONS Treatment with pregabalin did not significantly reduce the intensity of leg pain associated with sciatica and did not significantly improve other outcomes, as compared with placebo, over the course of 8 weeks.",
                    "offsetInBeginSection": 1877,
                    "offsetInEndSection": 2098,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15067505",
                    "text": "In neuropathic pain, different therapeutic approaches are effective, i.e., antidepressants such as amitriptyline and anticonvulsants such as gabapentin, carbamazepine, and pregabalin.",
                    "offsetInBeginSection": 883,
                    "offsetInEndSection": 1066,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26818733",
                    "text": "BACKGROUND Sciatica is a severe, disabling condition that lacks high quality evidence for effective treatment strategies.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26633090",
                    "text": "Whilst pregabalin (PGB) and gabapentin (GBP) are both used to treat neuropathic pain, their relative role in sciatica is unclear.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682273",
                    "text": "Pregabalin was effective for LBP with neuropathic pain, whereas opioids were effective for non-neuropathic pain.",
                    "offsetInBeginSection": 1005,
                    "offsetInEndSection": 1117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25682273",
                    "text": "Pregabalin was effective for LBP in patients with lower limb symptoms, whereas opioids were effective for those without lower limb symptoms.",
                    "offsetInBeginSection": 1188,
                    "offsetInEndSection": 1328,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19921480",
                    "text": "CONCLUSIONS Combination of celecoxib and pregabalin is more effective than monotherapy for chronic low-back pain, with similar adverse effects.",
                    "offsetInBeginSection": 1260,
                    "offsetInEndSection": 1403,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19092248",
                    "text": "RESULTS The combination of CR oxycodone plus pregabalin and CR oxycodone monotherapy were both more effective for alleviating neuropathic pain than pregabalin monotherapy (reduction in NRS value: 80, 76, and 46%, respectively; p </= 0.003).",
                    "offsetInBeginSection": 606,
                    "offsetInEndSection": 846,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d30241d1251d03b00001b",
            "body": "Can gas vesicles be detected by ultrasound?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24633522",
                "http://www.ncbi.nlm.nih.gov/pubmed/28880278",
                "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                "http://www.ncbi.nlm.nih.gov/pubmed/28889941",
                "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                "http://www.ncbi.nlm.nih.gov/pubmed/22562306",
                "http://www.ncbi.nlm.nih.gov/pubmed/24636363",
                "http://www.ncbi.nlm.nih.gov/pubmed/9810688",
                "http://www.ncbi.nlm.nih.gov/pubmed/23313452",
                "http://www.ncbi.nlm.nih.gov/pubmed/17520861"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24633522",
                    "text": "We show that gas vesicles produce stable ultrasound contrast that is readily detected in vitro and in vivo, that their genetically encoded physical properties enable multiple modes of imaging, and that contrast enhancement through aggregation permits their use as molecular biosensors.",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 816,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28880278",
                    "text": "Gas vesicles (GVs) are a unique class of gas-filled protein nanostructures that are detectable at subnanomolar concentrations and whose physical properties allow them to serve as highly sensitive imaging agents for ultrasound and MRI.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                    "text": "Gas vesicles-genetically encoded protein nanostructures isolated from buoyant photosynthetic microbes-have recently been identified as nanoscale reporters for ultrasound.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 357,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                    "text": "Here, we demonstrate that genetic engineering of gas vesicles results in nanostructures with new mechanical, acoustic, surface, and functional properties to enable harmonic, multiplexed, and multimodal ultrasound imaging as well as cell-specific molecular targeting.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 1040,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27351374",
                    "text": "Furthermore, as a genetically encoded material, gas vesicles present the possibility that the nanoscale mechanical, acoustic, and targeting properties of an imaging agent can be engineered at the level of its constituent proteins.",
                    "offsetInBeginSection": 543,
                    "offsetInEndSection": 773,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28889941",
                    "text": "Recently, biogenic gas vesicles (GVs), naturally formed by cyanobacteria and haloarchaea, have exhibited great potential as an ultrasound molecular imaging probe with a much smaller size (\u223c100\u00a0nm) and improved imaging contrast.",
                    "offsetInBeginSection": 191,
                    "offsetInEndSection": 421,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                    "text": "Gas vesicles (GVs) are a new and unique class of biologically derived ultrasound contrast agents with sub-micron size whose acoustic properties have not been fully elucidated.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28258771",
                    "text": "We illustrate that gas vesicles behave non-linearly when exposed to ultrasound at incident pressure ranging from 160\u00a0kPa to the collapse pressure and generate second harmonic amplitudes of -2 to -6\u00a0dB below the fundamental in media with viscosities ranging from 0.89 to 8\u00a0mPa\u00b7s.",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 801,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9810688",
                    "text": "The liposome entrapping CO2 gas inside the vesicle, which is called the echogenic liposome, has been made and characterized in vitro as an ultrasound contrast agent.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17520861",
                    "text": "The presence of gas bubbles in the vascular system is often considered a sign of decompression stress and several studies in the existing literature have addressed the relationship between the amount of bubbles detected by ultrasound Doppler systems and the incidence of decompression sickness.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa82388fcf4565872000001",
            "body": "Which proteins are regulated by Nrf2?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20427290",
                "http://www.ncbi.nlm.nih.gov/pubmed/20399915",
                "http://www.ncbi.nlm.nih.gov/pubmed/15601839",
                "http://www.ncbi.nlm.nih.gov/pubmed/22814021",
                "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
                "http://www.ncbi.nlm.nih.gov/pubmed/25827424",
                "http://www.ncbi.nlm.nih.gov/pubmed/20410673",
                "http://www.ncbi.nlm.nih.gov/pubmed/27816475",
                "http://www.ncbi.nlm.nih.gov/pubmed/15901726",
                "http://www.ncbi.nlm.nih.gov/pubmed/22641035"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20427290",
                    "text": "Mammalian cells respond to this damage by increased transcription of cytoprotective phase II genes, which are regulated by NRF2.",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20399915",
                    "text": "Correlative network analysis (MetaCore) identified two predominant groups of Nrf2-regulated proteins.",
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 908,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15601839",
                    "text": "Here we report that the human BTB-Kelch protein Keap1, a negative regulator of the antioxidative transcription factor Nrf2, binds to CUL3 and Nrf2 via its BTB and Kelch domains, respectively.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
                    "text": "The ARE binds different bZIP (basic-region leucine zipper) transcription factors, most notably Nrf2 (nuclear factor-erythroid 2-related factor 2) that functions as a transcriptional activator via heterodimerization with small Maf proteins.",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 567,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21812759",
                    "text": "In the present study, we have demonstrated that BACH1 itself is regulated by Nrf2 as it is induced by Nrf2 overexpression and by Nrf2-activating agents in an Nrf2-dependent manner.",
                    "offsetInBeginSection": 991,
                    "offsetInEndSection": 1171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424",
                    "text": "One such master regulator, the redox sensitive transcription factor NF E2 Related Factor 2 (NRF2), controls the expression of cellular defense genes including those encoding intracellular redox-balancing proteins involved in glutathione (GSH) synthesis.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25827424",
                    "text": "Overexpression of NRF2 up-regulated the activity of the xCT promoter, which contains a proximal ARE.",
                    "offsetInBeginSection": 1264,
                    "offsetInEndSection": 1364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20410673",
                    "text": "The transcription factor nuclear erythroid-derived 2-related factor 2 (Nrf2) regulates expression of genes encoding antioxidant proteins involved in cellular redox homeostasis, while gamma-ray irradiation is known to induce reactive oxygen species in vivo.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20410673",
                    "text": "Furthermore, the activation of Nrf2 was suppressed by U0126, which is an inhibitor of the extracellular signal regulated protein kinase 1/2 (ERK1/2) pathway, suggesting involvement of ERK1/2-dependent pathway in the irradiation-induced activation of Nrf2.",
                    "offsetInBeginSection": 900,
                    "offsetInEndSection": 1155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22641035",
                    "text": "As systems-level examples of NRF2-related signaling we identified regulatory loops of NRF2 interacting proteins (e.g., JNK1 and CBP) and a fine-tuned regulatory system, where 35 TFs regulated by NRF2 influence 63 miRNAs that down-regulate NRF2.",
                    "offsetInBeginSection": 404,
                    "offsetInEndSection": 648,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a9d31711d1251d03b00001c",
            "body": "What is the approximate size of gas vesicles?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3098234",
                "http://www.ncbi.nlm.nih.gov/pubmed/19007418",
                "http://www.ncbi.nlm.nih.gov/pubmed/19230840",
                "http://www.ncbi.nlm.nih.gov/pubmed/807555",
                "http://www.ncbi.nlm.nih.gov/pubmed/9573198",
                "http://www.ncbi.nlm.nih.gov/pubmed/7683649",
                "http://www.ncbi.nlm.nih.gov/pubmed/1956294",
                "http://www.ncbi.nlm.nih.gov/pubmed/2541878",
                "http://www.ncbi.nlm.nih.gov/pubmed/26743231",
                "http://www.ncbi.nlm.nih.gov/pubmed/9810688"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3098234",
                    "text": "This corresponds to the size of the repeating unit cell demonstrated by X-ray crystallography of intact gas vesicles.",
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418",
                    "text": "salinarum PHH1 and NRC-1 contained 5-20 small gas vesicles arranged in two to three aggregates per cell instead of the 30-80 gas vesicles present under oxic conditions.",
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19007418",
                    "text": "salinarum PHH1 and NRC-1 were grown with dimethyl sulphoxide or trimethylamine N-oxid under anoxic conditions the number but not the size of gas vesicles was reduced.",
                    "offsetInBeginSection": 1049,
                    "offsetInEndSection": 1215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19230840",
                    "text": "The turgor pressure decreases, however, as gas vesicles collapse; this decrease is minimised by calculating the turgor pressure in samples with few of their gas vesicles collapsed.",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 467,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9573198",
                    "text": "Evidence includes homologies by sequence analysis to known gas vesicle genes, the buoyancy phenotype of E. coli strains that carry this gvp gene cluster, the presence of pressure-sensitive, refractile bodies in phase-contrast microscopy, structural details in phase-contrast microscopy, structural details in direct interference-contrast microscopy, and shape and size revealed by transmission electron microscopy.",
                    "offsetInBeginSection": 631,
                    "offsetInEndSection": 1045,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1956294",
                    "text": "The comparison of the three genomic regions encoding gas vesicles in Halobacterium halobium (p-vac- and c-vac-region) and Haloferax mediterranei (mc-vac-region) indicates high DNA sequence similarity throughout a contiguous sequence of 9 kbp.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743231",
                    "text": "Using volumetric compression, gas vesicles were shown to comprise 17% of S39006 cells, whereas in Escherichia coli heterologously expressing the gas vesicle cluster in a deregulated environment, gas vesicles can occupy around half of cellular volume.",
                    "offsetInBeginSection": 945,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743231",
                    "text": "Gas vesicles are proteinaceous intracellular organelles, permeable only to gas, that enable flotation in aquatic niches.",
                    "offsetInBeginSection": 208,
                    "offsetInEndSection": 328,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743231",
                    "text": "One mode of taxis is flotation due to the production of gas vesicles.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9810688",
                    "text": "The acoustic reflectivity increased with the increase in size of the vesicle, largest for the gas filled MLV among the three liposome suspensions.",
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 552,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aacdcf1fcf4565872000009",
            "body": "List BET proteins.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                "http://www.ncbi.nlm.nih.gov/pubmed/12759485",
                "http://www.ncbi.nlm.nih.gov/pubmed/27283767",
                "http://www.ncbi.nlm.nih.gov/pubmed/27827996",
                "http://www.ncbi.nlm.nih.gov/pubmed/11487468",
                "http://www.ncbi.nlm.nih.gov/pubmed/24905006",
                "http://www.ncbi.nlm.nih.gov/pubmed/23420887",
                "http://www.ncbi.nlm.nih.gov/pubmed/23880220",
                "http://www.ncbi.nlm.nih.gov/pubmed/27769353",
                "http://www.ncbi.nlm.nih.gov/pubmed/25849938"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "The bromodomain and extra-terminal (BET) proteins are epigenetic readers which utilize tandem bromodomains (BRD) modules to recognize and dock themselves on the acetylated lysine tails.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 495,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26137204",
                    "text": "JQ1 is a prototype benzodiazepine molecule and a specific BET inhibitor with antineoplastic activity both in solid tumours and haematological malignancies.",
                    "offsetInBeginSection": 827,
                    "offsetInEndSection": 982,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27827996",
                    "text": "The mammalian BET family of proteins comprises BRD2, BRD3, BRD4, and BRDT, which are encoded by paralogous genes that may have been generated by repeated duplication of an ancestral gene during evolution.",
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 361,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11487468",
                    "text": "BET proteins are distinguished by an N-terminal bromodomain or bromodomains and an ET domain.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 281,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905006",
                    "text": "The bromodomain and extraterminal (BET) protein Brd4 recruits transcriptional regulatory complexes to acetylated chromatin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420887",
                    "text": "Bromodomain and extraterminal (BET) proteins are \"readers\" of histone acetylation marks, with demonstrated roles in gene transcription, but the ability of BET proteins to coordinate the response of inflammatory cytokine genes through translation of histone marks is unknown.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 583,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23420887",
                    "text": "Studies that use small interfering RNA knockdown and a small-molecule inhibitor of BET protein binding, JQ1, independently demonstrate BET proteins are critical for macrophage inflammatory responses.",
                    "offsetInBeginSection": 884,
                    "offsetInEndSection": 1083,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27769353",
                    "text": "Pharmacologic inhibitors of the bromodomain and extra-terminal motif (BET) protein family are in clinical trials for the treatment of hematologic malignancies, yet the functions of individual BET proteins remain largely uncharacterized.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25849938",
                    "text": "Proteins that share the feature of containing two BRDs and an extra-terminal domain belong to BET family, including BRD2, BRD3, BRD4 and BRDT.",
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 315,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25849938",
                    "text": "Thus, targeting BET proteins may be a promising strategy, and intense interest of BET proteins has fueled the development of structure-based bromodomain inhibitors in cancer.",
                    "offsetInBeginSection": 495,
                    "offsetInEndSection": 669,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa38f75d6d6b54f79000005",
            "body": "What is host induced gene silencing?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22678572",
                "http://www.ncbi.nlm.nih.gov/pubmed/21112837",
                "http://www.ncbi.nlm.nih.gov/pubmed/21818318",
                "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                "http://www.ncbi.nlm.nih.gov/pubmed/28856645",
                "http://www.ncbi.nlm.nih.gov/pubmed/21533687",
                "http://www.ncbi.nlm.nih.gov/pubmed/19573239",
                "http://www.ncbi.nlm.nih.gov/pubmed/17172752",
                "http://www.ncbi.nlm.nih.gov/pubmed/19547658",
                "http://www.ncbi.nlm.nih.gov/pubmed/25057444"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Planta-generated silencing of targeted genes inside biotrophic pathogens can be achieved by expression of M.oryzae-derived gene fragments in the BMV-mediated gene silencing system, a technique termed host-induced gene silencing (HIGS).",
                    "offsetInBeginSection": 511,
                    "offsetInEndSection": 746,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Brome mosaic virus (BMV)-induced RNA interference (RNAi) has emerged as a useful tool to study host-resistance genes for rice blast protection.",
                    "offsetInBeginSection": 367,
                    "offsetInEndSection": 510,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Systemic generation of fungal gene-specific small interfering RNA (siRNA) molecules induced by inoculation of BMV viral vectors inhibited disease development and reduced the transcription of targeted fungal genes after subsequent M.oryzae inoculation.",
                    "offsetInBeginSection": 902,
                    "offsetInEndSection": 1153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28954400",
                    "text": "Combined introduction of fungal gene sequences in sense and antisense orientation mediated by the BMV silencing vectors significantly enhanced the efficiency of this host-generated trans-specific RNAi, implying that these fungal genes played crucial roles in pathogenicity.",
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1427,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645",
                    "text": "We utilized Barley stripe mosaic virus-mediated virus induced gene silencing (BSMV-VIGS) to induce HIGS of candidate rust fungal genes in the wheat host to determine their role in plant-fungal interactions.",
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28856645",
                    "text": "Recently, Host-induced gene silencing (HIGS) has emerged as a useful tool to characterize gene function in rust fungi while infecting and growing in host plants.",
                    "offsetInBeginSection": 987,
                    "offsetInEndSection": 1148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19573239",
                    "text": "We demonstrate its ability to silence nuclear genes including ribulose bisphosphate carboxylase small subunit (rbcS), transketolase, the sulfur allele of magnesium chelatase (ChlI), and two homeotic transcription factors in spinach or tomato by generating gene-specific knock-down phenotypes.",
                    "offsetInBeginSection": 816,
                    "offsetInEndSection": 1108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17172752",
                    "text": "Virus-induced gene silencing (VIGS) is a powerful RNA-silencing based technology adapted for the study of host-gene function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19547658",
                    "text": "Virus-induced gene silencing (VIGS) is one of the reverse genetics tools for analysis of gene function that uses viral vectors carrying a target gene fragment to produce dsRNA which trigger RNA-mediated gene silencing.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19547658",
                    "text": "For instance, Barley stripe mosaic virus (BSMV)-mediated VIGS allows silencing of barley and wheat genes.",
                    "offsetInBeginSection": 1249,
                    "offsetInEndSection": 1354,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aad4b37fcf456587200000a",
            "body": "What is the proteoform?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28968100",
                "http://www.ncbi.nlm.nih.gov/pubmed/27451424",
                "http://www.ncbi.nlm.nih.gov/pubmed/28003265",
                "http://www.ncbi.nlm.nih.gov/pubmed/28453668",
                "http://www.ncbi.nlm.nih.gov/pubmed/26941048",
                "http://www.ncbi.nlm.nih.gov/pubmed/25752847",
                "http://www.ncbi.nlm.nih.gov/pubmed/27291504",
                "http://www.ncbi.nlm.nih.gov/pubmed/24807621",
                "http://www.ncbi.nlm.nih.gov/pubmed/28289760",
                "http://www.ncbi.nlm.nih.gov/pubmed/28706471"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100",
                    "text": "A proteoform family is a group of related molecular forms of a protein (proteoforms) derived from the same gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28968100",
                    "text": "In the present study, this strategy is extended by utilizing a global PTM discovery database and is applied to the widely studied model organism Escherichia coli, providing the most comprehensive elucidation of E. coli proteoforms and proteoform families to date.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 1136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451424",
                    "text": "Discovery of STAT1, WARS, MX1, and HSPB1 proteoform regulation by human respiratory syncytial virus highlighted the impact of the profiling strategy.",
                    "offsetInBeginSection": 1557,
                    "offsetInEndSection": 1706,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28003265",
                    "text": "We developed TopMG, a mass graph-based software tool for proteoform identification by top-down mass spectrometry.",
                    "offsetInBeginSection": 996,
                    "offsetInEndSection": 1109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28453668",
                    "text": "We developed TopMG, a mass graph-based software tool for proteoform identification by top-down mass spectrometry.",
                    "offsetInBeginSection": 996,
                    "offsetInEndSection": 1109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941048",
                    "text": "We present here a powerful new strategy for the identification of proteoforms and the elucidation of proteoform families (groups of related proteoforms) from the experimental determination of the accurate proteoform mass and number of lysine residues contained.",
                    "offsetInBeginSection": 381,
                    "offsetInEndSection": 642,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25752847",
                    "text": "Described here is the development of a multiplex mass spectrometric immunoassay (MSIA) for quantification of apolipoprotein C-I (apoC-I), apolipoprotein C-II (apoC-II), apolipoprotein C-III (apoC-III) and their proteoforms.",
                    "offsetInBeginSection": 267,
                    "offsetInEndSection": 490,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291504",
                    "text": "In top-down proteomics, proteoform identification is often performed by searching tandem mass spectra against a protein sequence database that contains only one reference protein sequence for each gene or transcript variant in a proteome.",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291504",
                    "text": "Proteoform characterization is to identify and localize PSAs in a proteoform.",
                    "offsetInBeginSection": 752,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24807621",
                    "text": "Here, we apply this new pipeline to measure the proteoform-level effects of deleting a histone deacetylase (rpd3) in S. cerevisiae.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 850,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5aa393b3d6d6b54f79000006",
            "body": "What does the Ribosome-bound Quality Control complex do?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28298488",
                "http://www.ncbi.nlm.nih.gov/pubmed/28528489",
                "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                "http://www.ncbi.nlm.nih.gov/pubmed/23007158",
                "http://www.ncbi.nlm.nih.gov/pubmed/23178123",
                "http://www.ncbi.nlm.nih.gov/pubmed/27129255",
                "http://www.ncbi.nlm.nih.gov/pubmed/22888004",
                "http://www.ncbi.nlm.nih.gov/pubmed/28757607",
                "http://www.ncbi.nlm.nih.gov/pubmed/25349383",
                "http://www.ncbi.nlm.nih.gov/pubmed/28077875"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28298488",
                    "text": "In eukaryotes, the ribosome-bound quality control (RQC) complex detects aberrant nascent peptides that remain stalled in 60S ribosomal particles due to a dysfunction in translation termination.",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28528489",
                    "text": "Among these processes, translational protein quality control is performed by the Ribosome-bound Quality Control complex (RQC), which recognizes nascent peptides translated from aberrant mRNAs, polyubiquitylates these aberrant peptides, extracts them from the stalled 60S subunit and finally escorts them to the proteasome for degradation.",
                    "offsetInBeginSection": 226,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25578875",
                    "text": "Structural and mutational analyses showed that ribosome-bound NEMF recruits and stabilizes Listerin's N-terminal domain, while Listerin's C-terminal RWD domain directly contacts the ribosome to position the adjacent ligase domain near the nascent polypeptide exit tunnel.",
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 868,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23007158",
                    "text": "Here we show that the ribosome-bound chaperone system consisting of the ribosome-associated complex (RAC) and the Hsp70 homolog Ssb is required to stabilize translationally repressed ribosome-polylysine protein complexes, without affecting the folding or the degradation of polylysine proteins.",
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 982,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23178123",
                    "text": "These included disruption of a ribosome-bound complex we named the Ribosome Quality Control Complex (RQC) comprising the Ltn1 E3 ubiquitin ligase, two highly conserved but poorly characterized proteins (Tae2 and Rqc1), and Cdc48 and its cofactors.",
                    "offsetInBeginSection": 339,
                    "offsetInEndSection": 586,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27129255",
                    "text": "Stalled ribosomes are dissociated, aberrant mRNAs are degraded by the cytoplasmic exosome, and the nascent peptides remaining in stalled 60S exit tunnels are detected by the ribosome-bound quality control complex (RQC) composed of Ltn1, Rqc1, Rqc2, and Cdc48.",
                    "offsetInBeginSection": 342,
                    "offsetInEndSection": 601,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28757607",
                    "text": "Rqt1 specifically ubiquitinates these arrested ribosomes to target them to the RQT complex, allowing subsequent RQC reactions including dissociation of the stalled ribosome into subunits.Several protein quality control mechanisms are in place to trigger the rapid degradation of aberrant polypeptides and mRNAs.",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 1164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28757607",
                    "text": "Here the authors describe a mechanism of ribosome-mediated quality control that involves the ubiquitination of ribosomal proteins by the E3 ubiquitin ligase Hel2/RQT1.",
                    "offsetInBeginSection": 1165,
                    "offsetInEndSection": 1332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25349383",
                    "text": "In eukaryotes, the large ribosomal subunit-associated quality control complex (RQC), composed of the listerin/Ltn1 E3 ubiquitin ligase and cofactors, mediates the ubiquitylation and extraction of ribosome-stalled nascent polypeptide chains for proteasomal degradation.",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28077875",
                    "text": "Here we report an electron cryo-microscopy structure of ArfA and RF2 in complex with the 70S ribosome bound to a nonstop mRNA.",
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 767,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}
